date generated: 2021-04-20
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## x
## A1BG -3.0045626
## A1BG-AS1 -0.6855588
## A1CF 0.3272035
## A2M 1.6308274
## A2M-AS1 1.0554888
## A2ML1 1.0055621
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genesets | 2408 |
num_genes_in_profile | 22124 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 8463 |
num_profile_genes_not_in_sets | 13661 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
Gene sets metrics | |
---|---|
num_genesets | 2408 |
num_genesets_excluded | 1041 |
num_genesets_included | 1367 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
Top N= 100 gene sets
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Peptide chain elongation | 88 | 6.36e-25 | -0.635 | 4.35e-22 |
Eukaryotic Translation Elongation | 93 | 5.98e-26 | -0.631 | 8.18e-23 |
Viral mRNA Translation | 88 | 1.04e-22 | -0.604 | 2.37e-20 |
Eukaryotic Translation Termination | 92 | 5.46e-23 | -0.595 | 1.87e-20 |
Selenocysteine synthesis | 92 | 8.98e-23 | -0.592 | 2.37e-20 |
Formation of a pool of free 40S subunits | 100 | 1.32e-23 | -0.579 | 6.02e-21 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 1.41e-20 | -0.554 | 2.75e-18 |
Incretin synthesis, secretion, and inactivation | 10 | 3.60e-03 | 0.532 | 4.06e-02 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 10 | 3.60e-03 | 0.532 | 4.06e-02 |
NF-kB is activated and signals survival | 12 | 2.07e-03 | -0.513 | 2.81e-02 |
WNT5A-dependent internalization of FZD4 | 13 | 1.53e-03 | -0.508 | 2.37e-02 |
L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 5.78e-20 | -0.504 | 9.88e-18 |
DNA methylation | 20 | 1.26e-04 | -0.495 | 2.88e-03 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 1.78e-17 | -0.492 | 2.02e-15 |
VLDLR internalisation and degradation | 11 | 5.00e-03 | -0.489 | 5.10e-02 |
tRNA processing in the mitochondrion | 32 | 1.71e-06 | -0.489 | 5.69e-05 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 6.92e-19 | -0.487 | 1.05e-16 |
AKT phosphorylates targets in the nucleus | 10 | 8.21e-03 | -0.483 | 6.81e-02 |
CDC6 association with the ORC:origin complex | 11 | 5.97e-03 | 0.479 | 5.62e-02 |
Josephin domain DUBs | 10 | 8.89e-03 | -0.478 | 7.10e-02 |
Cytosolic iron-sulfur cluster assembly | 13 | 3.62e-03 | -0.466 | 4.06e-02 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 114 | 4.58e-17 | -0.455 | 4.47e-15 |
Nonsense-Mediated Decay (NMD) | 114 | 4.58e-17 | -0.455 | 4.47e-15 |
Cap-dependent Translation Initiation | 118 | 1.45e-17 | -0.454 | 1.80e-15 |
Eukaryotic Translation Initiation | 118 | 1.45e-17 | -0.454 | 1.80e-15 |
Formation of the ternary complex, and subsequently, the 43S complex | 51 | 4.73e-08 | -0.442 | 2.31e-06 |
GP1b-IX-V activation signalling | 10 | 1.56e-02 | -0.442 | 1.02e-01 |
RNA Polymerase I Promoter Opening | 19 | 1.00e-03 | -0.436 | 1.67e-02 |
Condensation of Prometaphase Chromosomes | 11 | 1.25e-02 | 0.435 | 8.83e-02 |
Trafficking of GluR2-containing AMPA receptors | 12 | 9.31e-03 | -0.433 | 7.28e-02 |
Regulation of FZD by ubiquitination | 16 | 2.72e-03 | -0.433 | 3.38e-02 |
Presynaptic phase of homologous DNA pairing and strand exchange | 39 | 3.16e-06 | 0.431 | 9.81e-05 |
SUMOylation of DNA methylation proteins | 16 | 3.05e-03 | -0.428 | 3.69e-02 |
Selenoamino acid metabolism | 114 | 6.82e-15 | -0.422 | 6.22e-13 |
Processing and activation of SUMO | 10 | 2.18e-02 | 0.419 | 1.32e-01 |
SRP-dependent cotranslational protein targeting to membrane | 111 | 1.48e-13 | -0.406 | 1.13e-11 |
Olfactory Signaling Pathway | 61 | 5.11e-08 | 0.403 | 2.41e-06 |
Homologous DNA Pairing and Strand Exchange | 42 | 6.30e-06 | 0.403 | 1.91e-04 |
FOXO-mediated transcription of cell death genes | 16 | 5.58e-03 | -0.400 | 5.34e-02 |
A tetrasaccharide linker sequence is required for GAG synthesis | 18 | 3.39e-03 | -0.399 | 3.92e-02 |
rRNA processing in the mitochondrion | 29 | 2.27e-04 | -0.395 | 4.68e-03 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 6.39e-03 | -0.394 | 5.83e-02 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 2.08e-07 | -0.391 | 8.61e-06 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 2.49e-02 | -0.391 | 1.47e-01 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 12 | 1.93e-02 | -0.390 | 1.21e-01 |
Pexophagy | 11 | 2.51e-02 | -0.390 | 1.47e-01 |
Translation initiation complex formation | 58 | 2.90e-07 | -0.389 | 1.17e-05 |
Influenza Viral RNA Transcription and Replication | 135 | 9.54e-15 | -0.386 | 7.67e-13 |
MET activates RAP1 and RAC1 | 10 | 3.51e-02 | 0.385 | 1.83e-01 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 7.29e-04 | 0.383 | 1.26e-02 |
Signaling by Leptin | 10 | 3.70e-02 | -0.381 | 1.88e-01 |
Ribosomal scanning and start codon recognition | 58 | 5.74e-07 | -0.379 | 2.12e-05 |
Pausing and recovery of Tat-mediated HIV elongation | 30 | 3.24e-04 | -0.379 | 5.90e-03 |
Tat-mediated HIV elongation arrest and recovery | 30 | 3.24e-04 | -0.379 | 5.90e-03 |
HS-GAG degradation | 16 | 8.72e-03 | -0.379 | 7.10e-02 |
Interleukin-2 signaling | 11 | 3.16e-02 | -0.374 | 1.73e-01 |
p75NTR signals via NF-kB | 15 | 1.27e-02 | -0.372 | 8.87e-02 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 22 | 2.55e-03 | -0.372 | 3.29e-02 |
Activation of Matrix Metalloproteinases | 24 | 1.64e-03 | -0.371 | 2.47e-02 |
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 2.71e-02 | -0.369 | 1.54e-01 |
Diseases of hemostasis | 12 | 2.71e-02 | -0.369 | 1.54e-01 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 12 | 3.12e-02 | 0.359 | 1.72e-01 |
Establishment of Sister Chromatid Cohesion | 11 | 3.99e-02 | 0.358 | 1.94e-01 |
Pre-NOTCH Processing in Golgi | 18 | 9.04e-03 | -0.355 | 7.14e-02 |
Constitutive Signaling by NOTCH1 HD Domain Mutants | 14 | 2.16e-02 | -0.355 | 1.31e-01 |
Signaling by NOTCH1 HD Domain Mutants in Cancer | 14 | 2.16e-02 | -0.355 | 1.31e-01 |
HDR through Single Strand Annealing (SSA) | 37 | 1.89e-04 | 0.355 | 4.03e-03 |
p75NTR recruits signalling complexes | 12 | 3.54e-02 | -0.351 | 1.83e-01 |
RMTs methylate histone arginines | 37 | 2.31e-04 | -0.350 | 4.68e-03 |
Heparan sulfate/heparin (HS-GAG) metabolism | 38 | 2.32e-04 | -0.345 | 4.68e-03 |
Regulation of IFNG signaling | 14 | 2.55e-02 | 0.345 | 1.47e-01 |
Synthesis of PIPs at the late endosome membrane | 11 | 4.79e-02 | 0.344 | 2.19e-01 |
Collagen chain trimerization | 27 | 1.98e-03 | -0.344 | 2.76e-02 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 22 | 5.33e-03 | -0.343 | 5.16e-02 |
Plasma lipoprotein clearance | 29 | 1.47e-03 | -0.341 | 2.34e-02 |
IRAK4 deficiency (TLR2/4) | 10 | 6.21e-02 | 0.341 | 2.56e-01 |
MyD88 deficiency (TLR2/4) | 10 | 6.21e-02 | 0.341 | 2.56e-01 |
Constitutive Signaling by AKT1 E17K in Cancer | 26 | 2.70e-03 | -0.340 | 3.38e-02 |
Regulation of localization of FOXO transcription factors | 12 | 4.48e-02 | -0.335 | 2.10e-01 |
Retrograde neurotrophin signalling | 12 | 4.65e-02 | -0.332 | 2.16e-01 |
Lewis blood group biosynthesis | 13 | 3.89e-02 | -0.331 | 1.92e-01 |
Cleavage of the damaged purine | 24 | 5.20e-03 | -0.329 | 5.12e-02 |
Depurination | 24 | 5.20e-03 | -0.329 | 5.12e-02 |
Recognition and association of DNA glycosylase with site containing an affected purine | 24 | 5.20e-03 | -0.329 | 5.12e-02 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 23 | 6.29e-03 | -0.329 | 5.77e-02 |
Biosynthesis of DHA-derived SPMs | 14 | 3.36e-02 | -0.328 | 1.79e-01 |
Chondroitin sulfate/dermatan sulfate metabolism | 39 | 4.15e-04 | -0.327 | 7.37e-03 |
Common Pathway of Fibrin Clot Formation | 14 | 3.59e-02 | -0.324 | 1.84e-01 |
Packaging Of Telomere Ends | 20 | 1.22e-02 | -0.324 | 8.74e-02 |
Downregulation of ERBB2:ERBB3 signaling | 12 | 5.33e-02 | -0.322 | 2.35e-01 |
HIV elongation arrest and recovery | 32 | 1.64e-03 | -0.322 | 2.47e-02 |
Pausing and recovery of HIV elongation | 32 | 1.64e-03 | -0.322 | 2.47e-02 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 20 | 1.33e-02 | -0.320 | 9.12e-02 |
NGF-stimulated transcription | 33 | 1.49e-03 | -0.320 | 2.34e-02 |
EGFR downregulation | 27 | 4.23e-03 | -0.318 | 4.63e-02 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 32 | 1.94e-03 | -0.317 | 2.73e-02 |
Cyclin A/B1/B2 associated events during G2/M transition | 24 | 7.49e-03 | 0.315 | 6.40e-02 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 21 | 1.30e-02 | -0.313 | 8.95e-02 |
Formation of ATP by chemiosmotic coupling | 18 | 2.16e-02 | -0.313 | 1.31e-01 |
Influenza Infection | 154 | 2.27e-11 | -0.312 | 1.41e-09 |
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Peptide chain elongation | 88 | 6.36e-25 | -0.635000 | 4.35e-22 |
Eukaryotic Translation Elongation | 93 | 5.98e-26 | -0.631000 | 8.18e-23 |
Viral mRNA Translation | 88 | 1.04e-22 | -0.604000 | 2.37e-20 |
Eukaryotic Translation Termination | 92 | 5.46e-23 | -0.595000 | 1.87e-20 |
Selenocysteine synthesis | 92 | 8.98e-23 | -0.592000 | 2.37e-20 |
Formation of a pool of free 40S subunits | 100 | 1.32e-23 | -0.579000 | 6.02e-21 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 94 | 1.41e-20 | -0.554000 | 2.75e-18 |
Incretin synthesis, secretion, and inactivation | 10 | 3.60e-03 | 0.532000 | 4.06e-02 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | 10 | 3.60e-03 | 0.532000 | 4.06e-02 |
NF-kB is activated and signals survival | 12 | 2.07e-03 | -0.513000 | 2.81e-02 |
WNT5A-dependent internalization of FZD4 | 13 | 1.53e-03 | -0.508000 | 2.37e-02 |
L13a-mediated translational silencing of Ceruloplasmin expression | 110 | 5.78e-20 | -0.504000 | 9.88e-18 |
DNA methylation | 20 | 1.26e-04 | -0.495000 | 2.88e-03 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 100 | 1.78e-17 | -0.492000 | 2.02e-15 |
VLDLR internalisation and degradation | 11 | 5.00e-03 | -0.489000 | 5.10e-02 |
tRNA processing in the mitochondrion | 32 | 1.71e-06 | -0.489000 | 5.69e-05 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 111 | 6.92e-19 | -0.487000 | 1.05e-16 |
AKT phosphorylates targets in the nucleus | 10 | 8.21e-03 | -0.483000 | 6.81e-02 |
CDC6 association with the ORC:origin complex | 11 | 5.97e-03 | 0.479000 | 5.62e-02 |
Josephin domain DUBs | 10 | 8.89e-03 | -0.478000 | 7.10e-02 |
Cytosolic iron-sulfur cluster assembly | 13 | 3.62e-03 | -0.466000 | 4.06e-02 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 114 | 4.58e-17 | -0.455000 | 4.47e-15 |
Nonsense-Mediated Decay (NMD) | 114 | 4.58e-17 | -0.455000 | 4.47e-15 |
Cap-dependent Translation Initiation | 118 | 1.45e-17 | -0.454000 | 1.80e-15 |
Eukaryotic Translation Initiation | 118 | 1.45e-17 | -0.454000 | 1.80e-15 |
Formation of the ternary complex, and subsequently, the 43S complex | 51 | 4.73e-08 | -0.442000 | 2.31e-06 |
GP1b-IX-V activation signalling | 10 | 1.56e-02 | -0.442000 | 1.02e-01 |
RNA Polymerase I Promoter Opening | 19 | 1.00e-03 | -0.436000 | 1.67e-02 |
Condensation of Prometaphase Chromosomes | 11 | 1.25e-02 | 0.435000 | 8.83e-02 |
Trafficking of GluR2-containing AMPA receptors | 12 | 9.31e-03 | -0.433000 | 7.28e-02 |
Regulation of FZD by ubiquitination | 16 | 2.72e-03 | -0.433000 | 3.38e-02 |
Presynaptic phase of homologous DNA pairing and strand exchange | 39 | 3.16e-06 | 0.431000 | 9.81e-05 |
SUMOylation of DNA methylation proteins | 16 | 3.05e-03 | -0.428000 | 3.69e-02 |
Selenoamino acid metabolism | 114 | 6.82e-15 | -0.422000 | 6.22e-13 |
Processing and activation of SUMO | 10 | 2.18e-02 | 0.419000 | 1.32e-01 |
SRP-dependent cotranslational protein targeting to membrane | 111 | 1.48e-13 | -0.406000 | 1.13e-11 |
Olfactory Signaling Pathway | 61 | 5.11e-08 | 0.403000 | 2.41e-06 |
Homologous DNA Pairing and Strand Exchange | 42 | 6.30e-06 | 0.403000 | 1.91e-04 |
FOXO-mediated transcription of cell death genes | 16 | 5.58e-03 | -0.400000 | 5.34e-02 |
A tetrasaccharide linker sequence is required for GAG synthesis | 18 | 3.39e-03 | -0.399000 | 3.92e-02 |
rRNA processing in the mitochondrion | 29 | 2.27e-04 | -0.395000 | 4.68e-03 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 16 | 6.39e-03 | -0.394000 | 5.83e-02 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 59 | 2.08e-07 | -0.391000 | 8.61e-06 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 11 | 2.49e-02 | -0.391000 | 1.47e-01 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 12 | 1.93e-02 | -0.390000 | 1.21e-01 |
Pexophagy | 11 | 2.51e-02 | -0.390000 | 1.47e-01 |
Translation initiation complex formation | 58 | 2.90e-07 | -0.389000 | 1.17e-05 |
Influenza Viral RNA Transcription and Replication | 135 | 9.54e-15 | -0.386000 | 7.67e-13 |
MET activates RAP1 and RAC1 | 10 | 3.51e-02 | 0.385000 | 1.83e-01 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 26 | 7.29e-04 | 0.383000 | 1.26e-02 |
Signaling by Leptin | 10 | 3.70e-02 | -0.381000 | 1.88e-01 |
Ribosomal scanning and start codon recognition | 58 | 5.74e-07 | -0.379000 | 2.12e-05 |
Pausing and recovery of Tat-mediated HIV elongation | 30 | 3.24e-04 | -0.379000 | 5.90e-03 |
Tat-mediated HIV elongation arrest and recovery | 30 | 3.24e-04 | -0.379000 | 5.90e-03 |
HS-GAG degradation | 16 | 8.72e-03 | -0.379000 | 7.10e-02 |
Interleukin-2 signaling | 11 | 3.16e-02 | -0.374000 | 1.73e-01 |
p75NTR signals via NF-kB | 15 | 1.27e-02 | -0.372000 | 8.87e-02 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 22 | 2.55e-03 | -0.372000 | 3.29e-02 |
Activation of Matrix Metalloproteinases | 24 | 1.64e-03 | -0.371000 | 2.47e-02 |
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | 12 | 2.71e-02 | -0.369000 | 1.54e-01 |
Diseases of hemostasis | 12 | 2.71e-02 | -0.369000 | 1.54e-01 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 12 | 3.12e-02 | 0.359000 | 1.72e-01 |
Establishment of Sister Chromatid Cohesion | 11 | 3.99e-02 | 0.358000 | 1.94e-01 |
Pre-NOTCH Processing in Golgi | 18 | 9.04e-03 | -0.355000 | 7.14e-02 |
Constitutive Signaling by NOTCH1 HD Domain Mutants | 14 | 2.16e-02 | -0.355000 | 1.31e-01 |
Signaling by NOTCH1 HD Domain Mutants in Cancer | 14 | 2.16e-02 | -0.355000 | 1.31e-01 |
HDR through Single Strand Annealing (SSA) | 37 | 1.89e-04 | 0.355000 | 4.03e-03 |
p75NTR recruits signalling complexes | 12 | 3.54e-02 | -0.351000 | 1.83e-01 |
RMTs methylate histone arginines | 37 | 2.31e-04 | -0.350000 | 4.68e-03 |
Heparan sulfate/heparin (HS-GAG) metabolism | 38 | 2.32e-04 | -0.345000 | 4.68e-03 |
Regulation of IFNG signaling | 14 | 2.55e-02 | 0.345000 | 1.47e-01 |
Synthesis of PIPs at the late endosome membrane | 11 | 4.79e-02 | 0.344000 | 2.19e-01 |
Collagen chain trimerization | 27 | 1.98e-03 | -0.344000 | 2.76e-02 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | 22 | 5.33e-03 | -0.343000 | 5.16e-02 |
Plasma lipoprotein clearance | 29 | 1.47e-03 | -0.341000 | 2.34e-02 |
IRAK4 deficiency (TLR2/4) | 10 | 6.21e-02 | 0.341000 | 2.56e-01 |
MyD88 deficiency (TLR2/4) | 10 | 6.21e-02 | 0.341000 | 2.56e-01 |
Constitutive Signaling by AKT1 E17K in Cancer | 26 | 2.70e-03 | -0.340000 | 3.38e-02 |
Regulation of localization of FOXO transcription factors | 12 | 4.48e-02 | -0.335000 | 2.10e-01 |
Retrograde neurotrophin signalling | 12 | 4.65e-02 | -0.332000 | 2.16e-01 |
Lewis blood group biosynthesis | 13 | 3.89e-02 | -0.331000 | 1.92e-01 |
Cleavage of the damaged purine | 24 | 5.20e-03 | -0.329000 | 5.12e-02 |
Depurination | 24 | 5.20e-03 | -0.329000 | 5.12e-02 |
Recognition and association of DNA glycosylase with site containing an affected purine | 24 | 5.20e-03 | -0.329000 | 5.12e-02 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 23 | 6.29e-03 | -0.329000 | 5.77e-02 |
Biosynthesis of DHA-derived SPMs | 14 | 3.36e-02 | -0.328000 | 1.79e-01 |
Chondroitin sulfate/dermatan sulfate metabolism | 39 | 4.15e-04 | -0.327000 | 7.37e-03 |
Common Pathway of Fibrin Clot Formation | 14 | 3.59e-02 | -0.324000 | 1.84e-01 |
Packaging Of Telomere Ends | 20 | 1.22e-02 | -0.324000 | 8.74e-02 |
Downregulation of ERBB2:ERBB3 signaling | 12 | 5.33e-02 | -0.322000 | 2.35e-01 |
HIV elongation arrest and recovery | 32 | 1.64e-03 | -0.322000 | 2.47e-02 |
Pausing and recovery of HIV elongation | 32 | 1.64e-03 | -0.322000 | 2.47e-02 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 20 | 1.33e-02 | -0.320000 | 9.12e-02 |
NGF-stimulated transcription | 33 | 1.49e-03 | -0.320000 | 2.34e-02 |
EGFR downregulation | 27 | 4.23e-03 | -0.318000 | 4.63e-02 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 32 | 1.94e-03 | -0.317000 | 2.73e-02 |
Cyclin A/B1/B2 associated events during G2/M transition | 24 | 7.49e-03 | 0.315000 | 6.40e-02 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 21 | 1.30e-02 | -0.313000 | 8.95e-02 |
Formation of ATP by chemiosmotic coupling | 18 | 2.16e-02 | -0.313000 | 1.31e-01 |
Influenza Infection | 154 | 2.27e-11 | -0.312000 | 1.41e-09 |
E2F mediated regulation of DNA replication | 22 | 1.13e-02 | 0.312000 | 8.29e-02 |
Regulation of expression of SLITs and ROBOs | 162 | 7.62e-12 | -0.312000 | 5.21e-10 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 23 | 9.92e-03 | -0.311000 | 7.59e-02 |
Collagen biosynthesis and modifying enzymes | 46 | 2.92e-04 | -0.309000 | 5.46e-03 |
Regulation of TP53 Activity through Association with Co-factors | 12 | 6.47e-02 | -0.308000 | 2.64e-01 |
Glycogen storage diseases | 13 | 5.47e-02 | -0.308000 | 2.36e-01 |
ATF6 (ATF6-alpha) activates chaperone genes | 10 | 9.26e-02 | 0.307000 | 3.33e-01 |
Activated NOTCH1 Transmits Signal to the Nucleus | 27 | 6.01e-03 | -0.305000 | 5.62e-02 |
Diseases of carbohydrate metabolism | 29 | 4.52e-03 | -0.305000 | 4.83e-02 |
rRNA processing | 219 | 8.59e-15 | -0.304000 | 7.34e-13 |
Class C/3 (Metabotropic glutamate/pheromone receptors) | 11 | 8.43e-02 | 0.301000 | 3.16e-01 |
Glycogen synthesis | 13 | 6.35e-02 | -0.297000 | 2.60e-01 |
N-Glycan antennae elongation | 13 | 6.35e-02 | -0.297000 | 2.60e-01 |
PKA activation in glucagon signalling | 14 | 5.46e-02 | -0.297000 | 2.36e-01 |
Synthesis of IP3 and IP4 in the cytosol | 22 | 1.60e-02 | -0.297000 | 1.05e-01 |
Repression of WNT target genes | 14 | 5.51e-02 | -0.296000 | 2.36e-01 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 29 | 6.06e-03 | -0.294000 | 5.64e-02 |
Collagen formation | 64 | 4.87e-05 | -0.294000 | 1.26e-03 |
GAB1 signalosome | 15 | 4.91e-02 | -0.293000 | 2.22e-01 |
Nuclear Receptor transcription pathway | 41 | 1.19e-03 | -0.293000 | 1.94e-02 |
Chondroitin sulfate biosynthesis | 13 | 6.81e-02 | -0.292000 | 2.74e-01 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 27 | 9.16e-03 | -0.290000 | 7.20e-02 |
rRNA processing in the nucleus and cytosol | 190 | 6.12e-12 | -0.289000 | 4.40e-10 |
CD28 dependent PI3K/Akt signaling | 22 | 1.89e-02 | -0.289000 | 1.20e-01 |
Inhibition of DNA recombination at telomere | 35 | 3.14e-03 | -0.288000 | 3.71e-02 |
PKA activation | 15 | 5.36e-02 | -0.288000 | 2.35e-01 |
Major pathway of rRNA processing in the nucleolus and cytosol | 180 | 2.80e-11 | -0.287000 | 1.67e-09 |
Antiviral mechanism by IFN-stimulated genes | 80 | 9.57e-06 | 0.286000 | 2.78e-04 |
Defective B3GAT3 causes JDSSDHD | 12 | 8.64e-02 | -0.286000 | 3.21e-01 |
Formation of Fibrin Clot (Clotting Cascade) | 26 | 1.20e-02 | -0.284000 | 8.67e-02 |
EPH-ephrin mediated repulsion of cells | 40 | 2.04e-03 | -0.282000 | 2.81e-02 |
Interferon alpha/beta signaling | 57 | 2.33e-04 | 0.282000 | 4.68e-03 |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | 12 | 9.41e-02 | -0.279000 | 3.33e-01 |
NS1 Mediated Effects on Host Pathways | 40 | 2.37e-03 | 0.278000 | 3.12e-02 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 32 | 6.63e-03 | 0.277000 | 5.92e-02 |
Spry regulation of FGF signaling | 16 | 5.56e-02 | -0.276000 | 2.38e-01 |
Effects of PIP2 hydrolysis | 24 | 1.92e-02 | -0.276000 | 1.20e-01 |
Defective B4GALT7 causes EDS, progeroid type | 12 | 1.01e-01 | -0.274000 | 3.43e-01 |
Base-Excision Repair, AP Site Formation | 31 | 8.35e-03 | -0.274000 | 6.88e-02 |
Regulation of TP53 Activity through Acetylation | 29 | 1.09e-02 | -0.273000 | 8.09e-02 |
Regulation of TLR by endogenous ligand | 11 | 1.22e-01 | 0.269000 | 3.75e-01 |
Negative regulation of FGFR4 signaling | 21 | 3.27e-02 | -0.269000 | 1.78e-01 |
HSF1-dependent transactivation | 29 | 1.24e-02 | -0.268000 | 8.82e-02 |
Collagen degradation | 29 | 1.24e-02 | -0.268000 | 8.82e-02 |
Assembly of collagen fibrils and other multimeric structures | 42 | 2.66e-03 | -0.268000 | 3.38e-02 |
Cytochrome c-mediated apoptotic response | 13 | 9.45e-02 | 0.268000 | 3.33e-01 |
Downregulation of ERBB2 signaling | 24 | 2.38e-02 | -0.267000 | 1.43e-01 |
Signaling by PDGFRA extracellular domain mutants | 12 | 1.13e-01 | 0.264000 | 3.62e-01 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 1.13e-01 | 0.264000 | 3.62e-01 |
Biosynthesis of specialized proresolving mediators (SPMs) | 16 | 6.83e-02 | -0.263000 | 2.74e-01 |
Formation of the beta-catenin:TCF transactivating complex | 46 | 2.09e-03 | -0.262000 | 2.81e-02 |
Mucopolysaccharidoses | 11 | 1.34e-01 | -0.261000 | 3.91e-01 |
Other semaphorin interactions | 16 | 7.10e-02 | -0.261000 | 2.81e-01 |
Hyaluronan metabolism | 13 | 1.05e-01 | -0.260000 | 3.51e-01 |
Gap junction trafficking | 14 | 9.23e-02 | -0.260000 | 3.33e-01 |
Signal regulatory protein family interactions | 12 | 1.20e-01 | -0.259000 | 3.72e-01 |
Acetylcholine Neurotransmitter Release Cycle | 11 | 1.36e-01 | -0.259000 | 3.92e-01 |
NRIF signals cell death from the nucleus | 15 | 8.41e-02 | -0.258000 | 3.16e-01 |
Elevation of cytosolic Ca2+ levels | 13 | 1.09e-01 | -0.257000 | 3.57e-01 |
Deadenylation of mRNA | 22 | 3.81e-02 | 0.255000 | 1.89e-01 |
Transport of the SLBP Dependant Mature mRNA | 36 | 8.17e-03 | 0.255000 | 6.81e-02 |
Signaling by ROBO receptors | 202 | 4.30e-10 | -0.255000 | 2.26e-08 |
Activation of ATR in response to replication stress | 36 | 8.52e-03 | 0.253000 | 6.98e-02 |
The role of Nef in HIV-1 replication and disease pathogenesis | 28 | 2.06e-02 | -0.253000 | 1.27e-01 |
Degradation of cysteine and homocysteine | 13 | 1.15e-01 | -0.252000 | 3.65e-01 |
IRAK2 mediated activation of TAK1 complex | 10 | 1.68e-01 | -0.252000 | 4.46e-01 |
Senescence-Associated Secretory Phenotype (SASP) | 66 | 4.07e-04 | -0.252000 | 7.32e-03 |
Signaling by NODAL | 13 | 1.17e-01 | -0.251000 | 3.68e-01 |
Resolution of D-Loop Structures | 33 | 1.29e-02 | 0.250000 | 8.95e-02 |
ISG15 antiviral mechanism | 72 | 2.56e-04 | 0.249000 | 5.00e-03 |
Resolution of Sister Chromatid Cohesion | 104 | 1.13e-05 | 0.249000 | 3.09e-04 |
Signaling by NOTCH3 | 43 | 5.11e-03 | -0.247000 | 5.12e-02 |
AKT phosphorylates targets in the cytosol | 14 | 1.11e-01 | -0.246000 | 3.59e-01 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 22 | 4.58e-02 | -0.246000 | 2.14e-01 |
Transport of the SLBP independent Mature mRNA | 35 | 1.27e-02 | 0.243000 | 8.87e-02 |
Response of EIF2AK1 (HRI) to heme deficiency | 14 | 1.15e-01 | 0.243000 | 3.65e-01 |
NEP/NS2 Interacts with the Cellular Export Machinery | 32 | 1.79e-02 | 0.242000 | 1.15e-01 |
Assembly Of The HIV Virion | 15 | 1.05e-01 | -0.242000 | 3.51e-01 |
TRAF6 mediated IRF7 activation | 15 | 1.06e-01 | 0.241000 | 3.51e-01 |
Negative regulation of FGFR3 signaling | 20 | 6.18e-02 | -0.241000 | 2.56e-01 |
Neurexins and neuroligins | 38 | 1.04e-02 | -0.240000 | 7.79e-02 |
Gluconeogenesis | 28 | 2.80e-02 | -0.240000 | 1.58e-01 |
Cleavage of the damaged pyrimidine | 29 | 2.54e-02 | -0.240000 | 1.47e-01 |
Depyrimidination | 29 | 2.54e-02 | -0.240000 | 1.47e-01 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 29 | 2.54e-02 | -0.240000 | 1.47e-01 |
Glycogen metabolism | 23 | 4.69e-02 | -0.239000 | 2.16e-01 |
Amyloid fiber formation | 51 | 3.17e-03 | -0.239000 | 3.71e-02 |
Transport of Ribonucleoproteins into the Host Nucleus | 32 | 1.95e-02 | 0.238000 | 1.21e-01 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 53 | 2.68e-03 | -0.238000 | 3.38e-02 |
Notch-HLH transcription pathway | 28 | 2.91e-02 | -0.238000 | 1.63e-01 |
HDACs deacetylate histones | 47 | 5.00e-03 | -0.237000 | 5.10e-02 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 43 | 7.38e-03 | 0.236000 | 6.35e-02 |
Pre-NOTCH Transcription and Translation | 49 | 4.34e-03 | -0.236000 | 4.71e-02 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 12 | 1.58e-01 | 0.235000 | 4.32e-01 |
Platelet Aggregation (Plug Formation) | 28 | 3.28e-02 | -0.233000 | 1.78e-01 |
TBC/RABGAPs | 45 | 6.96e-03 | -0.232000 | 6.10e-02 |
Plasma lipoprotein assembly, remodeling, and clearance | 54 | 3.17e-03 | -0.232000 | 3.71e-02 |
Glycosaminoglycan metabolism | 93 | 1.14e-04 | -0.232000 | 2.68e-03 |
Translation of structural proteins | 28 | 3.47e-02 | -0.231000 | 1.82e-01 |
Interleukin-7 signaling | 21 | 6.76e-02 | -0.230000 | 2.74e-01 |
Nuclear Events (kinase and transcription factor activation) | 55 | 3.17e-03 | -0.230000 | 3.71e-02 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 91 | 1.50e-04 | 0.230000 | 3.30e-03 |
Amplification of signal from the kinetochores | 91 | 1.50e-04 | 0.230000 | 3.30e-03 |
MicroRNA (miRNA) biogenesis | 24 | 5.30e-02 | -0.228000 | 2.35e-01 |
SUMOylation of ubiquitinylation proteins | 39 | 1.38e-02 | 0.228000 | 9.38e-02 |
Transport of Mature mRNA Derived from an Intronless Transcript | 42 | 1.12e-02 | 0.226000 | 8.28e-02 |
HS-GAG biosynthesis | 20 | 8.02e-02 | -0.226000 | 3.06e-01 |
Pre-NOTCH Expression and Processing | 65 | 1.70e-03 | -0.225000 | 2.50e-02 |
Cristae formation | 31 | 3.02e-02 | -0.225000 | 1.68e-01 |
Basigin interactions | 23 | 6.24e-02 | -0.224000 | 2.57e-01 |
Laminin interactions | 21 | 7.51e-02 | -0.224000 | 2.91e-01 |
Gap junction trafficking and regulation | 16 | 1.21e-01 | -0.224000 | 3.74e-01 |
HDR through MMEJ (alt-NHEJ) | 10 | 2.20e-01 | 0.224000 | 5.11e-01 |
Termination of O-glycan biosynthesis | 16 | 1.23e-01 | -0.223000 | 3.76e-01 |
Interferon Signaling | 177 | 3.30e-07 | 0.222000 | 1.29e-05 |
NR1H2 and NR1H3-mediated signaling | 40 | 1.49e-02 | -0.222000 | 1.00e-01 |
Mitotic Spindle Checkpoint | 108 | 6.77e-05 | 0.222000 | 1.65e-03 |
Cohesin Loading onto Chromatin | 10 | 2.26e-01 | 0.221000 | 5.18e-01 |
Processing of Intronless Pre-mRNAs | 19 | 9.60e-02 | 0.221000 | 3.34e-01 |
Nuclear signaling by ERBB4 | 24 | 6.19e-02 | -0.220000 | 2.56e-01 |
Norepinephrine Neurotransmitter Release Cycle | 13 | 1.71e-01 | -0.219000 | 4.50e-01 |
Hyaluronan uptake and degradation | 10 | 2.30e-01 | -0.219000 | 5.24e-01 |
Signaling by PDGFR in disease | 19 | 9.90e-02 | 0.219000 | 3.40e-01 |
MASTL Facilitates Mitotic Progression | 10 | 2.32e-01 | 0.218000 | 5.27e-01 |
Regulation of TP53 Activity through Methylation | 19 | 1.01e-01 | -0.217000 | 3.43e-01 |
PKA-mediated phosphorylation of CREB | 17 | 1.21e-01 | -0.217000 | 3.74e-01 |
Signaling by NOTCH2 | 30 | 3.97e-02 | -0.217000 | 1.94e-01 |
Pyrimidine salvage | 10 | 2.35e-01 | -0.217000 | 5.28e-01 |
Cell-extracellular matrix interactions | 14 | 1.61e-01 | -0.216000 | 4.37e-01 |
EML4 and NUDC in mitotic spindle formation | 95 | 2.77e-04 | 0.216000 | 5.30e-03 |
CaM pathway | 27 | 5.36e-02 | -0.215000 | 2.35e-01 |
Calmodulin induced events | 27 | 5.36e-02 | -0.215000 | 2.35e-01 |
Assembly of active LPL and LIPC lipase complexes | 11 | 2.19e-01 | -0.214000 | 5.10e-01 |
Activation of HOX genes during differentiation | 71 | 1.82e-03 | -0.214000 | 2.61e-02 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 71 | 1.82e-03 | -0.214000 | 2.61e-02 |
Gamma carboxylation, hypusine formation and arylsulfatase activation | 34 | 3.08e-02 | -0.214000 | 1.71e-01 |
Metabolism of fat-soluble vitamins | 28 | 5.07e-02 | -0.213000 | 2.27e-01 |
NOTCH4 Intracellular Domain Regulates Transcription | 18 | 1.18e-01 | -0.213000 | 3.69e-01 |
Activation of RAC1 | 11 | 2.21e-01 | 0.213000 | 5.13e-01 |
Insulin processing | 20 | 9.95e-02 | 0.213000 | 3.41e-01 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 31 | 4.06e-02 | 0.213000 | 1.95e-01 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 31 | 4.06e-02 | 0.213000 | 1.95e-01 |
Nuclear Pore Complex (NPC) Disassembly | 36 | 2.76e-02 | 0.212000 | 1.56e-01 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 10 | 2.45e-01 | -0.212000 | 5.35e-01 |
Defective EXT2 causes exostoses 2 | 10 | 2.45e-01 | -0.212000 | 5.35e-01 |
Response of Mtb to phagocytosis | 22 | 8.68e-02 | -0.211000 | 3.21e-01 |
Retinoid metabolism and transport | 24 | 7.37e-02 | -0.211000 | 2.88e-01 |
Export of Viral Ribonucleoproteins from Nucleus | 33 | 3.60e-02 | 0.211000 | 1.84e-01 |
N-glycan antennae elongation in the medial/trans-Golgi | 21 | 9.46e-02 | -0.211000 | 3.33e-01 |
Signaling by EGFR | 46 | 1.39e-02 | -0.210000 | 9.38e-02 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 15 | 1.60e-01 | -0.210000 | 4.34e-01 |
NRAGE signals death through JNK | 52 | 9.45e-03 | -0.208000 | 7.30e-02 |
PRC2 methylates histones and DNA | 29 | 5.30e-02 | -0.208000 | 2.35e-01 |
SUMOylation of DNA replication proteins | 46 | 1.51e-02 | 0.207000 | 1.00e-01 |
RHO GTPases Activate NADPH Oxidases | 21 | 1.02e-01 | -0.206000 | 3.44e-01 |
Disorders of Developmental Biology | 12 | 2.18e-01 | -0.206000 | 5.08e-01 |
Disorders of Nervous System Development | 12 | 2.18e-01 | -0.206000 | 5.08e-01 |
Loss of function of MECP2 in Rett syndrome | 12 | 2.18e-01 | -0.206000 | 5.08e-01 |
Pervasive developmental disorders | 12 | 2.18e-01 | -0.206000 | 5.08e-01 |
Negative regulation of FGFR1 signaling | 24 | 8.17e-02 | -0.205000 | 3.09e-01 |
Plasma lipoprotein assembly | 11 | 2.40e-01 | -0.205000 | 5.33e-01 |
Metabolism of non-coding RNA | 53 | 1.01e-02 | 0.204000 | 7.64e-02 |
snRNP Assembly | 53 | 1.01e-02 | 0.204000 | 7.64e-02 |
Adenylate cyclase inhibitory pathway | 11 | 2.41e-01 | -0.204000 | 5.35e-01 |
Acyl chain remodelling of PG | 11 | 2.41e-01 | 0.204000 | 5.35e-01 |
SUMOylation of immune response proteins | 11 | 2.42e-01 | -0.204000 | 5.35e-01 |
Extracellular matrix organization | 220 | 1.90e-07 | -0.204000 | 8.10e-06 |
Pentose phosphate pathway | 13 | 2.04e-01 | -0.204000 | 4.93e-01 |
G2/M DNA damage checkpoint | 67 | 4.09e-03 | 0.203000 | 4.51e-02 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 1.89e-01 | -0.203000 | 4.79e-01 |
Metabolism of Angiotensinogen to Angiotensins | 11 | 2.46e-01 | -0.202000 | 5.35e-01 |
Antimicrobial peptides | 34 | 4.20e-02 | -0.201000 | 2.00e-01 |
Uptake and function of anthrax toxins | 10 | 2.72e-01 | -0.201000 | 5.67e-01 |
CRMPs in Sema3A signaling | 14 | 1.94e-01 | -0.200000 | 4.84e-01 |
Cytosolic tRNA aminoacylation | 24 | 9.08e-02 | 0.199000 | 3.31e-01 |
Purine catabolism | 16 | 1.67e-01 | -0.199000 | 4.46e-01 |
DAG and IP3 signaling | 33 | 4.75e-02 | -0.199000 | 2.18e-01 |
Nef mediated downregulation of MHC class I complex cell surface expression | 10 | 2.75e-01 | -0.199000 | 5.70e-01 |
HDR through Homologous Recombination (HRR) | 66 | 5.12e-03 | 0.199000 | 5.12e-02 |
Phosphorylation of the APC/C | 20 | 1.24e-01 | 0.199000 | 3.78e-01 |
Attenuation phase | 23 | 9.97e-02 | -0.198000 | 3.41e-01 |
Other interleukin signaling | 18 | 1.46e-01 | -0.198000 | 4.08e-01 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 12 | 2.35e-01 | 0.198000 | 5.28e-01 |
alpha-linolenic acid (ALA) metabolism | 12 | 2.35e-01 | 0.198000 | 5.28e-01 |
PI3K/AKT Signaling in Cancer | 81 | 2.10e-03 | -0.198000 | 2.81e-02 |
LDL clearance | 17 | 1.58e-01 | -0.198000 | 4.32e-01 |
Complex I biogenesis | 55 | 1.14e-02 | -0.197000 | 8.33e-02 |
Regulation of PTEN gene transcription | 59 | 8.92e-03 | -0.197000 | 7.10e-02 |
Rap1 signalling | 13 | 2.19e-01 | 0.197000 | 5.11e-01 |
tRNA processing in the nucleus | 59 | 8.94e-03 | 0.197000 | 7.10e-02 |
Regulation of TP53 Activity through Phosphorylation | 89 | 1.35e-03 | 0.197000 | 2.16e-02 |
Leading Strand Synthesis | 14 | 2.03e-01 | 0.197000 | 4.93e-01 |
Polymerase switching | 14 | 2.03e-01 | 0.197000 | 4.93e-01 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 4.26e-02 | -0.195000 | 2.02e-01 |
Blood group systems biosynthesis | 17 | 1.64e-01 | -0.195000 | 4.40e-01 |
Nuclear import of Rev protein | 34 | 4.95e-02 | 0.195000 | 2.23e-01 |
Maturation of nucleoprotein | 10 | 2.87e-01 | 0.194000 | 5.74e-01 |
Endosomal/Vacuolar pathway | 12 | 2.45e-01 | -0.194000 | 5.35e-01 |
Membrane binding and targetting of GAG proteins | 13 | 2.26e-01 | -0.194000 | 5.18e-01 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 13 | 2.26e-01 | -0.194000 | 5.18e-01 |
RORA activates gene expression | 18 | 1.54e-01 | -0.194000 | 4.26e-01 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 49 | 1.90e-02 | 0.194000 | 1.20e-01 |
Metabolism of porphyrins | 22 | 1.17e-01 | -0.193000 | 3.68e-01 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 1.26e-01 | 0.193000 | 3.81e-01 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 1.26e-01 | 0.193000 | 3.81e-01 |
ATF6 (ATF6-alpha) activates chaperones | 12 | 2.51e-01 | 0.192000 | 5.41e-01 |
Synthesis of PC | 23 | 1.12e-01 | 0.191000 | 3.61e-01 |
Defects in cobalamin (B12) metabolism | 13 | 2.33e-01 | 0.191000 | 5.27e-01 |
Activation of G protein gated Potassium channels | 20 | 1.41e-01 | 0.190000 | 3.99e-01 |
G protein gated Potassium channels | 20 | 1.41e-01 | 0.190000 | 3.99e-01 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 20 | 1.41e-01 | 0.190000 | 3.99e-01 |
Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 1.41e-01 | 0.190000 | 3.99e-01 |
SIRT1 negatively regulates rRNA expression | 24 | 1.07e-01 | -0.190000 | 3.54e-01 |
Diseases associated with glycosaminoglycan metabolism | 27 | 8.81e-02 | -0.190000 | 3.23e-01 |
Regulation of innate immune responses to cytosolic DNA | 14 | 2.22e-01 | -0.189000 | 5.13e-01 |
Cell Cycle Checkpoints | 259 | 1.77e-07 | 0.188000 | 8.06e-06 |
Chemokine receptors bind chemokines | 40 | 3.93e-02 | -0.188000 | 1.92e-01 |
SUMOylation of SUMOylation proteins | 35 | 5.47e-02 | 0.188000 | 2.36e-01 |
MET activates RAS signaling | 10 | 3.05e-01 | 0.187000 | 5.97e-01 |
Separation of Sister Chromatids | 168 | 2.91e-05 | 0.187000 | 7.65e-04 |
Negative regulation of FGFR2 signaling | 23 | 1.21e-01 | -0.187000 | 3.75e-01 |
Vpr-mediated nuclear import of PICs | 34 | 6.02e-02 | 0.186000 | 2.54e-01 |
Arachidonic acid metabolism | 44 | 3.29e-02 | -0.186000 | 1.78e-01 |
Deactivation of the beta-catenin transactivating complex | 36 | 5.51e-02 | -0.185000 | 2.36e-01 |
Long-term potentiation | 15 | 2.16e-01 | -0.184000 | 5.08e-01 |
HDMs demethylate histones | 22 | 1.36e-01 | -0.184000 | 3.92e-01 |
Inositol phosphate metabolism | 43 | 3.74e-02 | -0.183000 | 1.88e-01 |
Synthesis of PIPs at the early endosome membrane | 16 | 2.04e-01 | 0.183000 | 4.93e-01 |
Condensation of Prophase Chromosomes | 29 | 8.79e-02 | -0.183000 | 3.23e-01 |
Formation of Incision Complex in GG-NER | 43 | 3.81e-02 | 0.183000 | 1.89e-01 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 42 | 4.08e-02 | -0.182000 | 1.95e-01 |
HIV Transcription Elongation | 42 | 4.08e-02 | -0.182000 | 1.95e-01 |
Tat-mediated elongation of the HIV-1 transcript | 42 | 4.08e-02 | -0.182000 | 1.95e-01 |
Cell death signalling via NRAGE, NRIF and NADE | 69 | 8.92e-03 | -0.182000 | 7.10e-02 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 22 | 1.40e-01 | -0.182000 | 3.99e-01 |
G1/S-Specific Transcription | 29 | 9.07e-02 | 0.181000 | 3.31e-01 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 124 | 4.81e-04 | -0.181000 | 8.43e-03 |
PIWI-interacting RNA (piRNA) biogenesis | 24 | 1.26e-01 | -0.181000 | 3.81e-01 |
Metabolism of carbohydrates | 242 | 1.29e-06 | -0.181000 | 4.41e-05 |
Tight junction interactions | 19 | 1.73e-01 | -0.180000 | 4.55e-01 |
RHO GTPases activate IQGAPs | 11 | 3.01e-01 | 0.180000 | 5.90e-01 |
Cell junction organization | 59 | 1.68e-02 | -0.180000 | 1.10e-01 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 20 | 1.64e-01 | -0.180000 | 4.40e-01 |
Trafficking of AMPA receptors | 20 | 1.64e-01 | -0.180000 | 4.40e-01 |
Serotonin Neurotransmitter Release Cycle | 14 | 2.45e-01 | -0.179000 | 5.35e-01 |
Ephrin signaling | 18 | 1.88e-01 | -0.179000 | 4.78e-01 |
Synthesis of very long-chain fatty acyl-CoAs | 22 | 1.46e-01 | 0.179000 | 4.08e-01 |
Ca-dependent events | 29 | 9.53e-02 | -0.179000 | 3.33e-01 |
Interactions of Rev with host cellular proteins | 37 | 6.02e-02 | 0.179000 | 2.54e-01 |
Postmitotic nuclear pore complex (NPC) reformation | 27 | 1.09e-01 | 0.178000 | 3.57e-01 |
Transcriptional Regulation by E2F6 | 34 | 7.25e-02 | 0.178000 | 2.85e-01 |
Pregnenolone biosynthesis | 10 | 3.32e-01 | -0.177000 | 6.24e-01 |
RNA polymerase II transcribes snRNA genes | 72 | 9.94e-03 | 0.176000 | 7.59e-02 |
PERK regulates gene expression | 31 | 9.12e-02 | 0.175000 | 3.31e-01 |
TP53 Regulates Transcription of Death Receptors and Ligands | 12 | 2.93e-01 | -0.175000 | 5.80e-01 |
Heme biosynthesis | 14 | 2.56e-01 | -0.175000 | 5.51e-01 |
Axon guidance | 459 | 1.35e-10 | -0.175000 | 7.40e-09 |
Signaling by NOTCH1 | 67 | 1.33e-02 | -0.175000 | 9.12e-02 |
Mitotic Telophase/Cytokinesis | 13 | 2.76e-01 | 0.174000 | 5.70e-01 |
Oxidative Stress Induced Senescence | 79 | 7.57e-03 | -0.174000 | 6.43e-02 |
Nervous system development | 478 | 7.99e-11 | -0.173000 | 4.55e-09 |
Chromatin modifying enzymes | 218 | 1.02e-05 | -0.173000 | 2.85e-04 |
Chromatin organization | 218 | 1.02e-05 | -0.173000 | 2.85e-04 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 34 | 8.05e-02 | -0.173000 | 3.06e-01 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 13 | 2.82e-01 | -0.172000 | 5.70e-01 |
Gastrin-CREB signalling pathway via PKC and MAPK | 14 | 2.66e-01 | -0.172000 | 5.62e-01 |
SUMOylation of transcription cofactors | 44 | 4.87e-02 | -0.172000 | 2.21e-01 |
Respiratory electron transport | 101 | 2.90e-03 | -0.171000 | 3.57e-02 |
Caspase activation via Death Receptors in the presence of ligand | 16 | 2.35e-01 | 0.171000 | 5.28e-01 |
Mitotic Prometaphase | 184 | 6.05e-05 | 0.171000 | 1.50e-03 |
Vitamin D (calciferol) metabolism | 10 | 3.48e-01 | -0.171000 | 6.34e-01 |
Regulation of KIT signaling | 15 | 2.51e-01 | -0.171000 | 5.41e-01 |
Branched-chain amino acid catabolism | 21 | 1.75e-01 | 0.171000 | 4.59e-01 |
FGFR2 alternative splicing | 25 | 1.39e-01 | -0.171000 | 3.98e-01 |
PINK1-PRKN Mediated Mitophagy | 21 | 1.76e-01 | -0.171000 | 4.60e-01 |
Non-integrin membrane-ECM interactions | 37 | 7.26e-02 | -0.171000 | 2.85e-01 |
Intrinsic Pathway of Fibrin Clot Formation | 16 | 2.39e-01 | -0.170000 | 5.33e-01 |
Smooth Muscle Contraction | 31 | 1.02e-01 | -0.170000 | 3.44e-01 |
NOTCH3 Intracellular Domain Regulates Transcription | 21 | 1.79e-01 | -0.169000 | 4.65e-01 |
Cell-Cell communication | 88 | 6.17e-03 | -0.169000 | 5.70e-02 |
SUMOylation of transcription factors | 16 | 2.43e-01 | 0.169000 | 5.35e-01 |
HATs acetylate histones | 93 | 4.96e-03 | -0.169000 | 5.10e-02 |
RUNX3 regulates NOTCH signaling | 14 | 2.75e-01 | -0.168000 | 5.70e-01 |
Mitophagy | 28 | 1.23e-01 | -0.168000 | 3.76e-01 |
Activation of SMO | 13 | 2.94e-01 | -0.168000 | 5.81e-01 |
Sealing of the nuclear envelope (NE) by ESCRT-III | 25 | 1.47e-01 | -0.167000 | 4.10e-01 |
Glycosphingolipid metabolism | 36 | 8.24e-02 | -0.167000 | 3.10e-01 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation | 16 | 2.47e-01 | -0.167000 | 5.37e-01 |
APC/C-mediated degradation of cell cycle proteins | 87 | 7.31e-03 | 0.166000 | 6.33e-02 |
Regulation of mitotic cell cycle | 87 | 7.31e-03 | 0.166000 | 6.33e-02 |
Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 2.65e-01 | 0.166000 | 5.62e-01 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 36 | 8.48e-02 | 0.166000 | 3.17e-01 |
Syndecan interactions | 19 | 2.10e-01 | -0.166000 | 5.02e-01 |
CASP8 activity is inhibited | 11 | 3.41e-01 | 0.166000 | 6.27e-01 |
Dimerization of procaspase-8 | 11 | 3.41e-01 | 0.166000 | 6.27e-01 |
Regulation by c-FLIP | 11 | 3.41e-01 | 0.166000 | 6.27e-01 |
Activation of the pre-replicative complex | 32 | 1.06e-01 | 0.165000 | 3.51e-01 |
Signaling by FGFR4 in disease | 11 | 3.43e-01 | 0.165000 | 6.30e-01 |
Rev-mediated nuclear export of HIV RNA | 35 | 9.11e-02 | 0.165000 | 3.31e-01 |
Signaling by FGFR1 in disease | 30 | 1.18e-01 | 0.165000 | 3.69e-01 |
Degradation of the extracellular matrix | 81 | 1.04e-02 | -0.165000 | 7.79e-02 |
ECM proteoglycans | 36 | 8.78e-02 | -0.164000 | 3.23e-01 |
G-protein mediated events | 44 | 6.03e-02 | -0.164000 | 2.54e-01 |
Signaling by FGFR2 IIIa TM | 18 | 2.30e-01 | -0.163000 | 5.24e-01 |
p75 NTR receptor-mediated signalling | 88 | 8.08e-03 | -0.163000 | 6.77e-02 |
HuR (ELAVL1) binds and stabilizes mRNA | 10 | 3.74e-01 | 0.162000 | 6.54e-01 |
RAF-independent MAPK1/3 activation | 21 | 1.98e-01 | -0.162000 | 4.87e-01 |
TICAM1,TRAF6-dependent induction of TAK1 complex | 11 | 3.52e-01 | -0.162000 | 6.37e-01 |
G0 and Early G1 | 27 | 1.45e-01 | 0.162000 | 4.08e-01 |
Base Excision Repair | 58 | 3.30e-02 | -0.162000 | 1.78e-01 |
Integrin cell surface interactions | 52 | 4.37e-02 | -0.162000 | 2.06e-01 |
Estrogen-dependent gene expression | 99 | 5.44e-03 | -0.162000 | 5.23e-02 |
Translation | 295 | 1.90e-06 | -0.161000 | 6.18e-05 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 2.96e-01 | 0.161000 | 5.84e-01 |
Negative regulation of the PI3K/AKT network | 87 | 9.38e-03 | -0.161000 | 7.28e-02 |
Formation of the Early Elongation Complex | 33 | 1.10e-01 | -0.161000 | 3.58e-01 |
Formation of the HIV-1 Early Elongation Complex | 33 | 1.10e-01 | -0.161000 | 3.58e-01 |
Polo-like kinase mediated events | 15 | 2.82e-01 | 0.160000 | 5.70e-01 |
PECAM1 interactions | 12 | 3.36e-01 | -0.160000 | 6.25e-01 |
Cellular hexose transport | 15 | 2.84e-01 | -0.160000 | 5.70e-01 |
Protein-protein interactions at synapses | 59 | 3.40e-02 | -0.160000 | 1.80e-01 |
Lysosome Vesicle Biogenesis | 32 | 1.20e-01 | -0.159000 | 3.72e-01 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 13 | 3.21e-01 | 0.159000 | 6.10e-01 |
Heme degradation | 10 | 3.87e-01 | -0.158000 | 6.62e-01 |
RAF activation | 32 | 1.23e-01 | 0.158000 | 3.76e-01 |
Phase 4 - resting membrane potential | 10 | 3.90e-01 | 0.157000 | 6.66e-01 |
Elastic fibre formation | 32 | 1.25e-01 | -0.157000 | 3.80e-01 |
Initial triggering of complement | 78 | 1.73e-02 | 0.156000 | 1.11e-01 |
Platelet calcium homeostasis | 22 | 2.06e-01 | -0.156000 | 4.93e-01 |
FGFR2 mutant receptor activation | 22 | 2.09e-01 | -0.155000 | 5.01e-01 |
Synaptic adhesion-like molecules | 16 | 2.85e-01 | -0.155000 | 5.70e-01 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 17 | 2.70e-01 | -0.154000 | 5.67e-01 |
Signaling by NTRKs | 117 | 3.91e-03 | -0.154000 | 4.35e-02 |
cGMP effects | 12 | 3.55e-01 | -0.154000 | 6.39e-01 |
G alpha (z) signalling events | 36 | 1.09e-01 | -0.154000 | 3.57e-01 |
Processing of DNA double-strand break ends | 71 | 2.49e-02 | 0.154000 | 1.47e-01 |
DNA Replication | 126 | 3.02e-03 | 0.153000 | 3.69e-02 |
G2/M Checkpoints | 139 | 1.88e-03 | 0.153000 | 2.68e-02 |
Signaling by NTRK1 (TRKA) | 102 | 7.90e-03 | -0.152000 | 6.66e-02 |
HSF1 activation | 26 | 1.81e-01 | -0.152000 | 4.67e-01 |
Extra-nuclear estrogen signaling | 66 | 3.33e-02 | -0.151000 | 1.79e-01 |
ESR-mediated signaling | 161 | 9.11e-04 | -0.151000 | 1.54e-02 |
PLC beta mediated events | 43 | 8.58e-02 | -0.151000 | 3.20e-01 |
Signaling by FGFR3 in disease | 13 | 3.45e-01 | 0.151000 | 6.31e-01 |
Signaling by FGFR3 point mutants in cancer | 13 | 3.45e-01 | 0.151000 | 6.31e-01 |
Ion homeostasis | 41 | 9.41e-02 | -0.151000 | 3.33e-01 |
Signaling by Nuclear Receptors | 219 | 1.24e-04 | -0.150000 | 2.88e-03 |
NOTCH1 Intracellular Domain Regulates Transcription | 45 | 8.13e-02 | -0.150000 | 3.09e-01 |
Formation of HIV elongation complex in the absence of HIV Tat | 44 | 8.66e-02 | -0.149000 | 3.21e-01 |
Caspase-mediated cleavage of cytoskeletal proteins | 12 | 3.71e-01 | -0.149000 | 6.52e-01 |
Phase 2 - plateau phase | 11 | 3.93e-01 | 0.149000 | 6.66e-01 |
Late endosomal microautophagy | 30 | 1.60e-01 | -0.148000 | 4.34e-01 |
RUNX2 regulates osteoblast differentiation | 19 | 2.64e-01 | -0.148000 | 5.62e-01 |
TRAF6-mediated induction of TAK1 complex within TLR4 complex | 16 | 3.08e-01 | -0.147000 | 5.98e-01 |
Class B/2 (Secretin family receptors) | 57 | 5.47e-02 | -0.147000 | 2.36e-01 |
PI3K Cascade | 30 | 1.64e-01 | -0.147000 | 4.40e-01 |
BBSome-mediated cargo-targeting to cilium | 22 | 2.34e-01 | 0.147000 | 5.28e-01 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 75 | 2.83e-02 | 0.146000 | 1.59e-01 |
Infection with Mycobacterium tuberculosis | 26 | 1.97e-01 | -0.146000 | 4.87e-01 |
B-WICH complex positively regulates rRNA expression | 44 | 9.37e-02 | -0.146000 | 3.33e-01 |
TGF-beta receptor signaling activates SMADs | 32 | 1.55e-01 | -0.145000 | 4.27e-01 |
Lagging Strand Synthesis | 20 | 2.61e-01 | 0.145000 | 5.58e-01 |
RHO GTPases Activate Formins | 117 | 6.77e-03 | 0.145000 | 6.01e-02 |
Developmental Biology | 738 | 2.08e-11 | -0.145000 | 1.36e-09 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 80 | 2.52e-02 | -0.145000 | 1.47e-01 |
Mitotic Metaphase and Anaphase | 225 | 1.88e-04 | 0.144000 | 4.03e-03 |
Creation of C4 and C2 activators | 71 | 3.55e-02 | 0.144000 | 1.83e-01 |
Glycogen breakdown (glycogenolysis) | 13 | 3.69e-01 | -0.144000 | 6.50e-01 |
Positive epigenetic regulation of rRNA expression | 59 | 5.61e-02 | -0.144000 | 2.39e-01 |
Signaling by EGFR in Cancer | 23 | 2.33e-01 | -0.144000 | 5.27e-01 |
Diseases associated with O-glycosylation of proteins | 49 | 8.24e-02 | -0.143000 | 3.10e-01 |
Plasma lipoprotein remodeling | 19 | 2.81e-01 | -0.143000 | 5.70e-01 |
Platelet Adhesion to exposed collagen | 13 | 3.72e-01 | -0.143000 | 6.53e-01 |
Nicotinamide salvaging | 15 | 3.41e-01 | 0.142000 | 6.27e-01 |
ADORA2B mediated anti-inflammatory cytokines production | 74 | 3.46e-02 | -0.142000 | 1.82e-01 |
Mitochondrial protein import | 64 | 4.96e-02 | -0.142000 | 2.23e-01 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 46 | 9.63e-02 | -0.142000 | 3.34e-01 |
Transcriptional Regulation by MECP2 | 47 | 9.41e-02 | -0.141000 | 3.33e-01 |
Signaling by WNT in cancer | 30 | 1.81e-01 | -0.141000 | 4.67e-01 |
Classical antibody-mediated complement activation | 69 | 4.29e-02 | 0.141000 | 2.03e-01 |
Mitotic Anaphase | 224 | 2.79e-04 | 0.141000 | 5.30e-03 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 76 | 3.37e-02 | 0.141000 | 1.79e-01 |
Constitutive Signaling by Aberrant PI3K in Cancer | 54 | 7.38e-02 | -0.141000 | 2.88e-01 |
TRAF3-dependent IRF activation pathway | 13 | 3.81e-01 | 0.140000 | 6.56e-01 |
Response to elevated platelet cytosolic Ca2+ | 108 | 1.20e-02 | -0.140000 | 8.67e-02 |
TP53 Regulates Transcription of Caspase Activators and Caspases | 12 | 4.04e-01 | 0.139000 | 6.74e-01 |
Formation of apoptosome | 11 | 4.25e-01 | 0.139000 | 6.85e-01 |
Regulation of the apoptosome activity | 11 | 4.25e-01 | 0.139000 | 6.85e-01 |
ATF4 activates genes in response to endoplasmic reticulum stress | 26 | 2.22e-01 | 0.138000 | 5.13e-01 |
Platelet degranulation | 104 | 1.53e-02 | -0.138000 | 1.01e-01 |
RET signaling | 32 | 1.78e-01 | -0.137000 | 4.65e-01 |
Transcriptional regulation of granulopoiesis | 46 | 1.08e-01 | -0.137000 | 3.57e-01 |
Biotin transport and metabolism | 11 | 4.34e-01 | -0.136000 | 6.96e-01 |
RNA Polymerase I Promoter Clearance | 63 | 6.15e-02 | -0.136000 | 2.56e-01 |
RNA Polymerase I Transcription | 63 | 6.15e-02 | -0.136000 | 2.56e-01 |
Scavenging of heme from plasma | 71 | 4.85e-02 | 0.135000 | 2.21e-01 |
Glutamate and glutamine metabolism | 12 | 4.17e-01 | -0.135000 | 6.82e-01 |
Signaling by Receptor Tyrosine Kinases | 413 | 2.41e-06 | -0.135000 | 7.67e-05 |
G beta:gamma signalling through CDC42 | 17 | 3.35e-01 | 0.135000 | 6.25e-01 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 11 | 4.38e-01 | 0.135000 | 6.97e-01 |
tRNA Aminoacylation | 42 | 1.31e-01 | 0.135000 | 3.90e-01 |
Signaling by NOTCH | 183 | 1.67e-03 | -0.135000 | 2.49e-02 |
Regulation of APC/C activators between G1/S and early anaphase | 80 | 3.79e-02 | 0.134000 | 1.89e-01 |
Synthesis of DNA | 119 | 1.16e-02 | 0.134000 | 8.40e-02 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 73 | 4.78e-02 | 0.134000 | 2.19e-01 |
Transport of Mature Transcript to Cytoplasm | 81 | 3.75e-02 | 0.134000 | 1.88e-01 |
Assembly and cell surface presentation of NMDA receptors | 19 | 3.13e-01 | -0.134000 | 6.04e-01 |
Regulation of Complement cascade | 94 | 2.51e-02 | 0.134000 | 1.47e-01 |
Telomere Maintenance | 80 | 3.91e-02 | -0.133000 | 1.92e-01 |
Signaling by Hippo | 18 | 3.28e-01 | 0.133000 | 6.18e-01 |
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | 11 | 4.46e-01 | -0.133000 | 6.98e-01 |
RNA Polymerase III Chain Elongation | 18 | 3.31e-01 | -0.132000 | 6.22e-01 |
Erythrocytes take up carbon dioxide and release oxygen | 11 | 4.49e-01 | -0.132000 | 6.98e-01 |
O2/CO2 exchange in erythrocytes | 11 | 4.49e-01 | -0.132000 | 6.98e-01 |
Amino acid transport across the plasma membrane | 24 | 2.63e-01 | -0.132000 | 5.62e-01 |
Sema4D induced cell migration and growth-cone collapse | 19 | 3.21e-01 | -0.132000 | 6.10e-01 |
Constitutive Signaling by EGFRvIII | 14 | 3.94e-01 | 0.131000 | 6.66e-01 |
Signaling by EGFRvIII in Cancer | 14 | 3.94e-01 | 0.131000 | 6.66e-01 |
Interleukin-27 signaling | 11 | 4.51e-01 | 0.131000 | 6.99e-01 |
Cellular Senescence | 144 | 6.60e-03 | -0.131000 | 5.92e-02 |
ZBP1(DAI) mediated induction of type I IFNs | 20 | 3.11e-01 | -0.131000 | 6.00e-01 |
Switching of origins to a post-replicative state | 90 | 3.21e-02 | 0.131000 | 1.75e-01 |
ERKs are inactivated | 13 | 4.17e-01 | -0.130000 | 6.82e-01 |
Complement cascade | 98 | 2.63e-02 | 0.130000 | 1.51e-01 |
CD28 co-stimulation | 33 | 1.97e-01 | -0.130000 | 4.87e-01 |
Activation of the AP-1 family of transcription factors | 10 | 4.78e-01 | -0.130000 | 7.17e-01 |
Interactions of Vpr with host cellular proteins | 37 | 1.72e-01 | 0.130000 | 4.53e-01 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 24 | 2.72e-01 | -0.130000 | 5.67e-01 |
Cellular responses to stress | 500 | 6.97e-07 | -0.130000 | 2.51e-05 |
Cross-presentation of soluble exogenous antigens (endosomes) | 48 | 1.20e-01 | 0.130000 | 3.74e-01 |
Signaling by cytosolic FGFR1 fusion mutants | 17 | 3.56e-01 | 0.129000 | 6.39e-01 |
EPHB-mediated forward signaling | 33 | 1.99e-01 | 0.129000 | 4.89e-01 |
Apoptotic factor-mediated response | 18 | 3.44e-01 | 0.129000 | 6.31e-01 |
Nuclear Envelope Breakdown | 53 | 1.06e-01 | 0.128000 | 3.51e-01 |
Glyoxylate metabolism and glycine degradation | 24 | 2.76e-01 | 0.128000 | 5.70e-01 |
Cellular responses to external stimuli | 506 | 7.84e-07 | -0.128000 | 2.75e-05 |
Cargo trafficking to the periciliary membrane | 47 | 1.28e-01 | 0.128000 | 3.87e-01 |
DNA Double Strand Break Response | 47 | 1.29e-01 | -0.128000 | 3.87e-01 |
mitochondrial fatty acid beta-oxidation of saturated fatty acids | 11 | 4.63e-01 | -0.128000 | 7.07e-01 |
SHC-mediated cascade:FGFR2 | 12 | 4.44e-01 | 0.128000 | 6.98e-01 |
Cholesterol biosynthesis | 24 | 2.84e-01 | 0.126000 | 5.70e-01 |
Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 1.90e-01 | 0.126000 | 4.80e-01 |
Diseases of mitotic cell cycle | 36 | 1.90e-01 | 0.126000 | 4.80e-01 |
Mitotic G2-G2/M phases | 181 | 3.43e-03 | 0.126000 | 3.94e-02 |
Metabolism of amino acids and derivatives | 326 | 9.17e-05 | -0.126000 | 2.20e-03 |
Signaling by Non-Receptor Tyrosine Kinases | 48 | 1.31e-01 | -0.126000 | 3.90e-01 |
Signaling by PTK6 | 48 | 1.31e-01 | -0.126000 | 3.90e-01 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 14 | 4.15e-01 | 0.126000 | 6.82e-01 |
Prolactin receptor signaling | 11 | 4.70e-01 | 0.126000 | 7.11e-01 |
Oncogene Induced Senescence | 33 | 2.11e-01 | -0.126000 | 5.02e-01 |
Interleukin-4 and Interleukin-13 signaling | 94 | 3.52e-02 | -0.126000 | 1.83e-01 |
Translation of Replicase and Assembly of the Replication Transcription Complex | 12 | 4.52e-01 | 0.125000 | 7.00e-01 |
Orc1 removal from chromatin | 70 | 7.02e-02 | 0.125000 | 2.79e-01 |
TCF dependent signaling in response to WNT | 167 | 5.32e-03 | -0.125000 | 5.16e-02 |
The citric acid (TCA) cycle and respiratory electron transport | 172 | 4.80e-03 | -0.125000 | 5.05e-02 |
Signaling by FGFR2 | 60 | 9.50e-02 | -0.125000 | 3.33e-01 |
Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) | 10 | 4.95e-01 | 0.125000 | 7.32e-01 |
Nitric oxide stimulates guanylate cyclase | 15 | 4.04e-01 | -0.125000 | 6.74e-01 |
Recycling pathway of L1 | 26 | 2.72e-01 | -0.124000 | 5.67e-01 |
S Phase | 161 | 6.54e-03 | 0.124000 | 5.92e-02 |
Aquaporin-mediated transport | 38 | 1.85e-01 | -0.124000 | 4.75e-01 |
Keratinization | 34 | 2.11e-01 | -0.124000 | 5.02e-01 |
InlB-mediated entry of Listeria monocytogenes into host cell | 12 | 4.57e-01 | -0.124000 | 7.02e-01 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 72 | 6.89e-02 | 0.124000 | 2.75e-01 |
PCP/CE pathway | 87 | 4.60e-02 | -0.124000 | 2.14e-01 |
RIP-mediated NFkB activation via ZBP1 | 17 | 3.77e-01 | -0.124000 | 6.55e-01 |
Activation of BH3-only proteins | 30 | 2.43e-01 | -0.123000 | 5.35e-01 |
CDT1 association with the CDC6:ORC:origin complex | 58 | 1.05e-01 | 0.123000 | 3.51e-01 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 4.43e-01 | 0.123000 | 6.98e-01 |
G2/M Transition | 179 | 4.62e-03 | 0.123000 | 4.90e-02 |
Nucleobase biosynthesis | 13 | 4.45e-01 | -0.122000 | 6.98e-01 |
Interferon gamma signaling | 83 | 5.41e-02 | 0.122000 | 2.36e-01 |
Glucagon signaling in metabolic regulation | 27 | 2.74e-01 | -0.122000 | 5.69e-01 |
SARS-CoV-2 Infection | 63 | 9.51e-02 | -0.122000 | 3.33e-01 |
Regulation of beta-cell development | 20 | 3.47e-01 | -0.122000 | 6.33e-01 |
G1/S Transition | 130 | 1.69e-02 | 0.121000 | 1.10e-01 |
Inflammasomes | 20 | 3.48e-01 | 0.121000 | 6.34e-01 |
FOXO-mediated transcription of cell cycle genes | 15 | 4.17e-01 | -0.121000 | 6.82e-01 |
Carboxyterminal post-translational modifications of tubulin | 27 | 2.77e-01 | -0.121000 | 5.70e-01 |
TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 27 | 2.77e-01 | -0.121000 | 5.70e-01 |
Platelet activation, signaling and aggregation | 219 | 2.12e-03 | -0.120000 | 2.81e-02 |
DCC mediated attractive signaling | 13 | 4.54e-01 | -0.120000 | 7.00e-01 |
Signaling by ERBB2 | 44 | 1.69e-01 | -0.120000 | 4.49e-01 |
CS/DS degradation | 10 | 5.12e-01 | -0.120000 | 7.37e-01 |
Caspase activation via extrinsic apoptotic signalling pathway | 25 | 3.01e-01 | 0.120000 | 5.90e-01 |
Regulation of FOXO transcriptional activity by acetylation | 10 | 5.14e-01 | -0.119000 | 7.37e-01 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 54 | 1.32e-01 | -0.118000 | 3.90e-01 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 54 | 1.32e-01 | -0.118000 | 3.90e-01 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 54 | 1.32e-01 | -0.118000 | 3.90e-01 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 54 | 1.32e-01 | -0.118000 | 3.90e-01 |
Signaling by NOTCH1 in Cancer | 54 | 1.32e-01 | -0.118000 | 3.90e-01 |
Circadian Clock | 67 | 9.56e-02 | -0.118000 | 3.33e-01 |
Synthesis of bile acids and bile salts | 24 | 3.18e-01 | 0.118000 | 6.08e-01 |
TICAM1-dependent activation of IRF3/IRF7 | 12 | 4.80e-01 | -0.118000 | 7.19e-01 |
Intracellular signaling by second messengers | 273 | 8.21e-04 | -0.118000 | 1.40e-02 |
EPH-Ephrin signaling | 80 | 6.97e-02 | -0.117000 | 2.78e-01 |
Mitotic G1 phase and G1/S transition | 148 | 1.39e-02 | 0.117000 | 9.38e-02 |
O-glycosylation of TSR domain-containing proteins | 27 | 2.93e-01 | -0.117000 | 5.80e-01 |
MAP2K and MAPK activation | 34 | 2.38e-01 | -0.117000 | 5.32e-01 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 20 | 3.67e-01 | -0.116000 | 6.50e-01 |
Neurodegenerative Diseases | 20 | 3.67e-01 | -0.116000 | 6.50e-01 |
O-linked glycosylation | 84 | 6.56e-02 | -0.116000 | 2.67e-01 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 37 | 2.22e-01 | -0.116000 | 5.13e-01 |
Transcriptional regulation by RUNX1 | 185 | 6.97e-03 | -0.115000 | 6.10e-02 |
IRAK1 recruits IKK complex | 10 | 5.30e-01 | -0.115000 | 7.45e-01 |
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | 10 | 5.30e-01 | -0.115000 | 7.45e-01 |
G beta:gamma signalling through PI3Kgamma | 22 | 3.53e-01 | -0.114000 | 6.37e-01 |
Synthesis, secretion, and deacylation of Ghrelin | 11 | 5.12e-01 | 0.114000 | 7.37e-01 |
Chaperone Mediated Autophagy | 20 | 3.77e-01 | -0.114000 | 6.55e-01 |
Metabolism of cofactors | 19 | 3.90e-01 | 0.114000 | 6.66e-01 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 72 | 9.47e-02 | 0.114000 | 3.33e-01 |
RUNX3 regulates p14-ARF | 10 | 5.33e-01 | -0.114000 | 7.48e-01 |
RHO GTPases activate CIT | 18 | 4.03e-01 | 0.114000 | 6.74e-01 |
Cobalamin (Cbl, vitamin B12) transport and metabolism | 17 | 4.17e-01 | 0.114000 | 6.82e-01 |
Semaphorin interactions | 57 | 1.38e-01 | -0.114000 | 3.95e-01 |
Cargo concentration in the ER | 30 | 2.83e-01 | 0.113000 | 5.70e-01 |
Signaling by ERBB2 ECD mutants | 15 | 4.48e-01 | 0.113000 | 6.98e-01 |
RNA Polymerase I Promoter Escape | 44 | 1.95e-01 | -0.113000 | 4.85e-01 |
Voltage gated Potassium channels | 27 | 3.10e-01 | -0.113000 | 6.00e-01 |
Metabolism of nitric oxide: NOS3 activation and regulation | 12 | 4.99e-01 | -0.113000 | 7.33e-01 |
Signaling by FGFR4 | 31 | 2.77e-01 | -0.113000 | 5.70e-01 |
DNA Damage/Telomere Stress Induced Senescence | 44 | 1.96e-01 | -0.113000 | 4.86e-01 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 59 | 1.35e-01 | 0.112000 | 3.92e-01 |
Suppression of phagosomal maturation | 12 | 5.01e-01 | -0.112000 | 7.33e-01 |
Tryptophan catabolism | 12 | 5.01e-01 | 0.112000 | 7.33e-01 |
VEGFR2 mediated cell proliferation | 18 | 4.10e-01 | -0.112000 | 6.77e-01 |
Downregulation of TGF-beta receptor signaling | 26 | 3.23e-01 | -0.112000 | 6.11e-01 |
Visual phototransduction | 60 | 1.34e-01 | -0.112000 | 3.91e-01 |
Downstream signaling of activated FGFR2 | 19 | 3.99e-01 | 0.112000 | 6.73e-01 |
TP53 Regulates Transcription of DNA Repair Genes | 61 | 1.33e-01 | -0.111000 | 3.90e-01 |
DNA Replication Pre-Initiation | 83 | 7.96e-02 | 0.111000 | 3.05e-01 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 35 | 2.56e-01 | -0.111000 | 5.50e-01 |
FCGR activation | 76 | 9.47e-02 | 0.111000 | 3.33e-01 |
Downstream signaling of activated FGFR1 | 20 | 3.92e-01 | 0.111000 | 6.66e-01 |
Interleukin-12 family signaling | 54 | 1.60e-01 | 0.110000 | 4.34e-01 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 104 | 5.20e-02 | 0.110000 | 2.32e-01 |
SARS-CoV-1 Infection | 47 | 1.92e-01 | -0.110000 | 4.83e-01 |
Meiotic synapsis | 45 | 2.02e-01 | -0.110000 | 4.93e-01 |
Keratan sulfate biosynthesis | 22 | 3.74e-01 | -0.110000 | 6.54e-01 |
FRS-mediated FGFR2 signaling | 14 | 4.81e-01 | 0.109000 | 7.19e-01 |
Phase I - Functionalization of compounds | 64 | 1.33e-01 | -0.109000 | 3.91e-01 |
Integrin signaling | 22 | 3.78e-01 | -0.109000 | 6.55e-01 |
Synthesis of glycosylphosphatidylinositol (GPI) | 17 | 4.40e-01 | 0.108000 | 6.98e-01 |
XBP1(S) activates chaperone genes | 47 | 2.00e-01 | -0.108000 | 4.90e-01 |
Formation of the cornified envelope | 21 | 3.92e-01 | -0.108000 | 6.66e-01 |
MET activates PTK2 signaling | 15 | 4.70e-01 | -0.108000 | 7.11e-01 |
Nucleotide salvage | 21 | 3.94e-01 | -0.108000 | 6.66e-01 |
Insulin receptor signalling cascade | 39 | 2.45e-01 | -0.108000 | 5.35e-01 |
Inwardly rectifying K+ channels | 24 | 3.62e-01 | 0.107000 | 6.47e-01 |
IRE1alpha activates chaperones | 49 | 1.93e-01 | -0.107000 | 4.83e-01 |
CDK-mediated phosphorylation and removal of Cdc6 | 72 | 1.15e-01 | 0.107000 | 3.65e-01 |
mRNA Splicing - Minor Pathway | 52 | 1.81e-01 | -0.107000 | 4.67e-01 |
ERBB2 Regulates Cell Motility | 10 | 5.58e-01 | -0.107000 | 7.70e-01 |
Fertilization | 13 | 5.04e-01 | -0.107000 | 7.33e-01 |
Trafficking and processing of endosomal TLR | 13 | 5.05e-01 | 0.107000 | 7.33e-01 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 15 | 4.75e-01 | -0.107000 | 7.15e-01 |
Vasopressin regulates renal water homeostasis via Aquaporins | 34 | 2.82e-01 | -0.107000 | 5.70e-01 |
CD22 mediated BCR regulation | 59 | 1.57e-01 | 0.106000 | 4.31e-01 |
Processing of Capped Intronless Pre-mRNA | 28 | 3.30e-01 | 0.106000 | 6.22e-01 |
Dopamine Neurotransmitter Release Cycle | 19 | 4.24e-01 | -0.106000 | 6.85e-01 |
MyD88 cascade initiated on plasma membrane | 82 | 9.78e-02 | -0.106000 | 3.37e-01 |
Toll Like Receptor 10 (TLR10) Cascade | 82 | 9.78e-02 | -0.106000 | 3.37e-01 |
Toll Like Receptor 5 (TLR5) Cascade | 82 | 9.78e-02 | -0.106000 | 3.37e-01 |
G alpha (q) signalling events | 134 | 3.47e-02 | -0.106000 | 1.82e-01 |
Regulation of RUNX2 expression and activity | 67 | 1.35e-01 | 0.106000 | 3.92e-01 |
Presynaptic function of Kainate receptors | 18 | 4.38e-01 | -0.106000 | 6.97e-01 |
SHC-mediated cascade:FGFR1 | 12 | 5.27e-01 | 0.105000 | 7.43e-01 |
Molecules associated with elastic fibres | 22 | 3.93e-01 | -0.105000 | 6.66e-01 |
Cell Cycle, Mitotic | 501 | 5.66e-05 | 0.105000 | 1.43e-03 |
Peptide hormone metabolism | 49 | 2.04e-01 | 0.105000 | 4.93e-01 |
Constitutive Signaling by Overexpressed ERBB2 | 11 | 5.47e-01 | 0.105000 | 7.62e-01 |
Cell Cycle | 623 | 8.32e-06 | 0.105000 | 2.47e-04 |
G alpha (s) signalling events | 145 | 2.98e-02 | 0.105000 | 1.66e-01 |
DNA Double-Strand Break Repair | 135 | 3.60e-02 | 0.104000 | 1.84e-01 |
Regulation of Apoptosis | 52 | 1.94e-01 | 0.104000 | 4.83e-01 |
SUMOylation of DNA damage response and repair proteins | 77 | 1.15e-01 | 0.104000 | 3.65e-01 |
RNA Pol II CTD phosphorylation and interaction with CE | 27 | 3.50e-01 | -0.104000 | 6.36e-01 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 27 | 3.50e-01 | -0.104000 | 6.36e-01 |
Interleukin-12 signaling | 44 | 2.33e-01 | 0.104000 | 5.27e-01 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 16 | 4.72e-01 | 0.104000 | 7.13e-01 |
Transport of inorganic cations/anions and amino acids/oligopeptides | 80 | 1.09e-01 | -0.104000 | 3.57e-01 |
FGFR1 mutant receptor activation | 23 | 3.91e-01 | 0.103000 | 6.66e-01 |
PIP3 activates AKT signaling | 241 | 5.74e-03 | -0.103000 | 5.45e-02 |
Cell recruitment (pro-inflammatory response) | 22 | 4.02e-01 | 0.103000 | 6.74e-01 |
Purinergic signaling in leishmaniasis infection | 22 | 4.02e-01 | 0.103000 | 6.74e-01 |
Cell-cell junction organization | 38 | 2.71e-01 | -0.103000 | 5.67e-01 |
Initiation of Nuclear Envelope (NE) Reformation | 19 | 4.37e-01 | 0.103000 | 6.96e-01 |
IRS-related events triggered by IGF1R | 35 | 2.93e-01 | -0.103000 | 5.80e-01 |
Signaling by high-kinase activity BRAF mutants | 31 | 3.23e-01 | -0.103000 | 6.11e-01 |
Nephrin family interactions | 18 | 4.52e-01 | -0.102000 | 6.99e-01 |
Signaling by WNT | 255 | 4.86e-03 | -0.102000 | 5.07e-02 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 73 | 1.31e-01 | 0.102000 | 3.90e-01 |
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 5.58e-01 | -0.102000 | 7.70e-01 |
TNFs bind their physiological receptors | 25 | 3.78e-01 | -0.102000 | 6.55e-01 |
G beta:gamma signalling through PLC beta | 17 | 4.68e-01 | -0.102000 | 7.11e-01 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 53 | 2.01e-01 | 0.102000 | 4.91e-01 |
G alpha (12/13) signalling events | 68 | 1.48e-01 | -0.101000 | 4.12e-01 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 19 | 4.45e-01 | -0.101000 | 6.98e-01 |
Regulation of PTEN mRNA translation | 13 | 5.27e-01 | 0.101000 | 7.43e-01 |
IGF1R signaling cascade | 36 | 2.93e-01 | -0.101000 | 5.80e-01 |
Diseases of glycosylation | 110 | 6.80e-02 | -0.101000 | 2.74e-01 |
Bile acid and bile salt metabolism | 28 | 3.57e-01 | 0.101000 | 6.39e-01 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 3.68e-01 | -0.100000 | 6.50e-01 |
Neutrophil degranulation | 458 | 2.42e-04 | -0.100000 | 4.80e-03 |
Apoptosis induced DNA fragmentation | 10 | 5.84e-01 | 0.100000 | 7.84e-01 |
Cargo recognition for clathrin-mediated endocytosis | 90 | 1.01e-01 | -0.099900 | 3.44e-01 |
PI3K events in ERBB2 signaling | 11 | 5.66e-01 | -0.099800 | 7.74e-01 |
rRNA modification in the nucleus and cytosol | 59 | 1.86e-01 | -0.099600 | 4.76e-01 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 79 | 1.26e-01 | -0.099500 | 3.81e-01 |
MECP2 regulates neuronal receptors and channels | 13 | 5.35e-01 | -0.099300 | 7.51e-01 |
TICAM1, RIP1-mediated IKK complex recruitment | 19 | 4.54e-01 | 0.099200 | 7.00e-01 |
Downstream signaling of activated FGFR3 | 16 | 4.92e-01 | 0.099100 | 7.28e-01 |
Defective B3GALTL causes Peters-plus syndrome (PpS) | 26 | 3.82e-01 | -0.099000 | 6.56e-01 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 4.43e-01 | 0.099000 | 6.98e-01 |
Synthesis of PE | 12 | 5.53e-01 | 0.098900 | 7.68e-01 |
Thrombin signalling through proteinase activated receptors (PARs) | 27 | 3.75e-01 | -0.098700 | 6.54e-01 |
Binding and Uptake of Ligands by Scavenger Receptors | 92 | 1.02e-01 | 0.098700 | 3.44e-01 |
SCF(Skp2)-mediated degradation of p27/p21 | 60 | 1.86e-01 | 0.098700 | 4.76e-01 |
Homology Directed Repair | 110 | 7.43e-02 | 0.098500 | 2.89e-01 |
Transcription of E2F targets under negative control by DREAM complex | 19 | 4.58e-01 | 0.098400 | 7.02e-01 |
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 14 | 5.24e-01 | 0.098400 | 7.41e-01 |
SUMOylation of intracellular receptors | 27 | 3.77e-01 | -0.098300 | 6.55e-01 |
Phase 0 - rapid depolarisation | 23 | 4.15e-01 | 0.098300 | 6.82e-01 |
Metabolism of folate and pterines | 17 | 4.83e-01 | 0.098200 | 7.22e-01 |
RUNX2 regulates bone development | 24 | 4.08e-01 | -0.097600 | 6.76e-01 |
DNA Damage Recognition in GG-NER | 38 | 2.98e-01 | -0.097600 | 5.86e-01 |
Post-chaperonin tubulin folding pathway | 19 | 4.62e-01 | -0.097500 | 7.07e-01 |
Role of LAT2/NTAL/LAB on calcium mobilization | 74 | 1.47e-01 | 0.097500 | 4.10e-01 |
Diseases of metabolism | 190 | 2.07e-02 | -0.097300 | 1.27e-01 |
Signaling by FGFR | 69 | 1.63e-01 | -0.097100 | 4.40e-01 |
RHO GTPases activate PKNs | 47 | 2.50e-01 | -0.097000 | 5.41e-01 |
Interleukin-17 signaling | 68 | 1.67e-01 | -0.096800 | 4.46e-01 |
Nonhomologous End-Joining (NHEJ) | 42 | 2.81e-01 | 0.096100 | 5.70e-01 |
mRNA 3’-end processing | 56 | 2.17e-01 | 0.095300 | 5.08e-01 |
The NLRP3 inflammasome | 15 | 5.23e-01 | 0.095200 | 7.41e-01 |
G1/S DNA Damage Checkpoints | 66 | 1.82e-01 | 0.095100 | 4.67e-01 |
Signaling by VEGF | 97 | 1.07e-01 | -0.094700 | 3.54e-01 |
Activation of NMDA receptors and postsynaptic events | 60 | 2.05e-01 | -0.094600 | 4.93e-01 |
Early Phase of HIV Life Cycle | 14 | 5.40e-01 | 0.094600 | 7.56e-01 |
VxPx cargo-targeting to cilium | 19 | 4.76e-01 | 0.094500 | 7.16e-01 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 64 | 1.91e-01 | -0.094500 | 4.81e-01 |
Mitochondrial calcium ion transport | 22 | 4.45e-01 | -0.094100 | 6.98e-01 |
p53-Dependent G1 DNA Damage Response | 64 | 1.94e-01 | 0.094000 | 4.83e-01 |
p53-Dependent G1/S DNA damage checkpoint | 64 | 1.94e-01 | 0.094000 | 4.83e-01 |
Phase II - Conjugation of compounds | 66 | 1.89e-01 | 0.093500 | 4.79e-01 |
HCMV Late Events | 69 | 1.80e-01 | -0.093400 | 4.66e-01 |
Rab regulation of trafficking | 120 | 7.77e-02 | -0.093200 | 2.99e-01 |
APC/C:Cdc20 mediated degradation of Securin | 67 | 1.88e-01 | 0.093000 | 4.78e-01 |
M Phase | 360 | 2.48e-03 | 0.092800 | 3.23e-02 |
APC-Cdc20 mediated degradation of Nek2A | 26 | 4.14e-01 | 0.092600 | 6.82e-01 |
Uptake and actions of bacterial toxins | 27 | 4.07e-01 | -0.092200 | 6.76e-01 |
Signaling by Erythropoietin | 24 | 4.35e-01 | -0.092000 | 6.96e-01 |
NoRC negatively regulates rRNA expression | 59 | 2.24e-01 | -0.091600 | 5.16e-01 |
IKK complex recruitment mediated by RIP1 | 23 | 4.48e-01 | 0.091500 | 6.98e-01 |
Glucagon-type ligand receptors | 20 | 4.80e-01 | -0.091300 | 7.19e-01 |
Signaling by BMP | 21 | 4.70e-01 | 0.091100 | 7.11e-01 |
ERK/MAPK targets | 22 | 4.60e-01 | -0.091000 | 7.05e-01 |
Assembly of the pre-replicative complex | 67 | 1.98e-01 | 0.091000 | 4.87e-01 |
Removal of the Flap Intermediate | 14 | 5.56e-01 | 0.090900 | 7.69e-01 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 87 | 1.44e-01 | -0.090700 | 4.04e-01 |
DNA Damage Bypass | 47 | 2.83e-01 | 0.090500 | 5.70e-01 |
SUMOylation of RNA binding proteins | 47 | 2.85e-01 | 0.090100 | 5.71e-01 |
Death Receptor Signalling | 131 | 7.53e-02 | -0.090000 | 2.91e-01 |
FRS-mediated FGFR3 signaling | 11 | 6.06e-01 | 0.089900 | 7.96e-01 |
FRS-mediated FGFR1 signaling | 14 | 5.60e-01 | 0.089900 | 7.71e-01 |
CTLA4 inhibitory signaling | 21 | 4.77e-01 | -0.089700 | 7.17e-01 |
Interleukin-15 signaling | 14 | 5.62e-01 | -0.089600 | 7.72e-01 |
WNT ligand biogenesis and trafficking | 21 | 4.77e-01 | 0.089600 | 7.17e-01 |
Infectious disease | 778 | 2.16e-05 | -0.089500 | 5.79e-04 |
Ion transport by P-type ATPases | 43 | 3.10e-01 | -0.089400 | 6.00e-01 |
GABA receptor activation | 36 | 3.54e-01 | 0.089300 | 6.38e-01 |
Peroxisomal lipid metabolism | 27 | 4.23e-01 | 0.089100 | 6.85e-01 |
Negative epigenetic regulation of rRNA expression | 62 | 2.26e-01 | -0.088800 | 5.18e-01 |
Lysosphingolipid and LPA receptors | 11 | 6.12e-01 | -0.088400 | 7.98e-01 |
Metabolism | 1771 | 6.38e-10 | -0.088400 | 3.23e-08 |
Integration of energy metabolism | 86 | 1.57e-01 | -0.088300 | 4.31e-01 |
Signaling by Insulin receptor | 59 | 2.41e-01 | -0.088200 | 5.35e-01 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 4.21e-01 | -0.087900 | 6.83e-01 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 19 | 5.08e-01 | 0.087700 | 7.35e-01 |
Post NMDA receptor activation events | 50 | 2.85e-01 | -0.087500 | 5.70e-01 |
Regulation of MECP2 expression and activity | 28 | 4.24e-01 | -0.087400 | 6.85e-01 |
Cytosolic sensors of pathogen-associated DNA | 62 | 2.36e-01 | -0.086900 | 5.29e-01 |
Signaling by TGF-beta Receptor Complex | 72 | 2.05e-01 | -0.086400 | 4.93e-01 |
Resolution of Abasic Sites (AP sites) | 37 | 3.64e-01 | -0.086300 | 6.48e-01 |
Miscellaneous transport and binding events | 20 | 5.05e-01 | -0.086100 | 7.33e-01 |
Formation of RNA Pol II elongation complex | 57 | 2.66e-01 | -0.085200 | 5.62e-01 |
RNA Polymerase II Transcription Elongation | 57 | 2.66e-01 | -0.085200 | 5.62e-01 |
GRB2 events in EGFR signaling | 11 | 6.25e-01 | -0.085100 | 8.07e-01 |
Butyrophilin (BTN) family interactions | 10 | 6.42e-01 | 0.085000 | 8.17e-01 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 184 | 4.68e-02 | -0.085000 | 2.16e-01 |
VEGFA-VEGFR2 Pathway | 90 | 1.65e-01 | -0.084700 | 4.40e-01 |
Termination of translesion DNA synthesis | 32 | 4.07e-01 | 0.084700 | 6.76e-01 |
Transcriptional regulation by small RNAs | 63 | 2.46e-01 | -0.084600 | 5.35e-01 |
Neuronal System | 262 | 1.86e-02 | -0.084500 | 1.18e-01 |
Post-translational protein phosphorylation | 69 | 2.27e-01 | -0.084200 | 5.18e-01 |
Mitochondrial biogenesis | 89 | 1.71e-01 | -0.084000 | 4.50e-01 |
Gap-filling DNA repair synthesis and ligation in GG-NER | 25 | 4.67e-01 | -0.084000 | 7.11e-01 |
FCERI mediated MAPK activation | 90 | 1.70e-01 | 0.083600 | 4.50e-01 |
MyD88 dependent cascade initiated on endosome | 88 | 1.76e-01 | -0.083400 | 4.60e-01 |
Cyclin E associated events during G1/S transition | 83 | 1.89e-01 | 0.083300 | 4.79e-01 |
Diseases of programmed cell death | 27 | 4.54e-01 | -0.083300 | 7.00e-01 |
Hedgehog ligand biogenesis | 59 | 2.68e-01 | 0.083300 | 5.64e-01 |
Frs2-mediated activation | 11 | 6.32e-01 | -0.083300 | 8.11e-01 |
Regulation of ornithine decarboxylase (ODC) | 50 | 3.09e-01 | 0.083100 | 5.99e-01 |
Activation of gene expression by SREBF (SREBP) | 42 | 3.52e-01 | -0.083100 | 6.37e-01 |
Metabolism of polyamines | 58 | 2.74e-01 | 0.083000 | 5.70e-01 |
HIV Transcription Initiation | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
RNA Polymerase II HIV Promoter Escape | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
RNA Polymerase II Promoter Escape | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
RNA Polymerase II Transcription Initiation | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 3.37e-01 | 0.082800 | 6.25e-01 |
SHC1 events in EGFR signaling | 12 | 6.22e-01 | -0.082100 | 8.07e-01 |
Stabilization of p53 | 55 | 2.92e-01 | 0.082100 | 5.80e-01 |
Sema3A PAK dependent Axon repulsion | 16 | 5.71e-01 | -0.081700 | 7.77e-01 |
Disease | 1354 | 4.44e-07 | -0.081700 | 1.69e-05 |
Activation of kainate receptors upon glutamate binding | 26 | 4.71e-01 | -0.081700 | 7.11e-01 |
Sema4D in semaphorin signaling | 22 | 5.08e-01 | -0.081400 | 7.35e-01 |
Anchoring of the basal body to the plasma membrane | 96 | 1.68e-01 | 0.081400 | 4.46e-01 |
Hemostasis | 546 | 1.15e-03 | -0.081400 | 1.89e-02 |
NOD1/2 Signaling Pathway | 32 | 4.26e-01 | 0.081300 | 6.87e-01 |
Cilium Assembly | 180 | 6.12e-02 | 0.080900 | 2.56e-01 |
Transcriptional activation of mitochondrial biogenesis | 51 | 3.19e-01 | -0.080700 | 6.08e-01 |
Aggrephagy | 22 | 5.13e-01 | -0.080500 | 7.37e-01 |
Advanced glycosylation endproduct receptor signaling | 12 | 6.30e-01 | -0.080300 | 8.11e-01 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 40 | 3.79e-01 | -0.080300 | 6.56e-01 |
Keratan sulfate/keratin metabolism | 27 | 4.70e-01 | -0.080200 | 7.11e-01 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 51 | 3.22e-01 | 0.080200 | 6.10e-01 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 6.07e-01 | 0.079500 | 7.96e-01 |
Acyl chain remodelling of PS | 14 | 6.07e-01 | 0.079300 | 7.96e-01 |
Glutathione conjugation | 26 | 4.85e-01 | 0.079100 | 7.23e-01 |
Budding and maturation of HIV virion | 26 | 4.85e-01 | -0.079100 | 7.23e-01 |
Beta-catenin independent WNT signaling | 137 | 1.12e-01 | -0.078600 | 3.61e-01 |
Platelet sensitization by LDL | 16 | 5.87e-01 | 0.078400 | 7.85e-01 |
Ub-specific processing proteases | 171 | 7.73e-02 | 0.078300 | 2.98e-01 |
MAP kinase activation | 63 | 2.83e-01 | -0.078100 | 5.70e-01 |
Deadenylation-dependent mRNA decay | 53 | 3.27e-01 | 0.077800 | 6.18e-01 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 89 | 2.04e-01 | -0.077800 | 4.93e-01 |
Opioid Signalling | 75 | 2.45e-01 | -0.077700 | 5.35e-01 |
Hh mutants abrogate ligand secretion | 55 | 3.19e-01 | 0.077600 | 6.09e-01 |
mRNA decay by 3’ to 5’ exoribonuclease | 16 | 5.91e-01 | -0.077600 | 7.88e-01 |
Degradation of GLI1 by the proteasome | 58 | 3.08e-01 | 0.077400 | 5.98e-01 |
Mitochondrial translation elongation | 91 | 2.02e-01 | -0.077300 | 4.93e-01 |
Protein localization | 157 | 9.45e-02 | -0.077300 | 3.33e-01 |
G alpha (i) signalling events | 245 | 3.74e-02 | -0.077200 | 1.88e-01 |
IRS-mediated signalling | 34 | 4.36e-01 | -0.077200 | 6.96e-01 |
Regulation of PLK1 Activity at G2/M Transition | 86 | 2.16e-01 | 0.077100 | 5.08e-01 |
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 17 | 5.82e-01 | -0.077100 | 7.83e-01 |
Neurotransmitter receptors and postsynaptic signal transmission | 127 | 1.34e-01 | -0.077100 | 3.91e-01 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 5.83e-01 | 0.077000 | 7.83e-01 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 5.83e-01 | 0.077000 | 7.83e-01 |
G-protein activation | 23 | 5.24e-01 | 0.076800 | 7.41e-01 |
Clathrin-mediated endocytosis | 127 | 1.36e-01 | -0.076600 | 3.92e-01 |
Rho GTPase cycle | 125 | 1.40e-01 | -0.076300 | 3.99e-01 |
Signaling by TGFB family members | 91 | 2.10e-01 | -0.076100 | 5.01e-01 |
Formation of TC-NER Pre-Incision Complex | 53 | 3.39e-01 | -0.075900 | 6.27e-01 |
Regulation of RAS by GAPs | 67 | 2.83e-01 | 0.075900 | 5.70e-01 |
Interleukin-6 family signaling | 19 | 5.67e-01 | -0.075800 | 7.74e-01 |
Hh mutants that don’t undergo autocatalytic processing are degraded by ERAD | 54 | 3.37e-01 | 0.075500 | 6.25e-01 |
Interleukin receptor SHC signaling | 23 | 5.32e-01 | -0.075300 | 7.48e-01 |
mTORC1-mediated signalling | 24 | 5.25e-01 | -0.075000 | 7.42e-01 |
Striated Muscle Contraction | 25 | 5.16e-01 | -0.075000 | 7.39e-01 |
RHO GTPases Activate ROCKs | 18 | 5.82e-01 | 0.074900 | 7.83e-01 |
RAS processing | 19 | 5.74e-01 | -0.074500 | 7.79e-01 |
RHO GTPases activate PAKs | 20 | 5.65e-01 | 0.074400 | 7.73e-01 |
ADP signalling through P2Y purinoceptor 12 | 18 | 5.90e-01 | 0.073300 | 7.87e-01 |
FCERI mediated Ca+2 mobilization | 89 | 2.33e-01 | 0.073200 | 5.27e-01 |
Transcriptional regulation of white adipocyte differentiation | 77 | 2.67e-01 | -0.073100 | 5.63e-01 |
SCF-beta-TrCP mediated degradation of Emi1 | 54 | 3.53e-01 | 0.073100 | 6.37e-01 |
CD28 dependent Vav1 pathway | 12 | 6.61e-01 | 0.073100 | 8.30e-01 |
Ion channel transport | 136 | 1.43e-01 | -0.072700 | 4.04e-01 |
Fatty acyl-CoA biosynthesis | 34 | 4.63e-01 | 0.072700 | 7.07e-01 |
Signal Transduction | 1899 | 1.85e-07 | -0.072200 | 8.10e-06 |
Acyl chain remodelling of PC | 19 | 5.86e-01 | 0.072200 | 7.85e-01 |
Cyclin A:Cdk2-associated events at S phase entry | 85 | 2.51e-01 | 0.072100 | 5.41e-01 |
Epigenetic regulation of gene expression | 100 | 2.13e-01 | -0.072000 | 5.05e-01 |
AURKA Activation by TPX2 | 71 | 2.95e-01 | 0.071900 | 5.81e-01 |
GPVI-mediated activation cascade | 31 | 4.88e-01 | -0.071900 | 7.24e-01 |
RNA Polymerase I Transcription Termination | 27 | 5.19e-01 | 0.071700 | 7.39e-01 |
RIPK1-mediated regulated necrosis | 29 | 5.04e-01 | 0.071700 | 7.33e-01 |
Regulated Necrosis | 29 | 5.04e-01 | 0.071700 | 7.33e-01 |
Regulation of necroptotic cell death | 29 | 5.04e-01 | 0.071700 | 7.33e-01 |
Sphingolipid metabolism | 78 | 2.77e-01 | -0.071200 | 5.70e-01 |
DNA strand elongation | 32 | 4.86e-01 | 0.071200 | 7.23e-01 |
GRB2 events in ERBB2 signaling | 11 | 6.83e-01 | -0.071000 | 8.46e-01 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 38 | 4.50e-01 | -0.070900 | 6.98e-01 |
Signaling by RAS mutants | 38 | 4.50e-01 | -0.070900 | 6.98e-01 |
Signaling by moderate kinase activity BRAF mutants | 38 | 4.50e-01 | -0.070900 | 6.98e-01 |
Signaling downstream of RAS mutants | 38 | 4.50e-01 | -0.070900 | 6.98e-01 |
GABA synthesis, release, reuptake and degradation | 13 | 6.59e-01 | -0.070600 | 8.29e-01 |
Recognition of DNA damage by PCNA-containing replication complex | 30 | 5.04e-01 | 0.070500 | 7.33e-01 |
Synthesis of PIPs at the plasma membrane | 52 | 3.80e-01 | -0.070400 | 6.56e-01 |
Transport of small molecules | 563 | 4.43e-03 | -0.070100 | 4.76e-02 |
UCH proteinases | 87 | 2.59e-01 | -0.070100 | 5.54e-01 |
Cell surface interactions at the vascular wall | 174 | 1.11e-01 | -0.070000 | 3.59e-01 |
Iron uptake and transport | 52 | 3.84e-01 | -0.069800 | 6.58e-01 |
SARS-CoV Infections | 140 | 1.54e-01 | -0.069800 | 4.26e-01 |
FCERI mediated NF-kB activation | 138 | 1.57e-01 | 0.069700 | 4.31e-01 |
Beta-oxidation of very long chain fatty acids | 10 | 7.03e-01 | -0.069700 | 8.59e-01 |
PI-3K cascade:FGFR2 | 12 | 6.76e-01 | 0.069600 | 8.42e-01 |
Regulation of signaling by CBL | 18 | 6.09e-01 | -0.069600 | 7.96e-01 |
RNA Polymerase III Transcription Termination | 23 | 5.64e-01 | -0.069600 | 7.73e-01 |
FOXO-mediated transcription | 59 | 3.57e-01 | -0.069400 | 6.39e-01 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 49 | 4.01e-01 | 0.069300 | 6.74e-01 |
DAP12 interactions | 39 | 4.56e-01 | -0.069000 | 7.02e-01 |
Beta-catenin phosphorylation cascade | 17 | 6.24e-01 | -0.068600 | 8.07e-01 |
Sulfur amino acid metabolism | 23 | 5.69e-01 | -0.068500 | 7.76e-01 |
SLC-mediated transmembrane transport | 180 | 1.13e-01 | -0.068400 | 3.62e-01 |
G beta:gamma signalling through BTK | 15 | 6.48e-01 | 0.068100 | 8.21e-01 |
Cyclin D associated events in G1 | 47 | 4.20e-01 | 0.068000 | 6.83e-01 |
G1 Phase | 47 | 4.20e-01 | 0.068000 | 6.83e-01 |
Translesion synthesis by POLK | 17 | 6.30e-01 | 0.067400 | 8.11e-01 |
Toll Like Receptor 9 (TLR9) Cascade | 92 | 2.66e-01 | -0.067100 | 5.62e-01 |
Carnitine metabolism | 10 | 7.14e-01 | -0.067100 | 8.65e-01 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 51 | 4.09e-01 | 0.066800 | 6.76e-01 |
p53-Independent DNA Damage Response | 51 | 4.09e-01 | 0.066800 | 6.76e-01 |
p53-Independent G1/S DNA damage checkpoint | 51 | 4.09e-01 | 0.066800 | 6.76e-01 |
Insulin receptor recycling | 21 | 5.98e-01 | -0.066400 | 7.93e-01 |
IL-6-type cytokine receptor ligand interactions | 13 | 6.79e-01 | -0.066200 | 8.45e-01 |
Class I peroxisomal membrane protein import | 20 | 6.09e-01 | 0.066000 | 7.96e-01 |
Alpha-protein kinase 1 signaling pathway | 11 | 7.05e-01 | -0.065900 | 8.61e-01 |
PKMTs methylate histone lysines | 45 | 4.45e-01 | -0.065800 | 6.98e-01 |
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 17 | 6.39e-01 | 0.065600 | 8.16e-01 |
Unblocking of NMDA receptors, glutamate binding and activation | 13 | 6.85e-01 | -0.065100 | 8.47e-01 |
ER-Phagosome pathway | 83 | 3.06e-01 | 0.064900 | 5.97e-01 |
Antigen processing-Cross presentation | 98 | 2.67e-01 | 0.064800 | 5.63e-01 |
Neurotransmitter release cycle | 37 | 4.97e-01 | 0.064600 | 7.32e-01 |
Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 5.55e-01 | 0.064500 | 7.69e-01 |
Listeria monocytogenes entry into host cells | 17 | 6.46e-01 | -0.064400 | 8.20e-01 |
APC/C:Cdc20 mediated degradation of Cyclin B | 24 | 5.85e-01 | 0.064400 | 7.85e-01 |
Interaction between L1 and Ankyrins | 22 | 6.02e-01 | 0.064300 | 7.96e-01 |
Signaling by RAF1 mutants | 34 | 5.18e-01 | -0.064100 | 7.39e-01 |
IRF3-mediated induction of type I IFN | 12 | 7.02e-01 | -0.063900 | 8.59e-01 |
Adrenaline,noradrenaline inhibits insulin secretion | 24 | 5.88e-01 | -0.063800 | 7.85e-01 |
Degradation of GLI2 by the proteasome | 57 | 4.06e-01 | 0.063600 | 6.76e-01 |
RNA Polymerase II Transcription Termination | 65 | 3.76e-01 | 0.063400 | 6.55e-01 |
SHC1 events in ERBB2 signaling | 17 | 6.51e-01 | -0.063400 | 8.22e-01 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 31 | 5.42e-01 | -0.063300 | 7.58e-01 |
Autodegradation of Cdh1 by Cdh1:APC/C | 64 | 3.81e-01 | 0.063300 | 6.56e-01 |
Global Genome Nucleotide Excision Repair (GG-NER) | 84 | 3.17e-01 | 0.063200 | 6.07e-01 |
Vif-mediated degradation of APOBEC3G | 53 | 4.28e-01 | 0.062900 | 6.89e-01 |
Translesion synthesis by POLI | 17 | 6.54e-01 | 0.062900 | 8.24e-01 |
Signaling by Activin | 10 | 7.31e-01 | -0.062700 | 8.76e-01 |
Degradation of AXIN | 54 | 4.27e-01 | 0.062500 | 6.88e-01 |
activated TAK1 mediates p38 MAPK activation | 19 | 6.38e-01 | -0.062300 | 8.16e-01 |
Signaling by Interleukins | 388 | 3.80e-02 | -0.061400 | 1.89e-01 |
Interleukin-10 signaling | 37 | 5.19e-01 | -0.061200 | 7.39e-01 |
MAPK6/MAPK4 signaling | 83 | 3.36e-01 | 0.061100 | 6.25e-01 |
Mismatch Repair | 15 | 6.83e-01 | 0.060900 | 8.46e-01 |
Signaling by ERBB4 | 44 | 4.87e-01 | -0.060500 | 7.23e-01 |
COPII-mediated vesicle transport | 65 | 3.99e-01 | 0.060400 | 6.73e-01 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 92 | 3.17e-01 | -0.060300 | 6.07e-01 |
Toll Like Receptor 2 (TLR2) Cascade | 92 | 3.17e-01 | -0.060300 | 6.07e-01 |
Toll Like Receptor TLR1:TLR2 Cascade | 92 | 3.17e-01 | -0.060300 | 6.07e-01 |
Toll Like Receptor TLR6:TLR2 Cascade | 92 | 3.17e-01 | -0.060300 | 6.07e-01 |
Defective CFTR causes cystic fibrosis | 60 | 4.20e-01 | 0.060200 | 6.83e-01 |
COPI-dependent Golgi-to-ER retrograde traffic | 78 | 3.58e-01 | 0.060200 | 6.41e-01 |
Dual Incision in GG-NER | 41 | 5.05e-01 | 0.060200 | 7.33e-01 |
TRAF6 mediated NF-kB activation | 23 | 6.18e-01 | -0.060000 | 8.05e-01 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 7.31e-01 | 0.059900 | 8.76e-01 |
Negative regulation of MAPK pathway | 42 | 5.02e-01 | -0.059900 | 7.33e-01 |
ROS and RNS production in phagocytes | 31 | 5.65e-01 | -0.059700 | 7.73e-01 |
Prefoldin mediated transfer of substrate to CCT/TriC | 26 | 5.98e-01 | -0.059700 | 7.93e-01 |
RHO GTPases activate KTN1 | 11 | 7.35e-01 | 0.058900 | 8.79e-01 |
Signaling by NTRK3 (TRKC) | 16 | 6.83e-01 | -0.058900 | 8.46e-01 |
Regulated proteolysis of p75NTR | 11 | 7.36e-01 | -0.058800 | 8.79e-01 |
ER to Golgi Anterograde Transport | 129 | 2.49e-01 | 0.058800 | 5.41e-01 |
Folding of actin by CCT/TriC | 10 | 7.48e-01 | 0.058700 | 8.90e-01 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 29 | 5.87e-01 | -0.058300 | 7.85e-01 |
Metalloprotease DUBs | 21 | 6.44e-01 | 0.058200 | 8.19e-01 |
Platelet homeostasis | 69 | 4.03e-01 | -0.058200 | 6.74e-01 |
Role of phospholipids in phagocytosis | 88 | 3.45e-01 | 0.058200 | 6.31e-01 |
G-protein beta:gamma signalling | 29 | 5.88e-01 | -0.058100 | 7.85e-01 |
Golgi-to-ER retrograde transport | 111 | 2.90e-01 | 0.058100 | 5.80e-01 |
COPI-mediated anterograde transport | 78 | 3.76e-01 | 0.058000 | 6.55e-01 |
FLT3 Signaling | 245 | 1.19e-01 | -0.057900 | 3.71e-01 |
Signaling by FGFR3 | 31 | 5.77e-01 | -0.057900 | 7.81e-01 |
Mitochondrial tRNA aminoacylation | 21 | 6.49e-01 | 0.057300 | 8.21e-01 |
Class I MHC mediated antigen processing & presentation | 349 | 6.61e-02 | 0.057300 | 2.68e-01 |
NOTCH2 intracellular domain regulates transcription | 11 | 7.43e-01 | -0.057100 | 8.85e-01 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 25 | 6.22e-01 | -0.056900 | 8.07e-01 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 25 | 6.23e-01 | 0.056700 | 8.07e-01 |
Costimulation by the CD28 family | 74 | 4.00e-01 | -0.056600 | 6.73e-01 |
Loss of Nlp from mitotic centrosomes | 68 | 4.20e-01 | 0.056600 | 6.83e-01 |
Loss of proteins required for interphase microtubule organization from the centrosome | 68 | 4.20e-01 | 0.056600 | 6.83e-01 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 84 | 3.70e-01 | 0.056500 | 6.52e-01 |
GPCR ligand binding | 237 | 1.34e-01 | -0.056500 | 3.91e-01 |
Metabolism of nucleotides | 86 | 3.71e-01 | -0.055800 | 6.52e-01 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 17 | 6.92e-01 | 0.055600 | 8.53e-01 |
Vpu mediated degradation of CD4 | 51 | 4.97e-01 | 0.055000 | 7.32e-01 |
PTEN Regulation | 139 | 2.63e-01 | -0.055000 | 5.62e-01 |
Zinc transporters | 14 | 7.22e-01 | 0.054900 | 8.73e-01 |
Transmission across Chemical Synapses | 173 | 2.13e-01 | -0.054900 | 5.05e-01 |
Mitochondrial translation initiation | 91 | 3.66e-01 | -0.054900 | 6.50e-01 |
Glucose metabolism | 83 | 3.88e-01 | -0.054800 | 6.64e-01 |
Formation of tubulin folding intermediates by CCT/TriC | 22 | 6.58e-01 | -0.054600 | 8.28e-01 |
tRNA modification in the nucleus and cytosol | 43 | 5.36e-01 | 0.054600 | 7.51e-01 |
Metabolism of RNA | 688 | 1.52e-02 | -0.054300 | 1.01e-01 |
VEGFR2 mediated vascular permeability | 26 | 6.32e-01 | -0.054300 | 8.11e-01 |
Regulation of TP53 Degradation | 35 | 5.80e-01 | -0.054000 | 7.83e-01 |
Regulation of PTEN stability and activity | 67 | 4.45e-01 | 0.054000 | 6.98e-01 |
SUMOylation of chromatin organization proteins | 57 | 4.86e-01 | 0.053400 | 7.23e-01 |
Mitochondrial iron-sulfur cluster biogenesis | 13 | 7.40e-01 | 0.053200 | 8.82e-01 |
Mitochondrial translation termination | 91 | 3.82e-01 | -0.053000 | 6.56e-01 |
COPI-independent Golgi-to-ER retrograde traffic | 33 | 6.00e-01 | 0.052700 | 7.94e-01 |
MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 6.11e-01 | -0.052700 | 7.98e-01 |
PI-3K cascade:FGFR4 | 10 | 7.73e-01 | -0.052700 | 9.02e-01 |
Stimuli-sensing channels | 75 | 4.30e-01 | -0.052700 | 6.91e-01 |
NIK–>noncanonical NF-kB signaling | 58 | 4.89e-01 | 0.052500 | 7.24e-01 |
FCGR3A-mediated IL10 synthesis | 99 | 3.68e-01 | 0.052300 | 6.50e-01 |
Unwinding of DNA | 12 | 7.54e-01 | -0.052200 | 8.92e-01 |
Signaling by FGFR1 | 38 | 5.77e-01 | -0.052200 | 7.81e-01 |
Intra-Golgi traffic | 43 | 5.54e-01 | -0.052200 | 7.68e-01 |
Translesion Synthesis by POLH | 18 | 7.03e-01 | -0.051900 | 8.59e-01 |
Amine ligand-binding receptors | 10 | 7.76e-01 | 0.051900 | 9.05e-01 |
Activation of BAD and translocation to mitochondria | 15 | 7.31e-01 | -0.051200 | 8.76e-01 |
Negative regulators of DDX58/IFIH1 signaling | 34 | 6.06e-01 | 0.051100 | 7.96e-01 |
Regulation of TNFR1 signaling | 34 | 6.07e-01 | -0.051000 | 7.96e-01 |
HIV Life Cycle | 144 | 2.91e-01 | 0.050900 | 5.80e-01 |
Triglyceride catabolism | 16 | 7.26e-01 | -0.050700 | 8.73e-01 |
RAF/MAP kinase cascade | 231 | 1.85e-01 | -0.050600 | 4.75e-01 |
Negative regulation of NOTCH4 signaling | 54 | 5.21e-01 | 0.050500 | 7.39e-01 |
NCAM1 interactions | 23 | 6.75e-01 | 0.050500 | 8.42e-01 |
Activation of GABAB receptors | 31 | 6.29e-01 | 0.050200 | 8.11e-01 |
GABA B receptor activation | 31 | 6.29e-01 | 0.050200 | 8.11e-01 |
RA biosynthesis pathway | 13 | 7.54e-01 | -0.050200 | 8.92e-01 |
Signaling by Retinoic Acid | 32 | 6.25e-01 | -0.050000 | 8.07e-01 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 29 | 6.43e-01 | -0.049800 | 8.18e-01 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 78 | 4.49e-01 | -0.049500 | 6.98e-01 |
Intraflagellar transport | 39 | 5.94e-01 | 0.049400 | 7.90e-01 |
Dectin-2 family | 19 | 7.10e-01 | 0.049200 | 8.65e-01 |
Association of TriC/CCT with target proteins during biosynthesis | 37 | 6.05e-01 | -0.049100 | 7.96e-01 |
Detoxification of Reactive Oxygen Species | 32 | 6.31e-01 | -0.049100 | 8.11e-01 |
Transcriptional regulation of pluripotent stem cells | 21 | 6.97e-01 | 0.049000 | 8.57e-01 |
RAB geranylgeranylation | 62 | 5.05e-01 | 0.049000 | 7.33e-01 |
TP53 Regulates Transcription of Cell Cycle Genes | 47 | 5.64e-01 | 0.048600 | 7.73e-01 |
Vitamin B5 (pantothenate) metabolism | 17 | 7.29e-01 | 0.048600 | 8.76e-01 |
Peptide ligand-binding receptors | 97 | 4.09e-01 | -0.048500 | 6.76e-01 |
Signal amplification | 28 | 6.57e-01 | 0.048400 | 8.28e-01 |
Class A/1 (Rhodopsin-like receptors) | 170 | 2.79e-01 | -0.048200 | 5.70e-01 |
Dual incision in TC-NER | 65 | 5.03e-01 | -0.048000 | 7.33e-01 |
Metabolism of steroids | 119 | 3.68e-01 | 0.047800 | 6.50e-01 |
EPHA-mediated growth cone collapse | 13 | 7.66e-01 | 0.047600 | 8.99e-01 |
Defects in vitamin and cofactor metabolism | 21 | 7.06e-01 | 0.047600 | 8.61e-01 |
PI-3K cascade:FGFR1 | 12 | 7.76e-01 | 0.047500 | 9.05e-01 |
Signal transduction by L1 | 20 | 7.14e-01 | -0.047400 | 8.65e-01 |
Regulation of actin dynamics for phagocytic cup formation | 123 | 3.65e-01 | 0.047300 | 6.49e-01 |
Metabolic disorders of biological oxidation enzymes | 24 | 6.88e-01 | -0.047300 | 8.50e-01 |
Diseases of signal transduction by growth factor receptors and second messengers | 342 | 1.35e-01 | -0.047000 | 3.92e-01 |
MAPK1/MAPK3 signaling | 236 | 2.14e-01 | -0.047000 | 5.06e-01 |
Processive synthesis on the lagging strand | 15 | 7.53e-01 | 0.047000 | 8.92e-01 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 25 | 6.86e-01 | -0.046700 | 8.48e-01 |
Signaling by the B Cell Receptor (BCR) | 163 | 3.07e-01 | 0.046400 | 5.97e-01 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 30 | 6.61e-01 | 0.046300 | 8.30e-01 |
Selective autophagy | 59 | 5.44e-01 | -0.045600 | 7.60e-01 |
Muscle contraction | 138 | 3.56e-01 | -0.045600 | 6.39e-01 |
GLI3 is processed to GLI3R by the proteasome | 58 | 5.50e-01 | 0.045400 | 7.66e-01 |
Acyl chain remodelling of PE | 20 | 7.26e-01 | 0.045300 | 8.73e-01 |
RNA Polymerase I Transcription Initiation | 44 | 6.04e-01 | -0.045200 | 7.96e-01 |
Transferrin endocytosis and recycling | 26 | 6.91e-01 | -0.045000 | 8.53e-01 |
Fc epsilon receptor (FCERI) signaling | 191 | 2.84e-01 | 0.044900 | 5.70e-01 |
Late Phase of HIV Life Cycle | 131 | 3.75e-01 | 0.044900 | 6.54e-01 |
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | 10 | 8.06e-01 | -0.044800 | 9.23e-01 |
Downstream signaling of activated FGFR4 | 17 | 7.50e-01 | 0.044600 | 8.90e-01 |
Signaling by GPCR | 547 | 7.60e-02 | -0.044300 | 2.94e-01 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 17 | 7.52e-01 | 0.044300 | 8.91e-01 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 73 | 5.14e-01 | 0.044200 | 7.37e-01 |
Antigen processing: Ubiquitination & Proteasome degradation | 288 | 1.98e-01 | 0.044100 | 4.87e-01 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 36 | 6.49e-01 | 0.043800 | 8.21e-01 |
Calnexin/calreticulin cycle | 26 | 7.02e-01 | -0.043300 | 8.59e-01 |
Innate Immune System | 968 | 2.26e-02 | -0.043300 | 1.36e-01 |
HCMV Infection | 96 | 4.64e-01 | -0.043200 | 7.07e-01 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 83 | 4.96e-01 | -0.043200 | 7.32e-01 |
Centrosome maturation | 80 | 5.06e-01 | 0.043000 | 7.33e-01 |
Recruitment of mitotic centrosome proteins and complexes | 80 | 5.06e-01 | 0.043000 | 7.33e-01 |
Gene Silencing by RNA | 88 | 4.87e-01 | -0.042900 | 7.23e-01 |
GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 7.97e-01 | -0.042800 | 9.17e-01 |
E3 ubiquitin ligases ubiquitinate target proteins | 52 | 5.95e-01 | -0.042600 | 7.91e-01 |
Regulation of TP53 Activity | 153 | 3.64e-01 | 0.042500 | 6.48e-01 |
Regulation of HSF1-mediated heat shock response | 79 | 5.14e-01 | 0.042500 | 7.37e-01 |
Amino acids regulate mTORC1 | 50 | 6.04e-01 | -0.042400 | 7.96e-01 |
Autodegradation of the E3 ubiquitin ligase COP1 | 50 | 6.04e-01 | 0.042400 | 7.96e-01 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 65 | 5.59e-01 | 0.041900 | 7.70e-01 |
RNA Polymerase III Transcription Initiation | 36 | 6.64e-01 | -0.041900 | 8.32e-01 |
Processing of Capped Intron-Containing Pre-mRNA | 238 | 2.68e-01 | 0.041700 | 5.64e-01 |
Signaling by SCF-KIT | 40 | 6.50e-01 | -0.041500 | 8.21e-01 |
p130Cas linkage to MAPK signaling for integrins | 11 | 8.12e-01 | -0.041500 | 9.25e-01 |
Signalling to RAS | 18 | 7.62e-01 | 0.041200 | 8.97e-01 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 7.90e-01 | 0.041100 | 9.14e-01 |
Nuclear Envelope (NE) Reassembly | 69 | 5.55e-01 | 0.041100 | 7.69e-01 |
Glutathione synthesis and recycling | 10 | 8.22e-01 | -0.041000 | 9.31e-01 |
Interleukin-35 Signalling | 12 | 8.07e-01 | 0.040800 | 9.23e-01 |
ABC transporters in lipid homeostasis | 14 | 7.92e-01 | 0.040600 | 9.15e-01 |
Nucleobase catabolism | 28 | 7.12e-01 | -0.040400 | 8.65e-01 |
Regulation of TP53 Expression and Degradation | 36 | 6.77e-01 | -0.040200 | 8.42e-01 |
Macroautophagy | 111 | 4.66e-01 | -0.040100 | 7.09e-01 |
Glutamate Neurotransmitter Release Cycle | 20 | 7.57e-01 | 0.039900 | 8.93e-01 |
Downstream signal transduction | 27 | 7.23e-01 | 0.039500 | 8.73e-01 |
Toll Like Receptor 3 (TLR3) Cascade | 92 | 5.13e-01 | -0.039500 | 7.37e-01 |
Potential therapeutics for SARS | 78 | 5.48e-01 | -0.039300 | 7.64e-01 |
Dectin-1 mediated noncanonical NF-kB signaling | 60 | 5.99e-01 | 0.039300 | 7.93e-01 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 32 | 7.02e-01 | -0.039100 | 8.59e-01 |
DNA Repair | 289 | 2.58e-01 | 0.038700 | 5.53e-01 |
Deubiquitination | 242 | 3.01e-01 | 0.038600 | 5.90e-01 |
Autophagy | 125 | 4.64e-01 | -0.038000 | 7.07e-01 |
Downstream signaling events of B Cell Receptor (BCR) | 80 | 5.57e-01 | 0.037900 | 7.70e-01 |
O-linked glycosylation of mucins | 47 | 6.53e-01 | -0.037900 | 8.24e-01 |
Leishmania infection | 246 | 3.06e-01 | -0.037900 | 5.97e-01 |
Regulation of insulin secretion | 60 | 6.14e-01 | -0.037700 | 8.00e-01 |
Chaperonin-mediated protein folding | 84 | 5.52e-01 | -0.037500 | 7.68e-01 |
CLEC7A (Dectin-1) induces NFAT activation | 11 | 8.29e-01 | -0.037500 | 9.32e-01 |
Signaling by KIT in disease | 20 | 7.73e-01 | 0.037300 | 9.02e-01 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 7.73e-01 | 0.037300 | 9.02e-01 |
Regulation of IFNA signaling | 12 | 8.24e-01 | 0.037200 | 9.31e-01 |
GPCR downstream signalling | 501 | 1.54e-01 | -0.037200 | 4.26e-01 |
Inactivation, recovery and regulation of the phototransduction cascade | 25 | 7.49e-01 | 0.036900 | 8.90e-01 |
Interleukin-2 family signaling | 38 | 6.97e-01 | -0.036500 | 8.57e-01 |
Receptor Mediated Mitophagy | 11 | 8.34e-01 | 0.036400 | 9.32e-01 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 18 | 7.89e-01 | -0.036400 | 9.14e-01 |
Signaling by Ligand-Responsive EGFR Variants in Cancer | 18 | 7.89e-01 | -0.036400 | 9.14e-01 |
Peroxisomal protein import | 57 | 6.38e-01 | 0.036100 | 8.16e-01 |
Signaling by NTRK2 (TRKB) | 20 | 7.82e-01 | 0.035700 | 9.10e-01 |
SUMO E3 ligases SUMOylate target proteins | 161 | 4.35e-01 | -0.035700 | 6.96e-01 |
ADP signalling through P2Y purinoceptor 1 | 21 | 7.79e-01 | 0.035400 | 9.07e-01 |
Apoptotic execution phase | 45 | 6.82e-01 | 0.035400 | 8.46e-01 |
Programmed Cell Death | 180 | 4.13e-01 | 0.035400 | 6.82e-01 |
MAPK family signaling cascades | 270 | 3.20e-01 | -0.035200 | 6.09e-01 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 88 | 5.71e-01 | 0.034900 | 7.77e-01 |
Signaling by ERBB2 in Cancer | 21 | 7.86e-01 | 0.034200 | 9.13e-01 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 7.72e-01 | 0.034200 | 9.02e-01 |
Protein folding | 90 | 5.75e-01 | -0.034200 | 7.79e-01 |
Metabolism of proteins | 1721 | 1.86e-02 | -0.034100 | 1.18e-01 |
Tie2 Signaling | 16 | 8.14e-01 | 0.033900 | 9.27e-01 |
Toll Like Receptor 4 (TLR4) Cascade | 121 | 5.20e-01 | -0.033900 | 7.39e-01 |
Transport of bile salts and organic acids, metal ions and amine compounds | 55 | 6.64e-01 | -0.033900 | 8.32e-01 |
FCGR3A-mediated phagocytosis | 121 | 5.21e-01 | 0.033800 | 7.39e-01 |
Leishmania phagocytosis | 121 | 5.21e-01 | 0.033800 | 7.39e-01 |
Parasite infection | 121 | 5.21e-01 | 0.033800 | 7.39e-01 |
Phospholipid metabolism | 184 | 4.36e-01 | -0.033300 | 6.96e-01 |
Mitochondrial translation | 97 | 5.74e-01 | -0.033100 | 7.79e-01 |
TNFR1-induced proapoptotic signaling | 12 | 8.44e-01 | 0.032800 | 9.36e-01 |
Regulation of RUNX1 Expression and Activity | 18 | 8.10e-01 | -0.032700 | 9.24e-01 |
Chromosome Maintenance | 105 | 5.65e-01 | -0.032500 | 7.73e-01 |
Adherens junctions interactions | 17 | 8.17e-01 | -0.032400 | 9.27e-01 |
mRNA Capping | 29 | 7.65e-01 | -0.032000 | 8.99e-01 |
DARPP-32 events | 22 | 7.97e-01 | -0.031700 | 9.17e-01 |
Glycerophospholipid biosynthesis | 106 | 5.74e-01 | -0.031600 | 7.79e-01 |
Acyl chain remodelling of PI | 10 | 8.63e-01 | -0.031600 | 9.52e-01 |
Signaling by ERBB2 KD Mutants | 20 | 8.07e-01 | 0.031500 | 9.23e-01 |
Diseases associated with the TLR signaling cascade | 23 | 7.95e-01 | 0.031300 | 9.16e-01 |
Diseases of Immune System | 23 | 7.95e-01 | 0.031300 | 9.16e-01 |
ABC-family proteins mediated transport | 94 | 6.08e-01 | 0.030600 | 7.96e-01 |
Recruitment of NuMA to mitotic centrosomes | 79 | 6.40e-01 | 0.030500 | 8.16e-01 |
Triglyceride metabolism | 25 | 7.96e-01 | 0.029900 | 9.17e-01 |
Cytosolic sulfonation of small molecules | 18 | 8.28e-01 | -0.029500 | 9.32e-01 |
L1CAM interactions | 85 | 6.38e-01 | -0.029500 | 8.16e-01 |
HIV Infection | 225 | 4.48e-01 | 0.029400 | 6.98e-01 |
Apoptosis | 168 | 5.11e-01 | 0.029400 | 7.37e-01 |
Oncogenic MAPK signaling | 73 | 6.64e-01 | 0.029400 | 8.32e-01 |
MyD88-independent TLR4 cascade | 96 | 6.25e-01 | -0.028900 | 8.07e-01 |
TRIF(TICAM1)-mediated TLR4 signaling | 96 | 6.25e-01 | -0.028900 | 8.07e-01 |
Meiotic recombination | 38 | 7.59e-01 | -0.028800 | 8.94e-01 |
Surfactant metabolism | 22 | 8.15e-01 | 0.028700 | 9.27e-01 |
trans-Golgi Network Vesicle Budding | 69 | 6.80e-01 | -0.028700 | 8.45e-01 |
Diseases of DNA repair | 10 | 8.75e-01 | 0.028700 | 9.61e-01 |
Ubiquitin-dependent degradation of Cyclin D | 51 | 7.26e-01 | 0.028400 | 8.73e-01 |
TNF signaling | 43 | 7.48e-01 | -0.028300 | 8.90e-01 |
Signaling by FGFR in disease | 50 | 7.32e-01 | 0.028000 | 8.77e-01 |
Viral Messenger RNA Synthesis | 44 | 7.48e-01 | 0.028000 | 8.90e-01 |
Interleukin-6 signaling | 10 | 8.79e-01 | -0.027800 | 9.62e-01 |
RNA Polymerase II Pre-transcription Events | 78 | 6.71e-01 | 0.027800 | 8.39e-01 |
Metabolism of steroid hormones | 20 | 8.30e-01 | 0.027700 | 9.32e-01 |
Pyruvate metabolism | 28 | 8.04e-01 | 0.027100 | 9.22e-01 |
TRP channels | 19 | 8.39e-01 | 0.027000 | 9.33e-01 |
Myogenesis | 21 | 8.32e-01 | 0.026800 | 9.32e-01 |
Biological oxidations | 136 | 5.93e-01 | -0.026500 | 7.90e-01 |
Metabolism of vitamins and cofactors | 158 | 5.66e-01 | -0.026500 | 7.73e-01 |
PCNA-Dependent Long Patch Base Excision Repair | 21 | 8.34e-01 | 0.026500 | 9.32e-01 |
Signaling by MET | 61 | 7.21e-01 | -0.026400 | 8.72e-01 |
Organelle biogenesis and maintenance | 269 | 4.57e-01 | 0.026300 | 7.02e-01 |
Protein ubiquitination | 72 | 7.02e-01 | -0.026100 | 8.59e-01 |
Glycolysis | 66 | 7.14e-01 | -0.026100 | 8.65e-01 |
Transcriptional regulation by RUNX2 | 102 | 6.49e-01 | 0.026100 | 8.21e-01 |
RHO GTPases Activate WASPs and WAVEs | 35 | 7.90e-01 | -0.026000 | 9.14e-01 |
Fatty acid metabolism | 153 | 5.82e-01 | -0.025800 | 7.83e-01 |
Transcription of the HIV genome | 67 | 7.18e-01 | 0.025500 | 8.69e-01 |
Removal of the Flap Intermediate from the C-strand | 17 | 8.57e-01 | 0.025200 | 9.48e-01 |
Immune System | 1896 | 7.16e-02 | -0.025000 | 2.83e-01 |
The canonical retinoid cycle in rods (twilight vision) | 10 | 8.92e-01 | -0.024800 | 9.63e-01 |
Interconversion of nucleotide di- and triphosphates | 27 | 8.24e-01 | 0.024700 | 9.31e-01 |
Scavenging by Class A Receptors | 12 | 8.83e-01 | 0.024500 | 9.63e-01 |
RAB GEFs exchange GTP for GDP on RABs | 87 | 6.95e-01 | -0.024300 | 8.56e-01 |
Signaling by Rho GTPases | 365 | 4.36e-01 | -0.023700 | 6.96e-01 |
Signaling by FGFR2 in disease | 32 | 8.17e-01 | -0.023600 | 9.27e-01 |
Degradation of DVL | 55 | 7.62e-01 | 0.023600 | 8.97e-01 |
Eicosanoid ligand-binding receptors | 13 | 8.83e-01 | -0.023500 | 9.63e-01 |
Aflatoxin activation and detoxification | 15 | 8.75e-01 | -0.023500 | 9.61e-01 |
Hedgehog ‘on’ state | 76 | 7.25e-01 | 0.023300 | 8.73e-01 |
Synthesis of PIPs at the Golgi membrane | 16 | 8.72e-01 | 0.023200 | 9.61e-01 |
Nucleotide Excision Repair | 110 | 6.76e-01 | -0.023100 | 8.42e-01 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | 16 | 8.74e-01 | -0.022900 | 9.61e-01 |
Regulation of RUNX3 expression and activity | 55 | 7.71e-01 | 0.022700 | 9.02e-01 |
PI Metabolism | 79 | 7.28e-01 | -0.022600 | 8.76e-01 |
Retrograde transport at the Trans-Golgi-Network | 49 | 7.86e-01 | 0.022400 | 9.13e-01 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 63 | 7.63e-01 | 0.022000 | 8.97e-01 |
Metabolism of amine-derived hormones | 10 | 9.05e-01 | -0.021700 | 9.65e-01 |
Purine salvage | 12 | 8.99e-01 | 0.021200 | 9.63e-01 |
Anti-inflammatory response favouring Leishmania parasite infection | 170 | 6.33e-01 | -0.021200 | 8.11e-01 |
Leishmania parasite growth and survival | 170 | 6.33e-01 | -0.021200 | 8.11e-01 |
STING mediated induction of host immune responses | 15 | 8.88e-01 | 0.021000 | 9.63e-01 |
Transcriptional Regulation by VENTX | 38 | 8.24e-01 | 0.020800 | 9.31e-01 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 43 | 8.16e-01 | -0.020500 | 9.27e-01 |
Telomere C-strand (Lagging Strand) Synthesis | 34 | 8.43e-01 | 0.019700 | 9.36e-01 |
Diseases associated with glycosylation precursor biosynthesis | 18 | 8.86e-01 | 0.019500 | 9.63e-01 |
Generic Transcription Pathway | 1087 | 2.80e-01 | -0.019400 | 5.70e-01 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 38 | 8.36e-01 | 0.019400 | 9.33e-01 |
AMER1 mutants destabilize the destruction complex | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
APC truncation mutants have impaired AXIN binding | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
AXIN missense mutants destabilize the destruction complex | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
AXIN mutants destabilize the destruction complex, activating WNT signaling | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
Truncations of AMER1 destabilize the destruction complex | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
truncated APC mutants destabilize the destruction complex | 14 | 9.02e-01 | -0.019100 | 9.63e-01 |
NCAM signaling for neurite out-growth | 43 | 8.29e-01 | 0.019000 | 9.32e-01 |
Signalling to ERKs | 31 | 8.55e-01 | 0.018900 | 9.47e-01 |
Asymmetric localization of PCP proteins | 61 | 7.99e-01 | -0.018800 | 9.18e-01 |
CD209 (DC-SIGN) signaling | 20 | 8.85e-01 | -0.018600 | 9.63e-01 |
mRNA Splicing - Major Pathway | 179 | 6.67e-01 | -0.018600 | 8.35e-01 |
TP53 Regulates Transcription of Cell Death Genes | 43 | 8.34e-01 | 0.018500 | 9.32e-01 |
tRNA processing | 136 | 7.10e-01 | -0.018400 | 8.65e-01 |
Synthesis of IP2, IP, and Ins in the cytosol | 13 | 9.09e-01 | 0.018400 | 9.66e-01 |
Thromboxane signalling through TP receptor | 20 | 8.89e-01 | -0.018100 | 9.63e-01 |
Downstream TCR signaling | 101 | 7.56e-01 | 0.017900 | 8.92e-01 |
Negative regulation of MET activity | 18 | 8.96e-01 | -0.017800 | 9.63e-01 |
Metabolism of lipids | 624 | 4.49e-01 | -0.017800 | 6.98e-01 |
Growth hormone receptor signaling | 20 | 8.91e-01 | -0.017700 | 9.63e-01 |
RNA Polymerase III Abortive And Retractive Initiation | 41 | 8.45e-01 | -0.017700 | 9.36e-01 |
RNA Polymerase III Transcription | 41 | 8.45e-01 | -0.017700 | 9.36e-01 |
SUMOylation | 167 | 6.95e-01 | -0.017600 | 8.56e-01 |
Activation of NF-kappaB in B cells | 66 | 8.07e-01 | 0.017400 | 9.23e-01 |
mRNA decay by 5’ to 3’ exoribonuclease | 15 | 9.08e-01 | -0.017200 | 9.66e-01 |
SHC-mediated cascade:FGFR4 | 10 | 9.26e-01 | 0.016900 | 9.76e-01 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 14 | 9.13e-01 | -0.016900 | 9.68e-01 |
SLC transporter disorders | 76 | 8.00e-01 | -0.016800 | 9.19e-01 |
Erythropoietin activates RAS | 13 | 9.17e-01 | 0.016700 | 9.71e-01 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 23 | 8.91e-01 | 0.016500 | 9.63e-01 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 52 | 8.40e-01 | 0.016200 | 9.34e-01 |
TNFR2 non-canonical NF-kB pathway | 96 | 7.84e-01 | 0.016200 | 9.11e-01 |
MET promotes cell motility | 26 | 8.86e-01 | 0.016200 | 9.63e-01 |
Ca2+ pathway | 57 | 8.34e-01 | -0.016000 | 9.32e-01 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 9.27e-01 | -0.015900 | 9.76e-01 |
C-type lectin receptors (CLRs) | 130 | 7.56e-01 | 0.015800 | 8.92e-01 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 18 | 9.08e-01 | -0.015800 | 9.66e-01 |
Membrane Trafficking | 559 | 5.27e-01 | -0.015600 | 7.43e-01 |
Synthesis of PA | 32 | 8.79e-01 | 0.015600 | 9.62e-01 |
Metal ion SLC transporters | 21 | 9.07e-01 | 0.014700 | 9.66e-01 |
Translesion synthesis by REV1 | 16 | 9.19e-01 | 0.014600 | 9.72e-01 |
Reproduction | 81 | 8.22e-01 | -0.014400 | 9.31e-01 |
Signaling by ERBB2 TMD/JMD mutants | 17 | 9.18e-01 | -0.014400 | 9.72e-01 |
DAP12 signaling | 28 | 8.95e-01 | 0.014300 | 9.63e-01 |
Dissolution of Fibrin Clot | 12 | 9.32e-01 | 0.014200 | 9.78e-01 |
Mitotic Prophase | 98 | 8.09e-01 | 0.014200 | 9.23e-01 |
Interleukin-1 signaling | 98 | 8.09e-01 | -0.014100 | 9.23e-01 |
Sialic acid metabolism | 28 | 8.97e-01 | 0.014100 | 9.63e-01 |
Transport to the Golgi and subsequent modification | 155 | 7.70e-01 | 0.013600 | 9.02e-01 |
Telomere Extension By Telomerase | 23 | 9.10e-01 | -0.013600 | 9.67e-01 |
Unfolded Protein Response (UPR) | 88 | 8.27e-01 | 0.013500 | 9.32e-01 |
FRS-mediated FGFR4 signaling | 12 | 9.36e-01 | 0.013500 | 9.78e-01 |
Signaling by NOTCH4 | 79 | 8.37e-01 | -0.013400 | 9.33e-01 |
Interleukin-37 signaling | 19 | 9.20e-01 | -0.013400 | 9.72e-01 |
Signaling by PDGF | 44 | 8.79e-01 | 0.013300 | 9.62e-01 |
Ovarian tumor domain proteases | 37 | 8.89e-01 | 0.013300 | 9.63e-01 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 10 | 9.43e-01 | 0.013200 | 9.78e-01 |
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 16 | 9.27e-01 | 0.013200 | 9.76e-01 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) | 36 | 8.96e-01 | -0.012600 | 9.63e-01 |
Generation of second messenger molecules | 38 | 8.94e-01 | -0.012500 | 9.63e-01 |
RHO GTPase Effectors | 249 | 7.36e-01 | 0.012400 | 8.79e-01 |
Purine ribonucleoside monophosphate biosynthesis | 10 | 9.47e-01 | 0.012200 | 9.78e-01 |
TNFR1-induced NFkappaB signaling pathway | 25 | 9.17e-01 | 0.012000 | 9.71e-01 |
Intrinsic Pathway for Apoptosis | 53 | 8.81e-01 | -0.011900 | 9.63e-01 |
PPARA activates gene expression | 104 | 8.35e-01 | 0.011800 | 9.32e-01 |
Mitochondrial Fatty Acid Beta-Oxidation | 36 | 9.02e-01 | -0.011800 | 9.63e-01 |
TCR signaling | 122 | 8.25e-01 | 0.011600 | 9.31e-01 |
Cellular response to heat stress | 93 | 8.47e-01 | -0.011600 | 9.39e-01 |
Sphingolipid de novo biosynthesis | 42 | 8.99e-01 | 0.011300 | 9.63e-01 |
Potassium Channels | 66 | 8.77e-01 | 0.011000 | 9.62e-01 |
Methylation | 12 | 9.48e-01 | 0.010800 | 9.78e-01 |
Interleukin-1 family signaling | 125 | 8.39e-01 | -0.010600 | 9.33e-01 |
Misspliced GSK3beta mutants stabilize beta-catenin | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
S33 mutants of beta-catenin aren’t phosphorylated | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
S37 mutants of beta-catenin aren’t phosphorylated | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
S45 mutants of beta-catenin aren’t phosphorylated | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
T41 mutants of beta-catenin aren’t phosphorylated | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | 15 | 9.44e-01 | 0.010400 | 9.78e-01 |
Nucleotide-like (purinergic) receptors | 13 | 9.48e-01 | 0.010300 | 9.78e-01 |
Toll-like Receptor Cascades | 143 | 8.31e-01 | -0.010300 | 9.32e-01 |
Prolonged ERK activation events | 13 | 9.49e-01 | -0.010200 | 9.78e-01 |
KSRP (KHSRP) binds and destabilizes mRNA | 17 | 9.42e-01 | 0.010200 | 9.78e-01 |
Fcgamma receptor (FCGR) dependent phagocytosis | 147 | 8.31e-01 | 0.010200 | 9.32e-01 |
Kinesins | 39 | 9.13e-01 | -0.010100 | 9.68e-01 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 54 | 8.99e-01 | 0.010000 | 9.63e-01 |
Telomere C-strand synthesis initiation | 13 | 9.51e-01 | 0.009860 | 9.78e-01 |
MHC class II antigen presentation | 101 | 8.73e-01 | 0.009230 | 9.61e-01 |
Processing of SMDT1 | 15 | 9.51e-01 | -0.009120 | 9.78e-01 |
Processive synthesis on the C-strand of the telomere | 19 | 9.46e-01 | 0.009020 | 9.78e-01 |
Ras activation upon Ca2+ influx through NMDA receptor | 16 | 9.50e-01 | -0.009000 | 9.78e-01 |
Citric acid cycle (TCA cycle) | 22 | 9.44e-01 | 0.008700 | 9.78e-01 |
Translocation of ZAP-70 to Immunological synapse | 24 | 9.42e-01 | -0.008600 | 9.78e-01 |
TP53 Regulates Metabolic Genes | 86 | 8.91e-01 | -0.008580 | 9.63e-01 |
Disorders of transmembrane transporters | 147 | 8.62e-01 | -0.008300 | 9.52e-01 |
Endogenous sterols | 16 | 9.55e-01 | -0.008090 | 9.79e-01 |
Diseases associated with N-glycosylation of proteins | 17 | 9.54e-01 | 0.008000 | 9.79e-01 |
Apoptotic cleavage of cellular proteins | 34 | 9.40e-01 | 0.007470 | 9.78e-01 |
Hedgehog ‘off’ state | 93 | 9.02e-01 | -0.007350 | 9.63e-01 |
Depolymerisation of the Nuclear Lamina | 15 | 9.61e-01 | -0.007250 | 9.79e-01 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 55 | 9.28e-01 | 0.007030 | 9.76e-01 |
Netrin-1 signaling | 40 | 9.40e-01 | 0.006930 | 9.78e-01 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 9.50e-01 | -0.006830 | 9.78e-01 |
Factors involved in megakaryocyte development and platelet production | 116 | 8.99e-01 | -0.006800 | 9.63e-01 |
Lysine catabolism | 11 | 9.69e-01 | -0.006740 | 9.83e-01 |
Cellular response to hypoxia | 72 | 9.22e-01 | 0.006650 | 9.73e-01 |
PD-1 signaling | 28 | 9.53e-01 | 0.006470 | 9.78e-01 |
Signaling by BRAF and RAF fusions | 57 | 9.35e-01 | -0.006270 | 9.78e-01 |
Degradation of beta-catenin by the destruction complex | 84 | 9.22e-01 | -0.006210 | 9.73e-01 |
Phosphorylation of CD3 and TCR zeta chains | 27 | 9.56e-01 | -0.006160 | 9.79e-01 |
The phototransduction cascade | 26 | 9.57e-01 | 0.006090 | 9.79e-01 |
Transport of vitamins, nucleosides, and related molecules | 33 | 9.52e-01 | -0.006040 | 9.78e-01 |
Gene expression (Transcription) | 1334 | 7.12e-01 | 0.006020 | 8.65e-01 |
p38MAPK events | 13 | 9.70e-01 | 0.005930 | 9.83e-01 |
Asparagine N-linked glycosylation | 269 | 8.68e-01 | 0.005870 | 9.57e-01 |
Deposition of new CENPA-containing nucleosomes at the centromere | 40 | 9.50e-01 | 0.005750 | 9.78e-01 |
Nucleosome assembly | 40 | 9.50e-01 | 0.005750 | 9.78e-01 |
Transcriptional regulation by RUNX3 | 90 | 9.29e-01 | -0.005420 | 9.76e-01 |
mRNA Splicing | 187 | 9.01e-01 | -0.005290 | 9.63e-01 |
Fanconi Anemia Pathway | 36 | 9.59e-01 | -0.004980 | 9.79e-01 |
Cytochrome P450 - arranged by substrate type | 36 | 9.59e-01 | 0.004900 | 9.79e-01 |
Prostacyclin signalling through prostacyclin receptor | 16 | 9.74e-01 | 0.004630 | 9.84e-01 |
Post-translational protein modification | 1196 | 7.92e-01 | -0.004520 | 9.15e-01 |
Nicotinate metabolism | 26 | 9.68e-01 | -0.004510 | 9.83e-01 |
MTOR signalling | 40 | 9.61e-01 | 0.004410 | 9.79e-01 |
Transcriptional Regulation by TP53 | 352 | 8.88e-01 | 0.004370 | 9.63e-01 |
Polymerase switching on the C-strand of the telomere | 26 | 9.71e-01 | -0.004080 | 9.83e-01 |
Regulation of lipid metabolism by PPARalpha | 106 | 9.45e-01 | 0.003910 | 9.78e-01 |
Cytokine Signaling in Immune system | 738 | 8.58e-01 | 0.003860 | 9.48e-01 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 179 | 9.36e-01 | 0.003490 | 9.78e-01 |
Meiosis | 68 | 9.62e-01 | 0.003310 | 9.80e-01 |
ER Quality Control Compartment (ERQC) | 21 | 9.81e-01 | -0.003070 | 9.89e-01 |
Protein methylation | 15 | 9.84e-01 | -0.002920 | 9.92e-01 |
Synthesis of substrates in N-glycan biosythesis | 58 | 9.69e-01 | -0.002910 | 9.83e-01 |
Signaling by Hedgehog | 121 | 9.56e-01 | 0.002890 | 9.79e-01 |
Post-translational modification: synthesis of GPI-anchored proteins | 58 | 9.70e-01 | -0.002860 | 9.83e-01 |
Xenobiotics | 12 | 9.87e-01 | -0.002620 | 9.93e-01 |
Cardiac conduction | 87 | 9.71e-01 | 0.002290 | 9.83e-01 |
HCMV Early Events | 74 | 9.73e-01 | -0.002240 | 9.84e-01 |
Neddylation | 219 | 9.57e-01 | 0.002130 | 9.79e-01 |
Golgi Associated Vesicle Biogenesis | 55 | 9.79e-01 | -0.002100 | 9.88e-01 |
SHC1 events in ERBB4 signaling | 10 | 9.91e-01 | 0.002060 | 9.95e-01 |
Extension of Telomeres | 51 | 9.81e-01 | -0.001960 | 9.89e-01 |
Interleukin-20 family signaling | 17 | 9.93e-01 | 0.001290 | 9.95e-01 |
Receptor-type tyrosine-protein phosphatases | 12 | 9.94e-01 | 0.001270 | 9.95e-01 |
Vesicle-mediated transport | 649 | 9.68e-01 | 0.000910 | 9.83e-01 |
ABC transporter disorders | 71 | 9.90e-01 | 0.000845 | 9.95e-01 |
RNA Polymerase II Transcription | 1206 | 9.61e-01 | 0.000843 | 9.79e-01 |
Host Interactions of HIV factors | 130 | 9.87e-01 | 0.000801 | 9.93e-01 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 9.97e-01 | 0.000778 | 9.97e-01 |
CLEC7A (Dectin-1) signaling | 98 | 9.93e-01 | 0.000533 | 9.95e-01 |
Metabolism of water-soluble vitamins and cofactors | 112 | 9.94e-01 | 0.000417 | 9.95e-01 |
Adaptive Immune System | 758 | 9.89e-01 | -0.000294 | 9.94e-01 |
Peptide chain elongation
810 | |
---|---|
set | Peptide chain elongation |
setSize | 88 |
pANOVA | 6.36e-25 |
s.dist | -0.635 |
p.adjustANOVA | 4.35e-22 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
EEF2 | -10214 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
EEF2 | -10214 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
EEF1A1 | -7887 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
RPS24 | -89 |
RPL23A | 138 |
RPL6 | 1290 |
RPS4X | 1825 |
RPS3A | 3173 |
RPSA | 5249 |
RPL22L1 | 8317 |
RPL3L | 8978 |
RPS27L | 9625 |
Eukaryotic Translation Elongation
353 | |
---|---|
set | Eukaryotic Translation Elongation |
setSize | 93 |
pANOVA | 5.98e-26 |
s.dist | -0.631 |
p.adjustANOVA | 8.18e-23 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
EEF2 | -10214 |
RPLP2 | -10185 |
EEF1G | -10158 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
EEF1D | -9841 |
EEF1B2 | -9772 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
EEF2 | -10214 |
RPLP2 | -10185 |
EEF1G | -10158 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
EEF1D | -9841 |
EEF1B2 | -9772 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
EEF1A1 | -7887 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
EEF1A1P5 | -5668 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
RPS24 | -89 |
RPL23A | 138 |
RPL6 | 1290 |
RPS4X | 1825 |
RPS3A | 3173 |
RPSA | 5249 |
EEF1A2 | 7880 |
RPL22L1 | 8317 |
RPL3L | 8978 |
RPS27L | 9625 |
Viral mRNA Translation
1318 | |
---|---|
set | Viral mRNA Translation |
setSize | 88 |
pANOVA | 1.04e-22 |
s.dist | -0.604 |
p.adjustANOVA | 2.37e-20 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
RPS24 | -89 |
RPL23A | 138 |
RPL6 | 1290 |
RPS4X | 1825 |
RPS3A | 3173 |
GRSF1 | 4059 |
RPSA | 5249 |
DNAJC3 | 7755 |
RPL22L1 | 8317 |
RPL3L | 8978 |
RPS27L | 9625 |
Eukaryotic Translation Termination
355 | |
---|---|
set | Eukaryotic Translation Termination |
setSize | 92 |
pANOVA | 5.46e-23 |
s.dist | -0.595 |
p.adjustANOVA | 1.87e-20 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
TRMT112 | -8912 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
APEH | -8642 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
GSPT2 | -972 |
RPS24 | -89 |
RPL23A | 138 |
N6AMT1 | 251 |
RPL6 | 1290 |
RPS4X | 1825 |
RPS3A | 3173 |
RPSA | 5249 |
GSPT1 | 7510 |
ETF1 | 8214 |
RPL22L1 | 8317 |
RPL3L | 8978 |
RPS27L | 9625 |
Selenocysteine synthesis
1063 | |
---|---|
set | Selenocysteine synthesis |
setSize | 92 |
pANOVA | 8.98e-23 |
s.dist | -0.592 |
p.adjustANOVA | 2.37e-20 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
SARS1 | -6084 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
EEFSEC | -5241 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
PSTK | -2534 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
RPS24 | -89 |
SEPHS2 | -59 |
RPL23A | 138 |
RPL6 | 1290 |
RPS4X | 1825 |
RPS3A | 3173 |
RPSA | 5249 |
SEPSECS | 7020 |
SECISBP2 | 7391 |
RPL22L1 | 8317 |
RPL3L | 8978 |
RPS27L | 9625 |
Formation of a pool of free 40S subunits
395 | |
---|---|
set | Formation of a pool of free 40S subunits |
setSize | 100 |
pANOVA | 1.32e-23 |
s.dist | -0.579 |
p.adjustANOVA | 6.02e-21 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
EIF3F | -10244 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
EIF3C | -9873 |
RPL3 | -9867 |
RPL8 | -9738 |
EIF3G | -9710 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
EIF3F | -10244 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
EIF3C | -9873 |
RPL3 | -9867 |
RPL8 | -9738 |
EIF3G | -9710 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
EIF3B | -8804 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
EIF3I | -7931 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
EIF3K | -6222 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
EIF3D | -5647 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
EIF3H | -1365 |
RPS24 | -89 |
RPL23A | 138 |
RPL6 | 1290 |
RPS4X | 1825 |
EIF3A | 1969 |
RPS3A | 3173 |
RPSA | 5249 |
EIF3E | 8272 |
RPL22L1 | 8317 |
EIF3M | 8578 |
EIF1AX | 8776 |
RPL3L | 8978 |
RPS27L | 9625 |
EIF3J | 9804 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
746 | |
---|---|
set | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) |
setSize | 94 |
pANOVA | 1.41e-20 |
s.dist | -0.554 |
p.adjustANOVA | 2.75e-18 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
EIF4G1 | -7029 |
RPL35A | -6977 |
RPL15 | -6926 |
UPF1 | -6778 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
GSPT2 | -972 |
RPS24 | -89 |
RPL23A | 138 |
RPL6 | 1290 |
RPS4X | 1825 |
RPS3A | 3173 |
PABPC1 | 4591 |
RPSA | 5249 |
GSPT1 | 7510 |
ETF1 | 8214 |
RPL22L1 | 8317 |
RPL3L | 8978 |
RPS27L | 9625 |
NCBP1 | 10864 |
NCBP2 | 11208 |
Incretin synthesis, secretion, and inactivation
525 | |
---|---|
set | Incretin synthesis, secretion, and inactivation |
setSize | 10 |
pANOVA | 0.0036 |
s.dist | 0.532 |
p.adjustANOVA | 0.0406 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TCF7L2 | 11426 |
SPCS2 | 11036 |
SEC11C | 10820 |
SPCS3 | 10797 |
GNB3 | 6586 |
CTNNB1 | 5359 |
SPCS1 | 4379 |
FFAR4 | 4223 |
SEC11A | 1049 |
DPP4 | -128 |
GeneID | Gene Rank |
---|---|
TCF7L2 | 11426 |
SPCS2 | 11036 |
SEC11C | 10820 |
SPCS3 | 10797 |
GNB3 | 6586 |
CTNNB1 | 5359 |
SPCS1 | 4379 |
FFAR4 | 4223 |
SEC11A | 1049 |
DPP4 | -128 |
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
1185 | |
---|---|
set | Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) |
setSize | 10 |
pANOVA | 0.0036 |
s.dist | 0.532 |
p.adjustANOVA | 0.0406 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TCF7L2 | 11426 |
SPCS2 | 11036 |
SEC11C | 10820 |
SPCS3 | 10797 |
GNB3 | 6586 |
CTNNB1 | 5359 |
SPCS1 | 4379 |
FFAR4 | 4223 |
SEC11A | 1049 |
DPP4 | -128 |
GeneID | Gene Rank |
---|---|
TCF7L2 | 11426 |
SPCS2 | 11036 |
SEC11C | 10820 |
SPCS3 | 10797 |
GNB3 | 6586 |
CTNNB1 | 5359 |
SPCS1 | 4379 |
FFAR4 | 4223 |
SEC11A | 1049 |
DPP4 | -128 |
NF-kB is activated and signals survival
700 | |
---|---|
set | NF-kB is activated and signals survival |
setSize | 12 |
pANOVA | 0.00207 |
s.dist | -0.513 |
p.adjustANOVA | 0.0281 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RELA | -9628 |
IRAK1 | -9487 |
RPS27A | -8388 |
SQSTM1 | -7746 |
UBA52 | -7375 |
UBB | -4944 |
NFKBIA | -4692 |
IKBKB | -4462 |
UBC | -4177 |
NGFR | -2692 |
NFKB1 | 1266 |
TRAF6 | 2326 |
GeneID | Gene Rank |
---|---|
RELA | -9628 |
IRAK1 | -9487 |
RPS27A | -8388 |
SQSTM1 | -7746 |
UBA52 | -7375 |
UBB | -4944 |
NFKBIA | -4692 |
IKBKB | -4462 |
UBC | -4177 |
NGFR | -2692 |
NFKB1 | 1266 |
TRAF6 | 2326 |
WNT5A-dependent internalization of FZD4
1328 | |
---|---|
set | WNT5A-dependent internalization of FZD4 |
setSize | 13 |
pANOVA | 0.00153 |
s.dist | -0.508 |
p.adjustANOVA | 0.0237 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DVL2 | -9361 |
AP2M1 | -8930 |
CLTB | -8800 |
PRKCB | -8270 |
AP2A2 | -7814 |
AP2A1 | -6826 |
PRKCA | -6088 |
ARRB2 | -5337 |
AP2S1 | -3863 |
AP2B1 | -3395 |
CLTA | 509 |
CLTC | 1283 |
FZD4 | 2728 |
GeneID | Gene Rank |
---|---|
DVL2 | -9361 |
AP2M1 | -8930 |
CLTB | -8800 |
PRKCB | -8270 |
AP2A2 | -7814 |
AP2A1 | -6826 |
PRKCA | -6088 |
ARRB2 | -5337 |
AP2S1 | -3863 |
AP2B1 | -3395 |
CLTA | 509 |
CLTC | 1283 |
FZD4 | 2728 |
L13a-mediated translational silencing of Ceruloplasmin expression
591 | |
---|---|
set | L13a-mediated translational silencing of Ceruloplasmin expression |
setSize | 110 |
pANOVA | 5.78e-20 |
s.dist | -0.504 |
p.adjustANOVA | 9.88e-18 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
EIF3F | -10244 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
EIF3C | -9873 |
RPL3 | -9867 |
EIF4H | -9779 |
RPL8 | -9738 |
EIF3G | -9710 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
EIF3F | -10244 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
EIF3C | -9873 |
RPL3 | -9867 |
EIF4H | -9779 |
RPL8 | -9738 |
EIF3G | -9710 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
EIF3B | -8804 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
EIF3I | -7931 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
EIF4G1 | -7029 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
EIF4B | -6655 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
EIF3K | -6222 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
EIF3D | -5647 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
EIF3H | -1365 |
RPS24 | -89 |
RPL23A | 138 |
RPL6 | 1290 |
EIF4A1 | 1541 |
RPS4X | 1825 |
EIF3A | 1969 |
RPS3A | 3173 |
PABPC1 | 4591 |
RPSA | 5249 |
EIF3E | 8272 |
RPL22L1 | 8317 |
EIF3M | 8578 |
EIF1AX | 8776 |
RPL3L | 8978 |
EIF2S2 | 9317 |
EIF2S1 | 9563 |
RPS27L | 9625 |
EIF3J | 9804 |
EIF4A2 | 10043 |
EIF2S3 | 10258 |
EIF4E | 11624 |
DNA methylation
247 | |
---|---|
set | DNA methylation |
setSize | 20 |
pANOVA | 0.000126 |
s.dist | -0.495 |
p.adjustANOVA | 0.00288 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DNMT3B | -9878.0 |
H2AZ1 | -8776.0 |
H2BC12 | -8742.0 |
DNMT1 | -8737.0 |
DNMT3A | -8681.0 |
H2BC17 | -8346.0 |
H3C15 | -8038.5 |
H2BC4 | -7928.0 |
H2AJ | -7536.0 |
H2BC9 | -6894.0 |
H2BC11 | -5751.0 |
H2BC21 | -5415.0 |
H2BC15 | -4416.0 |
H2AC6 | -4383.0 |
H2BC5 | -3070.0 |
H2AZ2 | -2475.0 |
UHRF1 | 1351.0 |
H2BU1 | 2721.0 |
H2AC20 | 3907.0 |
H3-3A | 5193.0 |
GeneID | Gene Rank |
---|---|
DNMT3B | -9878.0 |
H2AZ1 | -8776.0 |
H2BC12 | -8742.0 |
DNMT1 | -8737.0 |
DNMT3A | -8681.0 |
H2BC17 | -8346.0 |
H3C15 | -8038.5 |
H2BC4 | -7928.0 |
H2AJ | -7536.0 |
H2BC9 | -6894.0 |
H2BC11 | -5751.0 |
H2BC21 | -5415.0 |
H2BC15 | -4416.0 |
H2AC6 | -4383.0 |
H2BC5 | -3070.0 |
H2AZ2 | -2475.0 |
UHRF1 | 1351.0 |
H2BU1 | 2721.0 |
H2AC20 | 3907.0 |
H3-3A | 5193.0 |
Response of EIF2AK4 (GCN2) to amino acid deficiency
1010 | |
---|---|
set | Response of EIF2AK4 (GCN2) to amino acid deficiency |
setSize | 100 |
pANOVA | 1.78e-17 |
s.dist | -0.492 |
p.adjustANOVA | 2.02e-15 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
GCN1 | -4393 |
RPL24 | -3939 |
RPS26 | -3701 |
ATF4 | -3557 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
EIF2AK4 | -2072 |
TRIB3 | -1393 |
RPS24 | -89 |
RPL23A | 138 |
ATF3 | 451 |
CEBPB | 621 |
RPL6 | 1290 |
RPS4X | 1825 |
DDIT3 | 2994 |
RPS3A | 3173 |
RPSA | 5249 |
RPL22L1 | 8317 |
RPL3L | 8978 |
ASNS | 9230 |
EIF2S2 | 9317 |
EIF2S1 | 9563 |
RPS27L | 9625 |
EIF2S3 | 10258 |
IMPACT | 10622 |
CEBPG | 11104 |
ATF2 | 11312 |
VLDLR internalisation and degradation
1313 | |
---|---|
set | VLDLR internalisation and degradation |
setSize | 11 |
pANOVA | 0.005 |
s.dist | -0.489 |
p.adjustANOVA | 0.051 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NR1H2 | -9025 |
AP2M1 | -8930 |
AP2A2 | -7814 |
AP2A1 | -6826 |
NR1H3 | -4903 |
MYLIP | -4778 |
VLDLR | -4257 |
AP2S1 | -3863 |
AP2B1 | -3395 |
CLTA | 509 |
CLTC | 1283 |
GeneID | Gene Rank |
---|---|
NR1H2 | -9025 |
AP2M1 | -8930 |
AP2A2 | -7814 |
AP2A1 | -6826 |
NR1H3 | -4903 |
MYLIP | -4778 |
VLDLR | -4257 |
AP2S1 | -3863 |
AP2B1 | -3395 |
CLTA | 509 |
CLTC | 1283 |
tRNA processing in the mitochondrion
1364 | |
---|---|
set | tRNA processing in the mitochondrion |
setSize | 32 |
pANOVA | 1.71e-06 |
s.dist | -0.489 |
p.adjustANOVA | 5.69e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MT-TS1 | -10372 |
MT-TN | -10345 |
MT-ATP8 | -10332 |
MT-TC | -9831 |
MT-ATP6 | -9606 |
MT-TA | -9596 |
MT-TP | -9309 |
MT-ND4L | -9074 |
MT-CO3 | -8680 |
MT-ND3 | -8450 |
MT-TV | -8443 |
MT-TF | -8294 |
MT-TL2 | -7298 |
MT-TY | -7272 |
MT-CYB | -7017 |
MT-TM | -6674 |
MT-ND1 | -6593 |
MT-ND5 | -6176 |
MT-CO2 | -5700 |
MT-ND2 | -4966 |
GeneID | Gene Rank |
---|---|
MT-TS1 | -10372 |
MT-TN | -10345 |
MT-ATP8 | -10332 |
MT-TC | -9831 |
MT-ATP6 | -9606 |
MT-TA | -9596 |
MT-TP | -9309 |
MT-ND4L | -9074 |
MT-CO3 | -8680 |
MT-ND3 | -8450 |
MT-TV | -8443 |
MT-TF | -8294 |
MT-TL2 | -7298 |
MT-TY | -7272 |
MT-CYB | -7017 |
MT-TM | -6674 |
MT-ND1 | -6593 |
MT-ND5 | -6176 |
MT-CO2 | -5700 |
MT-ND2 | -4966 |
MT-TL1 | -3853 |
MT-TE | -3693 |
MT-RNR2 | -3648 |
MT-RNR1 | -3295 |
HSD17B10 | -2865 |
ELAC2 | -2324 |
MT-CO1 | -685 |
MT-ND6 | 1775 |
MT-ND4 | 3305 |
PRORP | 6071 |
TRMT10C | 10717 |
TRNT1 | 11446 |
GTP hydrolysis and joining of the 60S ribosomal subunit
437 | |
---|---|
set | GTP hydrolysis and joining of the 60S ribosomal subunit |
setSize | 111 |
pANOVA | 6.92e-19 |
s.dist | -0.487 |
p.adjustANOVA | 1.05e-16 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
EIF3F | -10244 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
EIF3C | -9873 |
RPL3 | -9867 |
EIF4H | -9779 |
RPL8 | -9738 |
EIF3G | -9710 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
EIF3F | -10244 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
EIF3C | -9873 |
RPL3 | -9867 |
EIF4H | -9779 |
RPL8 | -9738 |
EIF3G | -9710 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
EIF3B | -8804 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
EIF3I | -7931 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
EIF4G1 | -7029 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
EIF4B | -6655 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
EIF3K | -6222 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
EIF3D | -5647 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
EIF3H | -1365 |
RPS24 | -89 |
RPL23A | 138 |
RPL6 | 1290 |
EIF4A1 | 1541 |
RPS4X | 1825 |
EIF3A | 1969 |
RPS3A | 3173 |
RPSA | 5249 |
EIF3E | 8272 |
RPL22L1 | 8317 |
EIF3M | 8578 |
EIF1AX | 8776 |
RPL3L | 8978 |
EIF2S2 | 9317 |
EIF2S1 | 9563 |
RPS27L | 9625 |
EIF3J | 9804 |
EIF5B | 9825 |
EIF4A2 | 10043 |
EIF2S3 | 10258 |
EIF5 | 10905 |
EIF4E | 11624 |
AKT phosphorylates targets in the nucleus
9 | |
---|---|
set | AKT phosphorylates targets in the nucleus |
setSize | 10 |
pANOVA | 0.00821 |
s.dist | -0.483 |
p.adjustANOVA | 0.0681 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AKT2 | -10102 |
FOXO4 | -9911 |
AKT1 | -9799 |
FOXO1 | -8143 |
FOXO3 | -7061 |
FOXO6 | -6422 |
RPS6KB2 | -6218 |
NR4A1 | 2131 |
AKT3 | 2465 |
CREB1 | 6457 |
GeneID | Gene Rank |
---|---|
AKT2 | -10102 |
FOXO4 | -9911 |
AKT1 | -9799 |
FOXO1 | -8143 |
FOXO3 | -7061 |
FOXO6 | -6422 |
RPS6KB2 | -6218 |
NR4A1 | 2131 |
AKT3 | 2465 |
CREB1 | 6457 |
CDC6 association with the ORC:origin complex
127 | |
---|---|
set | CDC6 association with the ORC:origin complex |
setSize | 11 |
pANOVA | 0.00597 |
s.dist | 0.479 |
p.adjustANOVA | 0.0562 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ORC3 | 11135 |
ORC5 | 9801 |
ORC4 | 9610 |
E2F3 | 7730 |
ORC2 | 7384 |
CDC6 | 6081 |
E2F2 | 4801 |
MCM8 | 3500 |
E2F1 | 3051 |
ORC6 | 1568 |
ORC1 | 1006 |
GeneID | Gene Rank |
---|---|
ORC3 | 11135 |
ORC5 | 9801 |
ORC4 | 9610 |
E2F3 | 7730 |
ORC2 | 7384 |
CDC6 | 6081 |
E2F2 | 4801 |
MCM8 | 3500 |
E2F1 | 3051 |
ORC6 | 1568 |
ORC1 | 1006 |
Josephin domain DUBs
585 | |
---|---|
set | Josephin domain DUBs |
setSize | 10 |
pANOVA | 0.00889 |
s.dist | -0.478 |
p.adjustANOVA | 0.071 |
Top enriched genes
GeneID | Gene Rank |
---|---|
JOSD2 | -9000 |
RPS27A | -8388 |
JOSD1 | -8057 |
UBA52 | -7375 |
VCP | -5402 |
UBB | -4944 |
RAD23A | -4413 |
UBC | -4177 |
RAD23B | -1815 |
ATXN3 | 7508 |
GeneID | Gene Rank |
---|---|
JOSD2 | -9000 |
RPS27A | -8388 |
JOSD1 | -8057 |
UBA52 | -7375 |
VCP | -5402 |
UBB | -4944 |
RAD23A | -4413 |
UBC | -4177 |
RAD23B | -1815 |
ATXN3 | 7508 |
Cytosolic iron-sulfur cluster assembly
229 | |
---|---|
set | Cytosolic iron-sulfur cluster assembly |
setSize | 13 |
pANOVA | 0.00362 |
s.dist | -0.466 |
p.adjustANOVA | 0.0406 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NUBP2 | -9876 |
POLD1 | -8854 |
CIAO2B | -8649 |
CIAO3 | -8269 |
CIAO1 | -7175 |
CIAPIN1 | -6967 |
ERCC2 | -6248 |
RTEL1 | -6202 |
NDOR1 | -4525 |
MMS19 | -2760 |
NUBP1 | -2271 |
BRIP1 | 6803 |
ABCB7 | 6813 |
GeneID | Gene Rank |
---|---|
NUBP2 | -9876 |
POLD1 | -8854 |
CIAO2B | -8649 |
CIAO3 | -8269 |
CIAO1 | -7175 |
CIAPIN1 | -6967 |
ERCC2 | -6248 |
RTEL1 | -6202 |
NDOR1 | -4525 |
MMS19 | -2760 |
NUBP1 | -2271 |
BRIP1 | 6803 |
ABCB7 | 6813 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
745 | |
---|---|
set | Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) |
setSize | 114 |
pANOVA | 4.58e-17 |
s.dist | -0.455 |
p.adjustANOVA | 4.47e-15 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
MAGOH | -9339 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
MAGOH | -9339 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
PPP2R1A | -7631 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
EIF4G1 | -7029 |
RPL35A | -6977 |
RPL15 | -6926 |
SMG5 | -6880 |
UPF1 | -6778 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
RPL36A | -5966 |
EIF4A3 | -5845 |
RNPS1 | -5842 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
SMG6 | -5602 |
RPL5 | -5445 |
RBM8A | -5382 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
CASC3 | -5239 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
UPF3A | -4433 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
GSPT2 | -972 |
RPS24 | -89 |
RPL23A | 138 |
SMG1 | 158 |
SMG9 | 235 |
RPL6 | 1290 |
RPS4X | 1825 |
RPS3A | 3173 |
SMG7 | 4285 |
PABPC1 | 4591 |
RPSA | 5249 |
PPP2CA | 5682 |
SMG8 | 6313 |
MAGOHB | 7179 |
DCP1A | 7220 |
GSPT1 | 7510 |
UPF3B | 8196 |
ETF1 | 8214 |
RPL22L1 | 8317 |
RPL3L | 8978 |
RPS27L | 9625 |
UPF2 | 10521 |
NCBP1 | 10864 |
NCBP2 | 11208 |
PNRC2 | 11638 |
PPP2R2A | 11691 |
Nonsense-Mediated Decay (NMD)
747 | |
---|---|
set | Nonsense-Mediated Decay (NMD) |
setSize | 114 |
pANOVA | 4.58e-17 |
s.dist | -0.455 |
p.adjustANOVA | 4.47e-15 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
MAGOH | -9339 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
MAGOH | -9339 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
PPP2R1A | -7631 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
EIF4G1 | -7029 |
RPL35A | -6977 |
RPL15 | -6926 |
SMG5 | -6880 |
UPF1 | -6778 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
RPL36A | -5966 |
EIF4A3 | -5845 |
RNPS1 | -5842 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
SMG6 | -5602 |
RPL5 | -5445 |
RBM8A | -5382 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
CASC3 | -5239 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
UPF3A | -4433 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
GSPT2 | -972 |
RPS24 | -89 |
RPL23A | 138 |
SMG1 | 158 |
SMG9 | 235 |
RPL6 | 1290 |
RPS4X | 1825 |
RPS3A | 3173 |
SMG7 | 4285 |
PABPC1 | 4591 |
RPSA | 5249 |
PPP2CA | 5682 |
SMG8 | 6313 |
MAGOHB | 7179 |
DCP1A | 7220 |
GSPT1 | 7510 |
UPF3B | 8196 |
ETF1 | 8214 |
RPL22L1 | 8317 |
RPL3L | 8978 |
RPS27L | 9625 |
UPF2 | 10521 |
NCBP1 | 10864 |
NCBP2 | 11208 |
PNRC2 | 11638 |
PPP2R2A | 11691 |
Cap-dependent Translation Initiation
145 | |
---|---|
set | Cap-dependent Translation Initiation |
setSize | 118 |
pANOVA | 1.45e-17 |
s.dist | -0.454 |
p.adjustANOVA | 1.8e-15 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
EIF3F | -10244 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
EIF3C | -9873 |
RPL3 | -9867 |
EIF4H | -9779 |
RPL8 | -9738 |
EIF3G | -9710 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
EIF3F | -10244 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
EIF3C | -9873 |
RPL3 | -9867 |
EIF4H | -9779 |
RPL8 | -9738 |
EIF3G | -9710 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
EIF3B | -8804 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
EIF3I | -7931 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
EIF4G1 | -7029 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
EIF4B | -6655 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
EIF3K | -6222 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
EIF3D | -5647 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
EIF2B4 | -4674 |
EIF4EBP1 | -4513 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
EIF3H | -1365 |
RPS24 | -89 |
RPL23A | 138 |
EIF2B2 | 679 |
EIF2B5 | 1132 |
RPL6 | 1290 |
EIF4A1 | 1541 |
RPS4X | 1825 |
EIF3A | 1969 |
RPS3A | 3173 |
EIF2B3 | 3221 |
PABPC1 | 4591 |
RPSA | 5249 |
EIF3E | 8272 |
RPL22L1 | 8317 |
EIF3M | 8578 |
EIF1AX | 8776 |
RPL3L | 8978 |
EIF2S2 | 9317 |
EIF2S1 | 9563 |
RPS27L | 9625 |
EIF2B1 | 9745 |
EIF3J | 9804 |
EIF5B | 9825 |
EIF4A2 | 10043 |
EIF2S3 | 10258 |
EIF5 | 10905 |
EIF4E | 11624 |
Eukaryotic Translation Initiation
354 | |
---|---|
set | Eukaryotic Translation Initiation |
setSize | 118 |
pANOVA | 1.45e-17 |
s.dist | -0.454 |
p.adjustANOVA | 1.8e-15 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
EIF3F | -10244 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
EIF3C | -9873 |
RPL3 | -9867 |
EIF4H | -9779 |
RPL8 | -9738 |
EIF3G | -9710 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
EIF3F | -10244 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
EIF3C | -9873 |
RPL3 | -9867 |
EIF4H | -9779 |
RPL8 | -9738 |
EIF3G | -9710 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
EIF3B | -8804 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
EIF3I | -7931 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
EIF4G1 | -7029 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
EIF4B | -6655 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
EIF3K | -6222 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
EIF3D | -5647 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
EIF2B4 | -4674 |
EIF4EBP1 | -4513 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
EIF3H | -1365 |
RPS24 | -89 |
RPL23A | 138 |
EIF2B2 | 679 |
EIF2B5 | 1132 |
RPL6 | 1290 |
EIF4A1 | 1541 |
RPS4X | 1825 |
EIF3A | 1969 |
RPS3A | 3173 |
EIF2B3 | 3221 |
PABPC1 | 4591 |
RPSA | 5249 |
EIF3E | 8272 |
RPL22L1 | 8317 |
EIF3M | 8578 |
EIF1AX | 8776 |
RPL3L | 8978 |
EIF2S2 | 9317 |
EIF2S1 | 9563 |
RPS27L | 9625 |
EIF2B1 | 9745 |
EIF3J | 9804 |
EIF5B | 9825 |
EIF4A2 | 10043 |
EIF2S3 | 10258 |
EIF5 | 10905 |
EIF4E | 11624 |
Formation of the ternary complex, and subsequently, the 43S complex
401 | |
---|---|
set | Formation of the ternary complex, and subsequently, the 43S complex |
setSize | 51 |
pANOVA | 4.73e-08 |
s.dist | -0.442 |
p.adjustANOVA | 2.31e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3F | -10244 |
RPS2 | -10243 |
RPS29 | -10049 |
RPS17 | -9962 |
EIF3C | -9873 |
EIF3G | -9710 |
RPS16 | -9633 |
RPS21 | -9530 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPS28 | -8941 |
RPS19 | -8814 |
EIF3B | -8804 |
RPS11 | -8677 |
GeneID | Gene Rank |
---|---|
EIF3F | -10244 |
RPS2 | -10243 |
RPS29 | -10049 |
RPS17 | -9962 |
EIF3C | -9873 |
EIF3G | -9710 |
RPS16 | -9633 |
RPS21 | -9530 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPS28 | -8941 |
RPS19 | -8814 |
EIF3B | -8804 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPS14 | -8173 |
EIF3I | -7931 |
RPS15A | -7835 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPS6 | -7364 |
RPS7 | -6568 |
EIF3K | -6222 |
RPS25 | -5670 |
EIF3D | -5647 |
RPS13 | -5170 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
EIF3H | -1365 |
RPS24 | -89 |
RPS4X | 1825 |
EIF3A | 1969 |
RPS3A | 3173 |
RPSA | 5249 |
EIF3E | 8272 |
EIF3M | 8578 |
EIF1AX | 8776 |
EIF2S2 | 9317 |
EIF2S1 | 9563 |
RPS27L | 9625 |
EIF3J | 9804 |
EIF2S3 | 10258 |
GP1b-IX-V activation signalling
430 | |
---|---|
set | GP1b-IX-V activation signalling |
setSize | 10 |
pANOVA | 0.0156 |
s.dist | -0.442 |
p.adjustANOVA | 0.102 |
Top enriched genes
GeneID | Gene Rank |
---|---|
VWF | -8805 |
GP9 | -8734 |
FLNA | -8138 |
GP1BB | -7511 |
GP1BA | -6740 |
PIK3R1 | -5056 |
SRC | -4258 |
GP5 | -3922 |
RAF1 | 1476 |
YWHAZ | 9618 |
GeneID | Gene Rank |
---|---|
VWF | -8805 |
GP9 | -8734 |
FLNA | -8138 |
GP1BB | -7511 |
GP1BA | -6740 |
PIK3R1 | -5056 |
SRC | -4258 |
GP5 | -3922 |
RAF1 | 1476 |
YWHAZ | 9618 |
RNA Polymerase I Promoter Opening
904 | |
---|---|
set | RNA Polymerase I Promoter Opening |
setSize | 19 |
pANOVA | 0.001 |
s.dist | -0.436 |
p.adjustANOVA | 0.0167 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MAPK3 | -10100.0 |
H2AZ1 | -8776.0 |
H2BC12 | -8742.0 |
H2BC17 | -8346.0 |
H3C15 | -8038.5 |
UBTF | -8001.0 |
H2BC4 | -7928.0 |
H2AJ | -7536.0 |
H2BC9 | -6894.0 |
H2BC11 | -5751.0 |
H2BC21 | -5415.0 |
H2BC15 | -4416.0 |
H2AC6 | -4383.0 |
H2BC5 | -3070.0 |
H2AZ2 | -2475.0 |
H2BU1 | 2721.0 |
H2AC20 | 3907.0 |
H3-3A | 5193.0 |
MBD2 | 9375.0 |
GeneID | Gene Rank |
---|---|
MAPK3 | -10100.0 |
H2AZ1 | -8776.0 |
H2BC12 | -8742.0 |
H2BC17 | -8346.0 |
H3C15 | -8038.5 |
UBTF | -8001.0 |
H2BC4 | -7928.0 |
H2AJ | -7536.0 |
H2BC9 | -6894.0 |
H2BC11 | -5751.0 |
H2BC21 | -5415.0 |
H2BC15 | -4416.0 |
H2AC6 | -4383.0 |
H2BC5 | -3070.0 |
H2AZ2 | -2475.0 |
H2BU1 | 2721.0 |
H2AC20 | 3907.0 |
H3-3A | 5193.0 |
MBD2 | 9375.0 |
Condensation of Prometaphase Chromosomes
205 | |
---|---|
set | Condensation of Prometaphase Chromosomes |
setSize | 11 |
pANOVA | 0.0125 |
s.dist | 0.435 |
p.adjustANOVA | 0.0883 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SMC4 | 11305 |
SMC2 | 10493 |
CDK1 | 9135 |
NCAPG | 8163 |
NCAPH | 6083 |
CCNB1 | 5971 |
CCNB2 | 5588 |
CSNK2A1 | 3172 |
CSNK2A2 | 2068 |
CSNK2B | 178 |
NCAPD2 | -1837 |
GeneID | Gene Rank |
---|---|
SMC4 | 11305 |
SMC2 | 10493 |
CDK1 | 9135 |
NCAPG | 8163 |
NCAPH | 6083 |
CCNB1 | 5971 |
CCNB2 | 5588 |
CSNK2A1 | 3172 |
CSNK2A2 | 2068 |
CSNK2B | 178 |
NCAPD2 | -1837 |
Trafficking of GluR2-containing AMPA receptors
1251 | |
---|---|
set | Trafficking of GluR2-containing AMPA receptors |
setSize | 12 |
pANOVA | 0.00931 |
s.dist | -0.433 |
p.adjustANOVA | 0.0728 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PICK1 | -9237 |
AP2M1 | -8930 |
PRKCB | -8270 |
AP2A2 | -7814 |
AP2A1 | -6826 |
PRKCA | -6088 |
AP2S1 | -3863 |
AP2B1 | -3395 |
TSPAN7 | -2479 |
GRIP1 | -1255 |
NSF | 2368 |
GRIA4 | 6394 |
GeneID | Gene Rank |
---|---|
PICK1 | -9237 |
AP2M1 | -8930 |
PRKCB | -8270 |
AP2A2 | -7814 |
AP2A1 | -6826 |
PRKCA | -6088 |
AP2S1 | -3863 |
AP2B1 | -3395 |
TSPAN7 | -2479 |
GRIP1 | -1255 |
NSF | 2368 |
GRIA4 | 6394 |
Regulation of FZD by ubiquitination
954 | |
---|---|
set | Regulation of FZD by ubiquitination |
setSize | 16 |
pANOVA | 0.00272 |
s.dist | -0.433 |
p.adjustANOVA | 0.0338 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FZD8 | -10178 |
LRP6 | -8827 |
RPS27A | -8388 |
LRP5 | -7595 |
UBA52 | -7375 |
LGR4 | -6601 |
ZNRF3 | -6501 |
FZD6 | -5293 |
UBB | -4944 |
LGR6 | -4753 |
UBC | -4177 |
RSPO4 | -4068 |
RNF43 | -2783 |
FZD5 | 1477 |
FZD4 | 2728 |
USP8 | 11545 |
GeneID | Gene Rank |
---|---|
FZD8 | -10178 |
LRP6 | -8827 |
RPS27A | -8388 |
LRP5 | -7595 |
UBA52 | -7375 |
LGR4 | -6601 |
ZNRF3 | -6501 |
FZD6 | -5293 |
UBB | -4944 |
LGR6 | -4753 |
UBC | -4177 |
RSPO4 | -4068 |
RNF43 | -2783 |
FZD5 | 1477 |
FZD4 | 2728 |
USP8 | 11545 |
Presynaptic phase of homologous DNA pairing and strand exchange
854 | |
---|---|
set | Presynaptic phase of homologous DNA pairing and strand exchange |
setSize | 39 |
pANOVA | 3.16e-06 |
s.dist | 0.431 |
p.adjustANOVA | 9.81e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RAD51B | 11348 |
RBBP8 | 11241 |
RMI1 | 11215 |
RMI2 | 11085 |
NBN | 10610 |
RAD50 | 10371 |
DNA2 | 9957 |
RAD17 | 9946 |
RFC4 | 9891 |
BRCA2 | 9757 |
RAD9B | 9234 |
RAD51C | 9158 |
HUS1 | 9132 |
BARD1 | 9023 |
TOPBP1 | 8826 |
BRCA1 | 8138 |
RFC3 | 7972 |
CHEK1 | 7791 |
BRIP1 | 6803 |
RAD1 | 6800 |
GeneID | Gene Rank |
---|---|
RAD51B | 11348 |
RBBP8 | 11241 |
RMI1 | 11215 |
RMI2 | 11085 |
NBN | 10610 |
RAD50 | 10371 |
DNA2 | 9957 |
RAD17 | 9946 |
RFC4 | 9891 |
BRCA2 | 9757 |
RAD9B | 9234 |
RAD51C | 9158 |
HUS1 | 9132 |
BARD1 | 9023 |
TOPBP1 | 8826 |
BRCA1 | 8138 |
RFC3 | 7972 |
CHEK1 | 7791 |
BRIP1 | 6803 |
RAD1 | 6800 |
RAD51 | 6337 |
RPA2 | 5538 |
ATR | 4908 |
BLM | 4120 |
WRN | 4117 |
RHNO1 | 3076 |
EXO1 | 2398 |
RPA3 | 2293 |
ATRIP | 2287 |
MRE11 | 2275 |
RFC5 | 919 |
KAT5 | -301 |
XRCC2 | -645 |
RFC2 | -697 |
ATM | -768 |
RAD9A | -1761 |
TOP3A | -2746 |
RAD51D | -2821 |
RPA1 | -4771 |
SUMOylation of DNA methylation proteins
1048 | |
---|---|
set | SUMOylation of DNA methylation proteins |
setSize | 16 |
pANOVA | 0.00305 |
s.dist | -0.428 |
p.adjustANOVA | 0.0369 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DNMT3B | -9878 |
RING1 | -9757 |
CBX4 | -9599 |
CBX2 | -9370 |
DNMT1 | -8737 |
PHC1 | -8697 |
DNMT3A | -8681 |
PHC2 | -6906 |
PCGF2 | -6871 |
SCMH1 | -6232 |
UBE2I | -5999 |
CBX8 | -4050 |
PHC3 | 4542 |
BMI1 | 5940 |
RNF2 | 9121 |
SUMO1 | 10348 |
GeneID | Gene Rank |
---|---|
DNMT3B | -9878 |
RING1 | -9757 |
CBX4 | -9599 |
CBX2 | -9370 |
DNMT1 | -8737 |
PHC1 | -8697 |
DNMT3A | -8681 |
PHC2 | -6906 |
PCGF2 | -6871 |
SCMH1 | -6232 |
UBE2I | -5999 |
CBX8 | -4050 |
PHC3 | 4542 |
BMI1 | 5940 |
RNF2 | 9121 |
SUMO1 | 10348 |
Selenoamino acid metabolism
1062 | |
---|---|
set | Selenoamino acid metabolism |
setSize | 114 |
pANOVA | 6.82e-15 |
s.dist | -0.422 |
p.adjustANOVA | 6.22e-13 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
QARS1 | -9481 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
QARS1 | -9481 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
AHCY | -9076 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
SCLY | -6549 |
RPL14 | -6402 |
RPL21 | -6288 |
SARS1 | -6084 |
RPL36A | -5966 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
EEFSEC | -5241 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
AIMP2 | -3560 |
RPS8 | -3073 |
RPS20 | -3024 |
PSTK | -2534 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
GNMT | -2001 |
GSR | -1712 |
RPS24 | -89 |
SEPHS2 | -59 |
RPL23A | 138 |
IARS1 | 657 |
MARS1 | 916 |
RPL6 | 1290 |
RPS4X | 1825 |
INMT | 2731 |
RPS3A | 3173 |
TXNRD1 | 4413 |
KARS1 | 4630 |
RPSA | 5249 |
SEPSECS | 7020 |
HNMT | 7288 |
SECISBP2 | 7391 |
EPRS1 | 7458 |
CBS | 7520 |
CTH | 7660 |
RPL22L1 | 8317 |
RPL3L | 8978 |
RPS27L | 9625 |
LARS1 | 9915 |
PAPSS1 | 10005 |
EEF1E1 | 10288 |
RARS1 | 10725 |
PAPSS2 | 10749 |
DARS1 | 11223 |
AIMP1 | 11596 |
Processing and activation of SUMO
855 | |
---|---|
set | Processing and activation of SUMO |
setSize | 10 |
pANOVA | 0.0218 |
s.dist | 0.419 |
p.adjustANOVA | 0.132 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SUMO1 | 10348 |
SENP5 | 9908 |
SENP2 | 9874 |
RWDD3 | 9390 |
SUMO2 | 9303 |
SENP1 | 8191 |
UBA2 | 6139 |
SUMO3 | 4470 |
UBE2I | -5999 |
SAE1 | -8538 |
GeneID | Gene Rank |
---|---|
SUMO1 | 10348 |
SENP5 | 9908 |
SENP2 | 9874 |
RWDD3 | 9390 |
SUMO2 | 9303 |
SENP1 | 8191 |
UBA2 | 6139 |
SUMO3 | 4470 |
UBE2I | -5999 |
SAE1 | -8538 |
SRP-dependent cotranslational protein targeting to membrane
1043 | |
---|---|
set | SRP-dependent cotranslational protein targeting to membrane |
setSize | 111 |
pANOVA | 1.48e-13 |
s.dist | -0.406 |
p.adjustANOVA | 1.13e-11 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
RPS5 | -9130 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
DDOST | -8281 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
SSR4 | -6292 |
RPN1 | -6289 |
RPL21 | -6288 |
RPL36A | -5966 |
SRPRA | -5918 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
RPL10A | -4820 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
SEC61B | -2646 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
SEC61A1 | -977 |
RPS24 | -89 |
RPL23A | 138 |
SEC11A | 1049 |
RPL6 | 1290 |
RPS4X | 1825 |
SSR2 | 2011 |
RPS3A | 3173 |
SPCS1 | 4379 |
SRP68 | 4427 |
RPN2 | 4596 |
RPSA | 5249 |
SRP72 | 6253 |
SRPRB | 6450 |
SRP14 | 6458 |
SSR1 | 7422 |
SSR3 | 8240 |
RPL22L1 | 8317 |
RPL3L | 8978 |
SEC61A2 | 9571 |
RPS27L | 9625 |
TRAM1 | 9735 |
SPCS3 | 10797 |
SEC11C | 10820 |
SRP9 | 10867 |
SRP19 | 11022 |
SPCS2 | 11036 |
SEC61G | 11123 |
SRP54 | 11724 |
Olfactory Signaling Pathway
768 | |
---|---|
set | Olfactory Signaling Pathway |
setSize | 61 |
pANOVA | 5.11e-08 |
s.dist | 0.403 |
p.adjustANOVA | 2.41e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
OR2AT4 | 11604 |
OR8A1 | 11448 |
OR2M3 | 11395 |
RTP4 | 11292 |
OR10H5 | 10984 |
OR6Y1 | 10944 |
OR10G3 | 10629 |
OR2C3 | 10611 |
OR6K3 | 10427 |
OR7C1 | 10226 |
OR2A5 | 9979 |
OR2T33 | 9961 |
OR2I1P | 9910 |
OR2G6 | 9516 |
OR10A6 | 9513 |
OR2L2 | 9392 |
OR2V2 | 9225 |
OR52K1 | 9191 |
OR5A2 | 9048 |
OR7A5 | 9014 |
GeneID | Gene Rank |
---|---|
OR2AT4 | 11604 |
OR8A1 | 11448 |
OR2M3 | 11395 |
RTP4 | 11292 |
OR10H5 | 10984 |
OR6Y1 | 10944 |
OR10G3 | 10629 |
OR2C3 | 10611 |
OR6K3 | 10427 |
OR7C1 | 10226 |
OR2A5 | 9979 |
OR2T33 | 9961 |
OR2I1P | 9910 |
OR2G6 | 9516 |
OR10A6 | 9513 |
OR2L2 | 9392 |
OR2V2 | 9225 |
OR52K1 | 9191 |
OR5A2 | 9048 |
OR7A5 | 9014 |
REEP3 | 8840 |
OR4E1 | 8769 |
OR6C75 | 8698 |
OR1I1 | 8672 |
OR1D2 | 8419 |
OR51L1 | 8101 |
OR5AS1 | 8048 |
RTP5 | 7976 |
OR1C1 | 7818 |
REEP1 | 7706 |
OR56A1 | 7701 |
OR7G2 | 7525 |
OR2M4 | 7488 |
OR2H2 | 7445 |
OR52N4 | 6649 |
OR14J1 | 6491 |
OR4D9 | 6454 |
OR5A1 | 5489 |
REEP5 | 5355 |
OR7D4 | 4655 |
OR4D1 | 4519 |
OR5AU1 | 3772 |
OR5AN1 | 3574 |
OR4K17 | 1760 |
OR1M1 | 1175 |
OR1A1 | 1065 |
OR14L1P | 848 |
REEP2 | 459 |
OR2B11 | 252 |
OR7A17 | -658 |
OR52A1 | -2141 |
OR2W3 | -2772 |
OR10AC1 | -3145 |
OR7D2 | -3238 |
OR2A7 | -3414 |
OR3A3 | -3468 |
GNB1 | -5109 |
GNAL | -6950 |
REEP4 | -8128 |
OR2A1 | -8172 |
REEP6 | -10290 |
Homologous DNA Pairing and Strand Exchange
502 | |
---|---|
set | Homologous DNA Pairing and Strand Exchange |
setSize | 42 |
pANOVA | 6.3e-06 |
s.dist | 0.403 |
p.adjustANOVA | 0.000191 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RAD51B | 11348 |
RBBP8 | 11241 |
RMI1 | 11215 |
RMI2 | 11085 |
NBN | 10610 |
RAD50 | 10371 |
DNA2 | 9957 |
RAD17 | 9946 |
RFC4 | 9891 |
BRCA2 | 9757 |
RAD9B | 9234 |
RAD51C | 9158 |
HUS1 | 9132 |
BARD1 | 9023 |
TOPBP1 | 8826 |
BRCA1 | 8138 |
RFC3 | 7972 |
RAD51AP1 | 7821 |
CHEK1 | 7791 |
BRIP1 | 6803 |
GeneID | Gene Rank |
---|---|
RAD51B | 11348 |
RBBP8 | 11241 |
RMI1 | 11215 |
RMI2 | 11085 |
NBN | 10610 |
RAD50 | 10371 |
DNA2 | 9957 |
RAD17 | 9946 |
RFC4 | 9891 |
BRCA2 | 9757 |
RAD9B | 9234 |
RAD51C | 9158 |
HUS1 | 9132 |
BARD1 | 9023 |
TOPBP1 | 8826 |
BRCA1 | 8138 |
RFC3 | 7972 |
RAD51AP1 | 7821 |
CHEK1 | 7791 |
BRIP1 | 6803 |
RAD1 | 6800 |
RAD51 | 6337 |
RPA2 | 5538 |
ATR | 4908 |
BLM | 4120 |
WRN | 4117 |
PALB2 | 3783 |
RHNO1 | 3076 |
EXO1 | 2398 |
RPA3 | 2293 |
ATRIP | 2287 |
MRE11 | 2275 |
RFC5 | 919 |
KAT5 | -301 |
XRCC2 | -645 |
RFC2 | -697 |
ATM | -768 |
RAD9A | -1761 |
TOP3A | -2746 |
RAD51D | -2821 |
RPA1 | -4771 |
XRCC3 | -8531 |
FOXO-mediated transcription of cell death genes
373 | |
---|---|
set | FOXO-mediated transcription of cell death genes |
setSize | 16 |
pANOVA | 0.00558 |
s.dist | -0.4 |
p.adjustANOVA | 0.0534 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FOXO4 | -9911 |
PINK1 | -9108 |
STK11 | -8976 |
CREBBP | -8918 |
BBC3 | -8875 |
FOXO1 | -8143 |
FOXO3 | -7061 |
CITED2 | -5315 |
FASLG | -4042 |
EP300 | -2667 |
BCL6 | -2615 |
NFYA | -556 |
BCL2L11 | 196 |
DDIT3 | 2994 |
NFYC | 5216 |
NFYB | 7833 |
GeneID | Gene Rank |
---|---|
FOXO4 | -9911 |
PINK1 | -9108 |
STK11 | -8976 |
CREBBP | -8918 |
BBC3 | -8875 |
FOXO1 | -8143 |
FOXO3 | -7061 |
CITED2 | -5315 |
FASLG | -4042 |
EP300 | -2667 |
BCL6 | -2615 |
NFYA | -556 |
BCL2L11 | 196 |
DDIT3 | 2994 |
NFYC | 5216 |
NFYB | 7833 |
A tetrasaccharide linker sequence is required for GAG synthesis
1 | |
---|---|
set | A tetrasaccharide linker sequence is required for GAG synthesis |
setSize | 18 |
pANOVA | 0.00339 |
s.dist | -0.399 |
p.adjustANOVA | 0.0392 |
Top enriched genes
GeneID | Gene Rank |
---|---|
B3GAT3 | -9818 |
XYLT1 | -9723 |
GPC4 | -9454 |
B3GALT6 | -8920 |
XYLT2 | -8645 |
B4GALT7 | -8207 |
GPC1 | -8099 |
GPC2 | -7735 |
HSPG2 | -5458 |
CSPG4 | -4429 |
B3GAT2 | -1900 |
SDC4 | -1368 |
B3GAT1 | 18 |
SDC3 | 1680 |
VCAN | 1854 |
DCN | 2926 |
SDC2 | 3889 |
AGRN | 6202 |
GeneID | Gene Rank |
---|---|
B3GAT3 | -9818 |
XYLT1 | -9723 |
GPC4 | -9454 |
B3GALT6 | -8920 |
XYLT2 | -8645 |
B4GALT7 | -8207 |
GPC1 | -8099 |
GPC2 | -7735 |
HSPG2 | -5458 |
CSPG4 | -4429 |
B3GAT2 | -1900 |
SDC4 | -1368 |
B3GAT1 | 18 |
SDC3 | 1680 |
VCAN | 1854 |
DCN | 2926 |
SDC2 | 3889 |
AGRN | 6202 |
rRNA processing in the mitochondrion
1358 | |
---|---|
set | rRNA processing in the mitochondrion |
setSize | 29 |
pANOVA | 0.000227 |
s.dist | -0.395 |
p.adjustANOVA | 0.00468 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MT-ATP8 | -10332 |
MT-ATP6 | -9606 |
MT-ND4L | -9074 |
MT-CO3 | -8680 |
MT-ND3 | -8450 |
MT-TV | -8443 |
MT-TF | -8294 |
MT-TL2 | -7298 |
MT-CYB | -7017 |
MT-TM | -6674 |
MT-ND1 | -6593 |
MT-ND5 | -6176 |
MRM1 | -5820 |
MTERF4 | -5707 |
MT-CO2 | -5700 |
MT-ND2 | -4966 |
MT-TL1 | -3853 |
MT-RNR2 | -3648 |
MT-RNR1 | -3295 |
HSD17B10 | -2865 |
GeneID | Gene Rank |
---|---|
MT-ATP8 | -10332 |
MT-ATP6 | -9606 |
MT-ND4L | -9074 |
MT-CO3 | -8680 |
MT-ND3 | -8450 |
MT-TV | -8443 |
MT-TF | -8294 |
MT-TL2 | -7298 |
MT-CYB | -7017 |
MT-TM | -6674 |
MT-ND1 | -6593 |
MT-ND5 | -6176 |
MRM1 | -5820 |
MTERF4 | -5707 |
MT-CO2 | -5700 |
MT-ND2 | -4966 |
MT-TL1 | -3853 |
MT-RNR2 | -3648 |
MT-RNR1 | -3295 |
HSD17B10 | -2865 |
ELAC2 | -2324 |
MRM3 | -2058 |
MRM2 | -1116 |
MT-CO1 | -685 |
MT-ND4 | 3305 |
NSUN4 | 4732 |
PRORP | 6071 |
TFB1M | 6776 |
TRMT10C | 10717 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
1192 | |
---|---|
set | TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) |
setSize | 16 |
pANOVA | 0.00639 |
s.dist | -0.394 |
p.adjustANOVA | 0.0583 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PARD6A | -9275 |
RPS27A | -8388 |
TGFB1 | -8091 |
TGFBR2 | -8064 |
PRKCZ | -7701 |
UBA52 | -7375 |
ARHGEF18 | -5836 |
CGN | -5578 |
UBB | -4944 |
F11R | -4885 |
UBC | -4177 |
PARD3 | -2235 |
SMURF1 | -1891 |
TGFBR1 | 5352 |
FKBP1A | 6665 |
RHOA | 7611 |
GeneID | Gene Rank |
---|---|
PARD6A | -9275 |
RPS27A | -8388 |
TGFB1 | -8091 |
TGFBR2 | -8064 |
PRKCZ | -7701 |
UBA52 | -7375 |
ARHGEF18 | -5836 |
CGN | -5578 |
UBB | -4944 |
F11R | -4885 |
UBC | -4177 |
PARD3 | -2235 |
SMURF1 | -1891 |
TGFBR1 | 5352 |
FKBP1A | 6665 |
RHOA | 7611 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
50 | |
---|---|
set | Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S |
setSize | 59 |
pANOVA | 2.08e-07 |
s.dist | -0.391 |
p.adjustANOVA | 8.61e-06 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3F | -10244 |
RPS2 | -10243 |
RPS29 | -10049 |
RPS17 | -9962 |
EIF3C | -9873 |
EIF4H | -9779 |
EIF3G | -9710 |
RPS16 | -9633 |
RPS21 | -9530 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPS28 | -8941 |
RPS19 | -8814 |
EIF3B | -8804 |
GeneID | Gene Rank |
---|---|
EIF3F | -10244 |
RPS2 | -10243 |
RPS29 | -10049 |
RPS17 | -9962 |
EIF3C | -9873 |
EIF4H | -9779 |
EIF3G | -9710 |
RPS16 | -9633 |
RPS21 | -9530 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPS28 | -8941 |
RPS19 | -8814 |
EIF3B | -8804 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPS14 | -8173 |
EIF3I | -7931 |
RPS15A | -7835 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPS6 | -7364 |
EIF4G1 | -7029 |
EIF4B | -6655 |
RPS7 | -6568 |
EIF3K | -6222 |
RPS25 | -5670 |
EIF3D | -5647 |
RPS13 | -5170 |
EIF4EBP1 | -4513 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
EIF3H | -1365 |
RPS24 | -89 |
EIF4A1 | 1541 |
RPS4X | 1825 |
EIF3A | 1969 |
RPS3A | 3173 |
PABPC1 | 4591 |
RPSA | 5249 |
EIF3E | 8272 |
EIF3M | 8578 |
EIF1AX | 8776 |
EIF2S2 | 9317 |
EIF2S1 | 9563 |
RPS27L | 9625 |
EIF3J | 9804 |
EIF4A2 | 10043 |
EIF2S3 | 10258 |
EIF4E | 11624 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2
1327 | |
---|---|
set | WNT5A-dependent internalization of FZD2, FZD5 and ROR2 |
setSize | 11 |
pANOVA | 0.0249 |
s.dist | -0.391 |
p.adjustANOVA | 0.147 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AP2M1 | -8930 |
CLTB | -8800 |
AP2A2 | -7814 |
FZD2 | -7097 |
AP2A1 | -6826 |
AP2S1 | -3863 |
AP2B1 | -3395 |
CLTA | 509 |
CLTC | 1283 |
FZD5 | 1477 |
ROR1 | 3385 |
GeneID | Gene Rank |
---|---|
AP2M1 | -8930 |
CLTB | -8800 |
AP2A2 | -7814 |
FZD2 | -7097 |
AP2A1 | -6826 |
AP2S1 | -3863 |
AP2B1 | -3395 |
CLTA | 509 |
CLTC | 1283 |
FZD5 | 1477 |
ROR1 | 3385 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
1177 | |
---|---|
set | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) |
setSize | 12 |
pANOVA | 0.0193 |
s.dist | -0.39 |
p.adjustANOVA | 0.121 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PTGS2 | -10227 |
PTGES2 | -9522 |
PRXL2B | -9063 |
AKR1C3 | -7972 |
PTGDS | -6443 |
PTGS1 | -6287 |
PTGR2 | -5053 |
CBR1 | -4667 |
PTGES | 202 |
TBXAS1 | 500 |
HPGD | 4018 |
PTGES3 | 10886 |
GeneID | Gene Rank |
---|---|
PTGS2 | -10227 |
PTGES2 | -9522 |
PRXL2B | -9063 |
AKR1C3 | -7972 |
PTGDS | -6443 |
PTGS1 | -6287 |
PTGR2 | -5053 |
CBR1 | -4667 |
PTGES | 202 |
TBXAS1 | 500 |
HPGD | 4018 |
PTGES3 | 10886 |
Pexophagy
816 | |
---|---|
set | Pexophagy |
setSize | 11 |
pANOVA | 0.0251 |
s.dist | -0.39 |
p.adjustANOVA | 0.147 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PEX5 | -8871 |
RPS27A | -8388 |
SQSTM1 | -7746 |
UBA52 | -7375 |
UBB | -4944 |
UBC | -4177 |
USP30 | -2323 |
ATM | -768 |
NBR1 | 483 |
MAP1LC3B | 1057 |
EPAS1 | 3063 |
GeneID | Gene Rank |
---|---|
PEX5 | -8871 |
RPS27A | -8388 |
SQSTM1 | -7746 |
UBA52 | -7375 |
UBB | -4944 |
UBC | -4177 |
USP30 | -2323 |
ATM | -768 |
NBR1 | 483 |
MAP1LC3B | 1057 |
EPAS1 | 3063 |
Translation initiation complex formation
1272 | |
---|---|
set | Translation initiation complex formation |
setSize | 58 |
pANOVA | 2.9e-07 |
s.dist | -0.389 |
p.adjustANOVA | 1.17e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3F | -10244 |
RPS2 | -10243 |
RPS29 | -10049 |
RPS17 | -9962 |
EIF3C | -9873 |
EIF4H | -9779 |
EIF3G | -9710 |
RPS16 | -9633 |
RPS21 | -9530 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPS28 | -8941 |
RPS19 | -8814 |
EIF3B | -8804 |
GeneID | Gene Rank |
---|---|
EIF3F | -10244 |
RPS2 | -10243 |
RPS29 | -10049 |
RPS17 | -9962 |
EIF3C | -9873 |
EIF4H | -9779 |
EIF3G | -9710 |
RPS16 | -9633 |
RPS21 | -9530 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPS28 | -8941 |
RPS19 | -8814 |
EIF3B | -8804 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPS14 | -8173 |
EIF3I | -7931 |
RPS15A | -7835 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPS6 | -7364 |
EIF4G1 | -7029 |
EIF4B | -6655 |
RPS7 | -6568 |
EIF3K | -6222 |
RPS25 | -5670 |
EIF3D | -5647 |
RPS13 | -5170 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
EIF3H | -1365 |
RPS24 | -89 |
EIF4A1 | 1541 |
RPS4X | 1825 |
EIF3A | 1969 |
RPS3A | 3173 |
PABPC1 | 4591 |
RPSA | 5249 |
EIF3E | 8272 |
EIF3M | 8578 |
EIF1AX | 8776 |
EIF2S2 | 9317 |
EIF2S1 | 9563 |
RPS27L | 9625 |
EIF3J | 9804 |
EIF4A2 | 10043 |
EIF2S3 | 10258 |
EIF4E | 11624 |
Influenza Viral RNA Transcription and Replication
530 | |
---|---|
set | Influenza Viral RNA Transcription and Replication |
setSize | 135 |
pANOVA | 9.54e-15 |
s.dist | -0.386 |
p.adjustANOVA | 7.67e-13 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
POLR2L | -10282 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
POM121C | -9374 |
GTF2F1 | -9355 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
GeneID | Gene Rank |
---|---|
RPL37 | -10308 |
POLR2L | -10282 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
POM121C | -9374 |
GTF2F1 | -9355 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
POLR2I | -9194 |
POLR2F | -9158 |
RPS5 | -9130 |
NUP210 | -9099 |
POLR2E | -9034 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
POM121 | -8910 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
RPL32 | -8070 |
POLR2G | -8006 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
POLR2A | -6255 |
POLR2J | -5993 |
RPL36A | -5966 |
NUP188 | -5843 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
PARP1 | -4864 |
RPL10A | -4820 |
POLR2H | -4752 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
SEC13 | -3159 |
NUP62 | -3119 |
RPS8 | -3073 |
RPS20 | -3024 |
POLR2C | -2998 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
IPO5 | -1917 |
AAAS | -1609 |
RPS24 | -89 |
NDC1 | -77 |
RPL23A | 138 |
RPL6 | 1290 |
RPS4X | 1825 |
NUP214 | 2090 |
NUP98 | 2149 |
NUP93 | 3043 |
NUP155 | 3103 |
RPS3A | 3173 |
NUP160 | 3296 |
NUP205 | 3520 |
NUP153 | 3654 |
NUP37 | 3973 |
GRSF1 | 4059 |
NUP88 | 4512 |
POLR2D | 4912 |
TPR | 4956 |
RPSA | 5249 |
GTF2F2 | 5332 |
NUP133 | 5417 |
RANBP2 | 5691 |
RAE1 | 6124 |
NUP85 | 6578 |
NUP58 | 6817 |
NUP50 | 7082 |
POLR2B | 7601 |
DNAJC3 | 7755 |
NUP107 | 7988 |
RPL22L1 | 8317 |
HSP90AA1 | 8431 |
NUP35 | 8941 |
RPL3L | 8978 |
RPS27L | 9625 |
SEH1L | 9849 |
POLR2K | 9927 |
NUP43 | 10569 |
NUP42 | 10900 |
NUP54 | 11540 |
MET activates RAP1 and RAC1
622 | |
---|---|
set | MET activates RAP1 and RAC1 |
setSize | 10 |
pANOVA | 0.0351 |
s.dist | 0.385 |
p.adjustANOVA | 0.183 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RAP1A | 11696 |
RAC1 | 9649 |
GAB1 | 8927 |
CRK | 8347 |
HGF | 8211 |
RAP1B | 7493 |
DOCK7 | 6267 |
GRB2 | 75 |
CRKL | -3376 |
RAPGEF1 | -7965 |
GeneID | Gene Rank |
---|---|
RAP1A | 11696 |
RAC1 | 9649 |
GAB1 | 8927 |
CRK | 8347 |
HGF | 8211 |
RAP1B | 7493 |
DOCK7 | 6267 |
GRB2 | 75 |
CRKL | -3376 |
RAPGEF1 | -7965 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
1005 | |
---|---|
set | Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) |
setSize | 26 |
pANOVA | 0.000729 |
s.dist | 0.383 |
p.adjustANOVA | 0.0126 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RAD51B | 11348 |
RBBP8 | 11241 |
RMI1 | 11215 |
RMI2 | 11085 |
NBN | 10610 |
RAD50 | 10371 |
DNA2 | 9957 |
BRCA2 | 9757 |
RAD51C | 9158 |
BARD1 | 9023 |
BRCA1 | 8138 |
RAD51AP1 | 7821 |
BRIP1 | 6803 |
RAD51 | 6337 |
BLM | 4120 |
WRN | 4117 |
PALB2 | 3783 |
EXO1 | 2398 |
MRE11 | 2275 |
KAT5 | -301 |
GeneID | Gene Rank |
---|---|
RAD51B | 11348 |
RBBP8 | 11241 |
RMI1 | 11215 |
RMI2 | 11085 |
NBN | 10610 |
RAD50 | 10371 |
DNA2 | 9957 |
BRCA2 | 9757 |
RAD51C | 9158 |
BARD1 | 9023 |
BRCA1 | 8138 |
RAD51AP1 | 7821 |
BRIP1 | 6803 |
RAD51 | 6337 |
BLM | 4120 |
WRN | 4117 |
PALB2 | 3783 |
EXO1 | 2398 |
MRE11 | 2275 |
KAT5 | -301 |
XRCC2 | -645 |
ATM | -768 |
TOP3A | -2746 |
RAD51D | -2821 |
RTEL1 | -6202 |
XRCC3 | -8531 |
Signaling by Leptin
1107 | |
---|---|
set | Signaling by Leptin |
setSize | 10 |
pANOVA | 0.037 |
s.dist | -0.381 |
p.adjustANOVA | 0.188 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SOCS3 | -10318 |
IRS1 | -9921 |
IRS2 | -9048 |
STAT5A | -7264 |
STAT5B | -6114 |
SH2B1 | -4573 |
LEPR | -1573 |
PTPN11 | -619 |
STAT3 | 2791 |
JAK2 | 11299 |
GeneID | Gene Rank |
---|---|
SOCS3 | -10318 |
IRS1 | -9921 |
IRS2 | -9048 |
STAT5A | -7264 |
STAT5B | -6114 |
SH2B1 | -4573 |
LEPR | -1573 |
PTPN11 | -619 |
STAT3 | 2791 |
JAK2 | 11299 |
Ribosomal scanning and start codon recognition
1018 | |
---|---|
set | Ribosomal scanning and start codon recognition |
setSize | 58 |
pANOVA | 5.74e-07 |
s.dist | -0.379 |
p.adjustANOVA | 2.12e-05 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EIF3F | -10244 |
RPS2 | -10243 |
RPS29 | -10049 |
RPS17 | -9962 |
EIF3C | -9873 |
EIF4H | -9779 |
EIF3G | -9710 |
RPS16 | -9633 |
RPS21 | -9530 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPS28 | -8941 |
RPS19 | -8814 |
EIF3B | -8804 |
GeneID | Gene Rank |
---|---|
EIF3F | -10244 |
RPS2 | -10243 |
RPS29 | -10049 |
RPS17 | -9962 |
EIF3C | -9873 |
EIF4H | -9779 |
EIF3G | -9710 |
RPS16 | -9633 |
RPS21 | -9530 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
EIF3L | -9269 |
RPS10 | -9222 |
RPS5 | -9130 |
RPS28 | -8941 |
RPS19 | -8814 |
EIF3B | -8804 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPS14 | -8173 |
EIF3I | -7931 |
RPS15A | -7835 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPS6 | -7364 |
EIF4G1 | -7029 |
EIF4B | -6655 |
RPS7 | -6568 |
EIF3K | -6222 |
RPS25 | -5670 |
EIF3D | -5647 |
RPS13 | -5170 |
RPS26 | -3701 |
RPS8 | -3073 |
RPS20 | -3024 |
EIF3H | -1365 |
RPS24 | -89 |
EIF4A1 | 1541 |
RPS4X | 1825 |
EIF3A | 1969 |
RPS3A | 3173 |
RPSA | 5249 |
EIF3E | 8272 |
EIF3M | 8578 |
EIF1AX | 8776 |
EIF2S2 | 9317 |
EIF2S1 | 9563 |
RPS27L | 9625 |
EIF3J | 9804 |
EIF4A2 | 10043 |
EIF2S3 | 10258 |
EIF5 | 10905 |
EIF4E | 11624 |
Pausing and recovery of Tat-mediated HIV elongation
808 | |
---|---|
set | Pausing and recovery of Tat-mediated HIV elongation |
setSize | 30 |
pANOVA | 0.000324 |
s.dist | -0.379 |
p.adjustANOVA | 0.0059 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2L | -10282 |
CDK9 | -10180 |
CTDP1 | -9955 |
NELFB | -9862 |
GTF2F1 | -9355 |
POLR2I | -9194 |
POLR2F | -9158 |
POLR2E | -9034 |
ELL | -8355 |
ELOB | -8164 |
POLR2G | -8006 |
SUPT5H | -7930 |
POLR2A | -6255 |
POLR2J | -5993 |
SSRP1 | -5218 |
NELFA | -5007 |
POLR2H | -4752 |
NELFCD | -4629 |
CCNT1 | -3403 |
POLR2C | -2998 |
GeneID | Gene Rank |
---|---|
POLR2L | -10282 |
CDK9 | -10180 |
CTDP1 | -9955 |
NELFB | -9862 |
GTF2F1 | -9355 |
POLR2I | -9194 |
POLR2F | -9158 |
POLR2E | -9034 |
ELL | -8355 |
ELOB | -8164 |
POLR2G | -8006 |
SUPT5H | -7930 |
POLR2A | -6255 |
POLR2J | -5993 |
SSRP1 | -5218 |
NELFA | -5007 |
POLR2H | -4752 |
NELFCD | -4629 |
CCNT1 | -3403 |
POLR2C | -2998 |
NELFE | -2081 |
ELOC | 1200 |
SUPT4H1 | 1271 |
SUPT16H | 2912 |
ELOA | 2983 |
POLR2D | 4912 |
GTF2F2 | 5332 |
POLR2B | 7601 |
TCEA1 | 8287 |
POLR2K | 9927 |
Tat-mediated HIV elongation arrest and recovery
1220 | |
---|---|
set | Tat-mediated HIV elongation arrest and recovery |
setSize | 30 |
pANOVA | 0.000324 |
s.dist | -0.379 |
p.adjustANOVA | 0.0059 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2L | -10282 |
CDK9 | -10180 |
CTDP1 | -9955 |
NELFB | -9862 |
GTF2F1 | -9355 |
POLR2I | -9194 |
POLR2F | -9158 |
POLR2E | -9034 |
ELL | -8355 |
ELOB | -8164 |
POLR2G | -8006 |
SUPT5H | -7930 |
POLR2A | -6255 |
POLR2J | -5993 |
SSRP1 | -5218 |
NELFA | -5007 |
POLR2H | -4752 |
NELFCD | -4629 |
CCNT1 | -3403 |
POLR2C | -2998 |
GeneID | Gene Rank |
---|---|
POLR2L | -10282 |
CDK9 | -10180 |
CTDP1 | -9955 |
NELFB | -9862 |
GTF2F1 | -9355 |
POLR2I | -9194 |
POLR2F | -9158 |
POLR2E | -9034 |
ELL | -8355 |
ELOB | -8164 |
POLR2G | -8006 |
SUPT5H | -7930 |
POLR2A | -6255 |
POLR2J | -5993 |
SSRP1 | -5218 |
NELFA | -5007 |
POLR2H | -4752 |
NELFCD | -4629 |
CCNT1 | -3403 |
POLR2C | -2998 |
NELFE | -2081 |
ELOC | 1200 |
SUPT4H1 | 1271 |
SUPT16H | 2912 |
ELOA | 2983 |
POLR2D | 4912 |
GTF2F2 | 5332 |
POLR2B | 7601 |
TCEA1 | 8287 |
POLR2K | 9927 |
HS-GAG degradation
489 | |
---|---|
set | HS-GAG degradation |
setSize | 16 |
pANOVA | 0.00872 |
s.dist | -0.379 |
p.adjustANOVA | 0.071 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SGSH | -10002 |
NAGLU | -9725 |
GPC4 | -9454 |
GPC1 | -8099 |
GPC2 | -7735 |
GUSB | -5871 |
HSPG2 | -5458 |
IDS | -5405 |
IDUA | -4267 |
HPSE | -2954 |
SDC4 | -1368 |
GLB1L | 62 |
SDC3 | 1680 |
GLB1 | 2354 |
SDC2 | 3889 |
AGRN | 6202 |
GeneID | Gene Rank |
---|---|
SGSH | -10002 |
NAGLU | -9725 |
GPC4 | -9454 |
GPC1 | -8099 |
GPC2 | -7735 |
GUSB | -5871 |
HSPG2 | -5458 |
IDS | -5405 |
IDUA | -4267 |
HPSE | -2954 |
SDC4 | -1368 |
GLB1L | 62 |
SDC3 | 1680 |
GLB1 | 2354 |
SDC2 | 3889 |
AGRN | 6202 |
Interleukin-2 signaling
563 | |
---|---|
set | Interleukin-2 signaling |
setSize | 11 |
pANOVA | 0.0316 |
s.dist | -0.374 |
p.adjustANOVA | 0.173 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IL2RB | -10303 |
PTK2B | -8809 |
JAK1 | -8196 |
STAT5A | -7264 |
STAT5B | -6114 |
LCK | -4371 |
JAK3 | -2805 |
SHC1 | 137 |
SYK | 2432 |
IL2RA | 2703 |
IL2RG | 4503 |
GeneID | Gene Rank |
---|---|
IL2RB | -10303 |
PTK2B | -8809 |
JAK1 | -8196 |
STAT5A | -7264 |
STAT5B | -6114 |
LCK | -4371 |
JAK3 | -2805 |
SHC1 | 137 |
SYK | 2432 |
IL2RA | 2703 |
IL2RG | 4503 |
p75NTR signals via NF-kB
1354 | |
---|---|
set | p75NTR signals via NF-kB |
setSize | 15 |
pANOVA | 0.0127 |
s.dist | -0.372 |
p.adjustANOVA | 0.0887 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RELA | -9628 |
IRAK1 | -9487 |
RPS27A | -8388 |
SQSTM1 | -7746 |
UBA52 | -7375 |
UBB | -4944 |
NFKBIA | -4692 |
IKBKB | -4462 |
UBC | -4177 |
NGFR | -2692 |
RIPK2 | 156 |
NFKB1 | 1266 |
TRAF6 | 2326 |
MYD88 | 4098 |
PRKCI | 4288 |
GeneID | Gene Rank |
---|---|
RELA | -9628 |
IRAK1 | -9487 |
RPS27A | -8388 |
SQSTM1 | -7746 |
UBA52 | -7375 |
UBB | -4944 |
NFKBIA | -4692 |
IKBKB | -4462 |
UBC | -4177 |
NGFR | -2692 |
RIPK2 | 156 |
NFKB1 | 1266 |
TRAF6 | 2326 |
MYD88 | 4098 |
PRKCI | 4288 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling
352 | |
---|---|
set | Estrogen-dependent nuclear events downstream of ESR-membrane signaling |
setSize | 22 |
pANOVA | 0.00255 |
s.dist | -0.372 |
p.adjustANOVA | 0.0329 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AKT2 | -10102 |
MAPK3 | -10100 |
FOS | -9975 |
AKT1 | -9799 |
HBEGF | -8469 |
AREG | -8418 |
ELK1 | -7817 |
SRF | -7749 |
EREG | -7409 |
FOXO3 | -7061 |
CCND1 | -5765 |
TGFA | -5162 |
PTK2 | -2003 |
MAPK1 | -1844 |
CDKN1B | -1307 |
EGF | 514 |
UHMK1 | 696 |
BCL2 | 2357 |
AKT3 | 2465 |
EPGN | 3595 |
GeneID | Gene Rank |
---|---|
AKT2 | -10102 |
MAPK3 | -10100 |
FOS | -9975 |
AKT1 | -9799 |
HBEGF | -8469 |
AREG | -8418 |
ELK1 | -7817 |
SRF | -7749 |
EREG | -7409 |
FOXO3 | -7061 |
CCND1 | -5765 |
TGFA | -5162 |
PTK2 | -2003 |
MAPK1 | -1844 |
CDKN1B | -1307 |
EGF | 514 |
UHMK1 | 696 |
BCL2 | 2357 |
AKT3 | 2465 |
EPGN | 3595 |
CREB1 | 6457 |
XPO1 | 11455 |
Activation of Matrix Metalloproteinases
41 | |
---|---|
set | Activation of Matrix Metalloproteinases |
setSize | 24 |
pANOVA | 0.00164 |
s.dist | -0.371 |
p.adjustANOVA | 0.0247 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MMP9 | -10277 |
FURIN | -10276 |
TPSAB1 | -9796 |
MMP14 | -8825 |
CTSG | -7910 |
MMP15 | -7494 |
ELANE | -6634 |
COL18A1 | -6216 |
MMP8 | -6018 |
TIMP2 | -5731 |
MMP24 | -5305 |
PRSS2 | -4636 |
KLKB1 | -4063 |
MMP7 | -2929 |
MMP1 | -2757 |
MMP25 | -2400 |
PRSS1 | -1563 |
CTSV | -759 |
MMP11 | -513 |
MMP17 | -8 |
GeneID | Gene Rank |
---|---|
MMP9 | -10277 |
FURIN | -10276 |
TPSAB1 | -9796 |
MMP14 | -8825 |
CTSG | -7910 |
MMP15 | -7494 |
ELANE | -6634 |
COL18A1 | -6216 |
MMP8 | -6018 |
TIMP2 | -5731 |
MMP24 | -5305 |
PRSS2 | -4636 |
KLKB1 | -4063 |
MMP7 | -2929 |
MMP1 | -2757 |
MMP25 | -2400 |
PRSS1 | -1563 |
CTSV | -759 |
MMP11 | -513 |
MMP17 | -8 |
TIMP1 | 1642 |
KLK2 | 4164 |
CTSK | 7149 |
PLG | 8929 |
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS)
267 | |
---|---|
set | Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) |
setSize | 12 |
pANOVA | 0.0271 |
s.dist | -0.369 |
p.adjustANOVA | 0.154 |
Top enriched genes
GeneID | Gene Rank |
---|---|
F12 | -9231 |
VWF | -8805 |
GP9 | -8734 |
GP1BB | -7511 |
GP1BA | -6740 |
TPST2 | -6004 |
KLKB1 | -4063 |
GP5 | -3922 |
TPST1 | -2552 |
GGCX | -505 |
F8 | 6093 |
SERPING1 | 11201 |
GeneID | Gene Rank |
---|---|
F12 | -9231 |
VWF | -8805 |
GP9 | -8734 |
GP1BB | -7511 |
GP1BA | -6740 |
TPST2 | -6004 |
KLKB1 | -4063 |
GP5 | -3922 |
TPST1 | -2552 |
GGCX | -505 |
F8 | 6093 |
SERPING1 | 11201 |
Diseases of hemostasis
295 | |
---|---|
set | Diseases of hemostasis |
setSize | 12 |
pANOVA | 0.0271 |
s.dist | -0.369 |
p.adjustANOVA | 0.154 |
Top enriched genes
GeneID | Gene Rank |
---|---|
F12 | -9231 |
VWF | -8805 |
GP9 | -8734 |
GP1BB | -7511 |
GP1BA | -6740 |
TPST2 | -6004 |
KLKB1 | -4063 |
GP5 | -3922 |
TPST1 | -2552 |
GGCX | -505 |
F8 | 6093 |
SERPING1 | 11201 |
GeneID | Gene Rank |
---|---|
F12 | -9231 |
VWF | -8805 |
GP9 | -8734 |
GP1BB | -7511 |
GP1BA | -6740 |
TPST2 | -6004 |
KLKB1 | -4063 |
GP5 | -3922 |
TPST1 | -2552 |
GGCX | -505 |
F8 | 6093 |
SERPING1 | 11201 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
176 | |
---|---|
set | Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex |
setSize | 12 |
pANOVA | 0.0312 |
s.dist | 0.359 |
p.adjustANOVA | 0.172 |
Top enriched genes
GeneID | Gene Rank |
---|---|
YWHAB | 11092 |
YWHAZ | 9618 |
CDK1 | 9135 |
CHEK1 | 7791 |
YWHAE | 6642 |
CCNB1 | 5971 |
CHEK2 | 5577 |
WEE1 | 4830 |
YWHAH | 3131 |
YWHAQ | 2580 |
YWHAG | -3999 |
SFN | -6586 |
GeneID | Gene Rank |
---|---|
YWHAB | 11092 |
YWHAZ | 9618 |
CDK1 | 9135 |
CHEK1 | 7791 |
YWHAE | 6642 |
CCNB1 | 5971 |
CHEK2 | 5577 |
WEE1 | 4830 |
YWHAH | 3131 |
YWHAQ | 2580 |
YWHAG | -3999 |
SFN | -6586 |
Establishment of Sister Chromatid Cohesion
350 | |
---|---|
set | Establishment of Sister Chromatid Cohesion |
setSize | 11 |
pANOVA | 0.0399 |
s.dist | 0.358 |
p.adjustANOVA | 0.194 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ESCO1 | 11353 |
SMC3 | 10955 |
PDS5B | 7409 |
RAD21 | 6566 |
STAG2 | 6346 |
ESCO2 | 4045 |
PDS5A | 3914 |
WAPL | 2842 |
CDCA5 | 1040 |
STAG1 | 71 |
SMC1A | -3594 |
GeneID | Gene Rank |
---|---|
ESCO1 | 11353 |
SMC3 | 10955 |
PDS5B | 7409 |
RAD21 | 6566 |
STAG2 | 6346 |
ESCO2 | 4045 |
PDS5A | 3914 |
WAPL | 2842 |
CDCA5 | 1040 |
STAG1 | 71 |
SMC1A | -3594 |
Pre-NOTCH Processing in Golgi
849 | |
---|---|
set | Pre-NOTCH Processing in Golgi |
setSize | 18 |
pANOVA | 0.00904 |
s.dist | -0.355 |
p.adjustANOVA | 0.0714 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MFNG | -10322 |
FURIN | -10276 |
ST3GAL4 | -9287 |
ATP2A3 | -8695 |
NOTCH1 | -8307 |
RFNG | -7532 |
ST3GAL3 | -6159 |
B4GALT1 | -6125 |
NOTCH3 | -5144 |
NOTCH2 | -5057 |
LFNG | -4880 |
NOTCH4 | -3355 |
ATP2A2 | -2559 |
ATP2A1 | -2334 |
SEL1L | 4617 |
RAB6A | 8257 |
ST3GAL6 | 9285 |
TMED2 | 9346 |
GeneID | Gene Rank |
---|---|
MFNG | -10322 |
FURIN | -10276 |
ST3GAL4 | -9287 |
ATP2A3 | -8695 |
NOTCH1 | -8307 |
RFNG | -7532 |
ST3GAL3 | -6159 |
B4GALT1 | -6125 |
NOTCH3 | -5144 |
NOTCH2 | -5057 |
LFNG | -4880 |
NOTCH4 | -3355 |
ATP2A2 | -2559 |
ATP2A1 | -2334 |
SEL1L | 4617 |
RAB6A | 8257 |
ST3GAL6 | 9285 |
TMED2 | 9346 |
Constitutive Signaling by NOTCH1 HD Domain Mutants
211 | |
---|---|
set | Constitutive Signaling by NOTCH1 HD Domain Mutants |
setSize | 14 |
pANOVA | 0.0216 |
s.dist | -0.355 |
p.adjustANOVA | 0.131 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NEURL1B | -9789 |
RPS27A | -8388 |
NOTCH1 | -8307 |
UBA52 | -7375 |
DLL1 | -7224 |
MIB2 | -6846 |
JAG1 | -6208 |
UBB | -4944 |
UBC | -4177 |
MIB1 | -2896 |
JAG2 | 96 |
NEURL1 | 3966 |
ADAM10 | 7907 |
ADAM17 | 8758 |
GeneID | Gene Rank |
---|---|
NEURL1B | -9789 |
RPS27A | -8388 |
NOTCH1 | -8307 |
UBA52 | -7375 |
DLL1 | -7224 |
MIB2 | -6846 |
JAG1 | -6208 |
UBB | -4944 |
UBC | -4177 |
MIB1 | -2896 |
JAG2 | 96 |
NEURL1 | 3966 |
ADAM10 | 7907 |
ADAM17 | 8758 |
Signaling by NOTCH1 HD Domain Mutants in Cancer
1113 | |
---|---|
set | Signaling by NOTCH1 HD Domain Mutants in Cancer |
setSize | 14 |
pANOVA | 0.0216 |
s.dist | -0.355 |
p.adjustANOVA | 0.131 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NEURL1B | -9789 |
RPS27A | -8388 |
NOTCH1 | -8307 |
UBA52 | -7375 |
DLL1 | -7224 |
MIB2 | -6846 |
JAG1 | -6208 |
UBB | -4944 |
UBC | -4177 |
MIB1 | -2896 |
JAG2 | 96 |
NEURL1 | 3966 |
ADAM10 | 7907 |
ADAM17 | 8758 |
GeneID | Gene Rank |
---|---|
NEURL1B | -9789 |
RPS27A | -8388 |
NOTCH1 | -8307 |
UBA52 | -7375 |
DLL1 | -7224 |
MIB2 | -6846 |
JAG1 | -6208 |
UBB | -4944 |
UBC | -4177 |
MIB1 | -2896 |
JAG2 | 96 |
NEURL1 | 3966 |
ADAM10 | 7907 |
ADAM17 | 8758 |
HDR through Single Strand Annealing (SSA)
482 | |
---|---|
set | HDR through Single Strand Annealing (SSA) |
setSize | 37 |
pANOVA | 0.000189 |
s.dist | 0.355 |
p.adjustANOVA | 0.00403 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RBBP8 | 11241 |
RMI1 | 11215 |
RMI2 | 11085 |
NBN | 10610 |
RAD50 | 10371 |
DNA2 | 9957 |
RAD17 | 9946 |
RFC4 | 9891 |
RAD9B | 9234 |
HUS1 | 9132 |
BARD1 | 9023 |
TOPBP1 | 8826 |
BRCA1 | 8138 |
RFC3 | 7972 |
ERCC4 | 7215 |
BRIP1 | 6803 |
RAD1 | 6800 |
RAD51 | 6337 |
RPA2 | 5538 |
ATR | 4908 |
GeneID | Gene Rank |
---|---|
RBBP8 | 11241 |
RMI1 | 11215 |
RMI2 | 11085 |
NBN | 10610 |
RAD50 | 10371 |
DNA2 | 9957 |
RAD17 | 9946 |
RFC4 | 9891 |
RAD9B | 9234 |
HUS1 | 9132 |
BARD1 | 9023 |
TOPBP1 | 8826 |
BRCA1 | 8138 |
RFC3 | 7972 |
ERCC4 | 7215 |
BRIP1 | 6803 |
RAD1 | 6800 |
RAD51 | 6337 |
RPA2 | 5538 |
ATR | 4908 |
BLM | 4120 |
WRN | 4117 |
RHNO1 | 3076 |
EXO1 | 2398 |
RPA3 | 2293 |
ATRIP | 2287 |
MRE11 | 2275 |
RAD52 | 2122 |
RFC5 | 919 |
KAT5 | -301 |
RFC2 | -697 |
ATM | -768 |
RAD9A | -1761 |
TOP3A | -2746 |
RPA1 | -4771 |
ABL1 | -7441 |
ERCC1 | -9432 |
p75NTR recruits signalling complexes
1353 | |
---|---|
set | p75NTR recruits signalling complexes |
setSize | 12 |
pANOVA | 0.0354 |
s.dist | -0.351 |
p.adjustANOVA | 0.183 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IRAK1 | -9487 |
RPS27A | -8388 |
SQSTM1 | -7746 |
UBA52 | -7375 |
UBB | -4944 |
IKBKB | -4462 |
UBC | -4177 |
NGFR | -2692 |
RIPK2 | 156 |
TRAF6 | 2326 |
MYD88 | 4098 |
PRKCI | 4288 |
GeneID | Gene Rank |
---|---|
IRAK1 | -9487 |
RPS27A | -8388 |
SQSTM1 | -7746 |
UBA52 | -7375 |
UBB | -4944 |
IKBKB | -4462 |
UBC | -4177 |
NGFR | -2692 |
RIPK2 | 156 |
TRAF6 | 2326 |
MYD88 | 4098 |
PRKCI | 4288 |
RMTs methylate histone arginines
899 | |
---|---|
set | RMTs methylate histone arginines |
setSize | 37 |
pANOVA | 0.000231 |
s.dist | -0.35 |
p.adjustANOVA | 0.00468 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS2 | -10243.0 |
H2AZ1 | -8776.0 |
DNMT3A | -8681.0 |
PRMT7 | -8305.0 |
SMARCA4 | -8195.0 |
PRMT1 | -8163.0 |
CARM1 | -8103.0 |
H3C15 | -8038.5 |
ARID1B | -7820.0 |
H2AJ | -7536.0 |
SMARCD2 | -6959.0 |
PRMT6 | -6823.0 |
SMARCA2 | -6736.0 |
H2AW | -6266.0 |
ARID1A | -5907.0 |
CDK4 | -5841.0 |
CCND1 | -5765.0 |
WDR5 | -5526.0 |
SMARCD3 | -5169.0 |
H2AC6 | -4383.0 |
GeneID | Gene Rank |
---|---|
RPS2 | -10243.0 |
H2AZ1 | -8776.0 |
DNMT3A | -8681.0 |
PRMT7 | -8305.0 |
SMARCA4 | -8195.0 |
PRMT1 | -8163.0 |
CARM1 | -8103.0 |
H3C15 | -8038.5 |
ARID1B | -7820.0 |
H2AJ | -7536.0 |
SMARCD2 | -6959.0 |
PRMT6 | -6823.0 |
SMARCA2 | -6736.0 |
H2AW | -6266.0 |
ARID1A | -5907.0 |
CDK4 | -5841.0 |
CCND1 | -5765.0 |
WDR5 | -5526.0 |
SMARCD3 | -5169.0 |
H2AC6 | -4383.0 |
SMARCE1 | -3958.0 |
H2AC11 | -3957.0 |
SMARCC2 | -3632.0 |
SMARCC1 | -2907.0 |
COPRS | -2686.0 |
H2AZ2 | -2475.0 |
SMARCD1 | -1501.0 |
SMARCB1 | -1331.0 |
PRMT5 | 1982.0 |
ARID2 | 2546.0 |
WDR77 | 2958.0 |
H2AC20 | 3907.0 |
PBRM1 | 4182.0 |
RBBP7 | 4858.0 |
ACTL6A | 5304.0 |
PRMT3 | 10740.0 |
JAK2 | 11299.0 |
Heparan sulfate/heparin (HS-GAG) metabolism
499 | |
---|---|
set | Heparan sulfate/heparin (HS-GAG) metabolism |
setSize | 38 |
pANOVA | 0.000232 |
s.dist | -0.345 |
p.adjustANOVA | 0.00468 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SGSH | -10002 |
B3GAT3 | -9818 |
NAGLU | -9725 |
XYLT1 | -9723 |
GPC4 | -9454 |
B3GALT6 | -8920 |
XYLT2 | -8645 |
HS3ST3A1 | -8515 |
HS6ST1 | -8243 |
B4GALT7 | -8207 |
GPC1 | -8099 |
GPC2 | -7735 |
GUSB | -5871 |
NDST1 | -5681 |
HSPG2 | -5458 |
IDS | -5405 |
NDST2 | -4937 |
CSPG4 | -4429 |
IDUA | -4267 |
HPSE | -2954 |
GeneID | Gene Rank |
---|---|
SGSH | -10002 |
B3GAT3 | -9818 |
NAGLU | -9725 |
XYLT1 | -9723 |
GPC4 | -9454 |
B3GALT6 | -8920 |
XYLT2 | -8645 |
HS3ST3A1 | -8515 |
HS6ST1 | -8243 |
B4GALT7 | -8207 |
GPC1 | -8099 |
GPC2 | -7735 |
GUSB | -5871 |
NDST1 | -5681 |
HSPG2 | -5458 |
IDS | -5405 |
NDST2 | -4937 |
CSPG4 | -4429 |
IDUA | -4267 |
HPSE | -2954 |
B3GAT2 | -1900 |
HS3ST1 | -1780 |
HS3ST3B1 | -1489 |
EXT2 | -1446 |
SDC4 | -1368 |
B3GAT1 | 18 |
GLB1L | 62 |
HS2ST1 | 1340 |
SDC3 | 1680 |
VCAN | 1854 |
GLB1 | 2354 |
GLCE | 2404 |
HS3ST2 | 2578 |
DCN | 2926 |
SDC2 | 3889 |
SLC35D2 | 4601 |
EXT1 | 5091 |
AGRN | 6202 |
Regulation of IFNG signaling
958 | |
---|---|
set | Regulation of IFNG signaling |
setSize | 14 |
pANOVA | 0.0255 |
s.dist | 0.345 |
p.adjustANOVA | 0.147 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PIAS1 | 11651 |
JAK2 | 11299 |
IFNG | 11066 |
SUMO1 | 10348 |
STAT1 | 9925 |
IFNGR1 | 9252 |
SOCS1 | 8886 |
IFNGR2 | 7797 |
PTPN2 | 7592 |
PTPN11 | -619 |
PTPN6 | -2890 |
PTPN1 | -2967 |
JAK1 | -8196 |
SOCS3 | -10318 |
GeneID | Gene Rank |
---|---|
PIAS1 | 11651 |
JAK2 | 11299 |
IFNG | 11066 |
SUMO1 | 10348 |
STAT1 | 9925 |
IFNGR1 | 9252 |
SOCS1 | 8886 |
IFNGR2 | 7797 |
PTPN2 | 7592 |
PTPN11 | -619 |
PTPN6 | -2890 |
PTPN1 | -2967 |
JAK1 | -8196 |
SOCS3 | -10318 |
Synthesis of PIPs at the late endosome membrane
1175 | |
---|---|
set | Synthesis of PIPs at the late endosome membrane |
setSize | 11 |
pANOVA | 0.0479 |
s.dist | 0.344 |
p.adjustANOVA | 0.219 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MTM1 | 11112 |
FIG4 | 8956 |
MTMR9 | 8405 |
PIK3C2A | 8129 |
PIK3C3 | 7079 |
PIK3R4 | 5876 |
MTMR7 | 5356 |
MTMR2 | 3647 |
PIKFYVE | 2542 |
MTMR4 | -2215 |
VAC14 | -9559 |
GeneID | Gene Rank |
---|---|
MTM1 | 11112 |
FIG4 | 8956 |
MTMR9 | 8405 |
PIK3C2A | 8129 |
PIK3C3 | 7079 |
PIK3R4 | 5876 |
MTMR7 | 5356 |
MTMR2 | 3647 |
PIKFYVE | 2542 |
MTMR4 | -2215 |
VAC14 | -9559 |
Collagen chain trimerization
198 | |
---|---|
set | Collagen chain trimerization |
setSize | 27 |
pANOVA | 0.00198 |
s.dist | -0.344 |
p.adjustANOVA | 0.0276 |
Top enriched genes
GeneID | Gene Rank |
---|---|
COL13A1 | -10378 |
COL5A1 | -10274 |
COL8A2 | -9359 |
COL26A1 | -9085 |
COL7A1 | -8954 |
COL27A1 | -8272 |
COL5A3 | -7982 |
COL24A1 | -7193 |
COL6A1 | -7192 |
COL11A2 | -6500 |
COL18A1 | -6216 |
COL5A2 | -5813 |
COL6A2 | -5676 |
COL28A1 | -4958 |
COL10A1 | -4755 |
COL15A1 | -4732 |
COL17A1 | -3908 |
COL19A1 | -3023 |
COL23A1 | -1246 |
COL4A2 | 917 |
GeneID | Gene Rank |
---|---|
COL13A1 | -10378 |
COL5A1 | -10274 |
COL8A2 | -9359 |
COL26A1 | -9085 |
COL7A1 | -8954 |
COL27A1 | -8272 |
COL5A3 | -7982 |
COL24A1 | -7193 |
COL6A1 | -7192 |
COL11A2 | -6500 |
COL18A1 | -6216 |
COL5A2 | -5813 |
COL6A2 | -5676 |
COL28A1 | -4958 |
COL10A1 | -4755 |
COL15A1 | -4732 |
COL17A1 | -3908 |
COL19A1 | -3023 |
COL23A1 | -1246 |
COL4A2 | 917 |
COL4A3 | 1778 |
COL4A4 | 3285 |
COL9A3 | 3915 |
COL9A2 | 4540 |
COL8A1 | 8161 |
COL1A2 | 8984 |
COL6A3 | 9600 |
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
32 | |
---|---|
set | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 |
setSize | 22 |
pANOVA | 0.00533 |
s.dist | -0.343 |
p.adjustANOVA | 0.0516 |
Top enriched genes
GeneID | Gene Rank |
---|---|
H2AZ1 | -8776.0 |
H2BC12 | -8742.0 |
PKN1 | -8565.0 |
H2BC17 | -8346.0 |
H3C15 | -8038.5 |
H2BC4 | -7928.0 |
H2AJ | -7536.0 |
H2BC9 | -6894.0 |
H2BC11 | -5751.0 |
H2BC21 | -5415.0 |
H2BC15 | -4416.0 |
H2AC6 | -4383.0 |
H2BC5 | -3070.0 |
H2AZ2 | -2475.0 |
AR | -366.0 |
NCOA2 | 1439.0 |
KDM1A | 2200.0 |
KDM4C | 2529.0 |
H2BU1 | 2721.0 |
H2AC20 | 3907.0 |
GeneID | Gene Rank |
---|---|
H2AZ1 | -8776.0 |
H2BC12 | -8742.0 |
PKN1 | -8565.0 |
H2BC17 | -8346.0 |
H3C15 | -8038.5 |
H2BC4 | -7928.0 |
H2AJ | -7536.0 |
H2BC9 | -6894.0 |
H2BC11 | -5751.0 |
H2BC21 | -5415.0 |
H2BC15 | -4416.0 |
H2AC6 | -4383.0 |
H2BC5 | -3070.0 |
H2AZ2 | -2475.0 |
AR | -366.0 |
NCOA2 | 1439.0 |
KDM1A | 2200.0 |
KDM4C | 2529.0 |
H2BU1 | 2721.0 |
H2AC20 | 3907.0 |
KLK2 | 4164.0 |
H3-3A | 5193.0 |
Plasma lipoprotein clearance
827 | |
---|---|
set | Plasma lipoprotein clearance |
setSize | 29 |
pANOVA | 0.00147 |
s.dist | -0.341 |
p.adjustANOVA | 0.0234 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SCARB1 | -9861 |
NR1H2 | -9025 |
AP2M1 | -8930 |
APOE | -8186 |
APOBR | -7903 |
AP2A2 | -7814 |
AP2A1 | -6826 |
LSR | -6787 |
CES3 | -6277 |
CUBN | -5579 |
LIPC | -4960 |
NR1H3 | -4903 |
MYLIP | -4778 |
AMN | -4299 |
NPC1 | -4273 |
VLDLR | -4257 |
AP2S1 | -3863 |
AP2B1 | -3395 |
LIPA | -3104 |
APOC4 | -2383 |
GeneID | Gene Rank |
---|---|
SCARB1 | -9861 |
NR1H2 | -9025 |
AP2M1 | -8930 |
APOE | -8186 |
APOBR | -7903 |
AP2A2 | -7814 |
AP2A1 | -6826 |
LSR | -6787 |
CES3 | -6277 |
CUBN | -5579 |
LIPC | -4960 |
NR1H3 | -4903 |
MYLIP | -4778 |
AMN | -4299 |
NPC1 | -4273 |
VLDLR | -4257 |
AP2S1 | -3863 |
AP2B1 | -3395 |
LIPA | -3104 |
APOC4 | -2383 |
LDLRAP1 | -1661 |
CLTA | 509 |
CLTC | 1283 |
HDLBP | 2104 |
NCEH1 | 3162 |
SOAT1 | 4111 |
LDLR | 4250 |
NPC2 | 6507 |
SOAT2 | 7476 |
IRAK4 deficiency (TLR2/4)
515 | |
---|---|
set | IRAK4 deficiency (TLR2/4) |
setSize | 10 |
pANOVA | 0.0621 |
s.dist | 0.341 |
p.adjustANOVA | 0.256 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TLR2 | 10184 |
CD36 | 9777 |
BTK | 9179 |
LY96 | 7947 |
TLR1 | 7591 |
MYD88 | 4098 |
TLR6 | 3066 |
TLR4 | 1481 |
TIRAP | -3612 |
CD14 | -5276 |
GeneID | Gene Rank |
---|---|
TLR2 | 10184 |
CD36 | 9777 |
BTK | 9179 |
LY96 | 7947 |
TLR1 | 7591 |
MYD88 | 4098 |
TLR6 | 3066 |
TLR4 | 1481 |
TIRAP | -3612 |
CD14 | -5276 |
MyD88 deficiency (TLR2/4)
688 | |
---|---|
set | MyD88 deficiency (TLR2/4) |
setSize | 10 |
pANOVA | 0.0621 |
s.dist | 0.341 |
p.adjustANOVA | 0.256 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TLR2 | 10184 |
CD36 | 9777 |
BTK | 9179 |
LY96 | 7947 |
TLR1 | 7591 |
MYD88 | 4098 |
TLR6 | 3066 |
TLR4 | 1481 |
TIRAP | -3612 |
CD14 | -5276 |
GeneID | Gene Rank |
---|---|
TLR2 | 10184 |
CD36 | 9777 |
BTK | 9179 |
LY96 | 7947 |
TLR1 | 7591 |
MYD88 | 4098 |
TLR6 | 3066 |
TLR4 | 1481 |
TIRAP | -3612 |
CD14 | -5276 |
Constitutive Signaling by AKT1 E17K in Cancer
207 | |
---|---|
set | Constitutive Signaling by AKT1 E17K in Cancer |
setSize | 26 |
pANOVA | 0.0027 |
s.dist | -0.34 |
p.adjustANOVA | 0.0338 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AKT2 | -10102 |
AKT1S1 | -10026 |
FOXO4 | -9911 |
AKT1 | -9799 |
PRR5 | -9351 |
BAD | -9119 |
MTOR | -8632 |
FOXO1 | -8143 |
PDPK1 | -7616 |
TSC2 | -7121 |
FOXO3 | -7061 |
FOXO6 | -6422 |
MLST8 | -6381 |
RPS6KB2 | -6218 |
GSK3A | -5827 |
CDKN1B | -1307 |
GSK3B | -223 |
CASP9 | 286 |
NR4A1 | 2131 |
AKT3 | 2465 |
GeneID | Gene Rank |
---|---|
AKT2 | -10102 |
AKT1S1 | -10026 |
FOXO4 | -9911 |
AKT1 | -9799 |
PRR5 | -9351 |
BAD | -9119 |
MTOR | -8632 |
FOXO1 | -8143 |
PDPK1 | -7616 |
TSC2 | -7121 |
FOXO3 | -7061 |
FOXO6 | -6422 |
MLST8 | -6381 |
RPS6KB2 | -6218 |
GSK3A | -5827 |
CDKN1B | -1307 |
GSK3B | -223 |
CASP9 | 286 |
NR4A1 | 2131 |
AKT3 | 2465 |
MAPKAP1 | 3210 |
CDKN1A | 3342 |
CREB1 | 6457 |
RICTOR | 6758 |
CHUK | 7378 |
MDM2 | 11204 |
Regulation of localization of FOXO transcription factors
989 | |
---|---|
set | Regulation of localization of FOXO transcription factors |
setSize | 12 |
pANOVA | 0.0448 |
s.dist | -0.335 |
p.adjustANOVA | 0.21 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AKT2 | -10102 |
FOXO4 | -9911 |
AKT1 | -9799 |
FOXO1 | -8143 |
FOXO3 | -7061 |
SFN | -6586 |
FOXO6 | -6422 |
YWHAG | -3999 |
AKT3 | 2465 |
YWHAQ | 2580 |
YWHAZ | 9618 |
YWHAB | 11092 |
GeneID | Gene Rank |
---|---|
AKT2 | -10102 |
FOXO4 | -9911 |
AKT1 | -9799 |
FOXO1 | -8143 |
FOXO3 | -7061 |
SFN | -6586 |
FOXO6 | -6422 |
YWHAG | -3999 |
AKT3 | 2465 |
YWHAQ | 2580 |
YWHAZ | 9618 |
YWHAB | 11092 |
Retrograde neurotrophin signalling
1014 | |
---|---|
set | Retrograde neurotrophin signalling |
setSize | 12 |
pANOVA | 0.0465 |
s.dist | -0.332 |
p.adjustANOVA | 0.216 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DNM2 | -9367 |
DNAL4 | -9030 |
AP2M1 | -8930 |
AP2A2 | -7814 |
AP2A1 | -6826 |
AP2S1 | -3863 |
AP2B1 | -3395 |
DNM3 | -1395 |
CLTA | 509 |
CLTC | 1283 |
NTRK1 | 5106 |
DNM1 | 7802 |
GeneID | Gene Rank |
---|---|
DNM2 | -9367 |
DNAL4 | -9030 |
AP2M1 | -8930 |
AP2A2 | -7814 |
AP2A1 | -6826 |
AP2S1 | -3863 |
AP2B1 | -3395 |
DNM3 | -1395 |
CLTA | 509 |
CLTC | 1283 |
NTRK1 | 5106 |
DNM1 | 7802 |
Lewis blood group biosynthesis
602 | |
---|---|
set | Lewis blood group biosynthesis |
setSize | 13 |
pANOVA | 0.0389 |
s.dist | -0.331 |
p.adjustANOVA | 0.192 |
Top enriched genes
GeneID | Gene Rank |
---|---|
B3GALT2 | -10110 |
FUT7 | -9983 |
ST3GAL4 | -9287 |
ST3GAL3 | -6159 |
B3GALT4 | -5604 |
B4GALNT2 | -5330 |
FUT4 | -4894 |
ST6GALNAC6 | -2666 |
FUT2 | -252 |
FUT10 | 1123 |
FUT11 | 1230 |
B3GALT1 | 3901 |
ST3GAL6 | 9285 |
GeneID | Gene Rank |
---|---|
B3GALT2 | -10110 |
FUT7 | -9983 |
ST3GAL4 | -9287 |
ST3GAL3 | -6159 |
B3GALT4 | -5604 |
B4GALNT2 | -5330 |
FUT4 | -4894 |
ST6GALNAC6 | -2666 |
FUT2 | -252 |
FUT10 | 1123 |
FUT11 | 1230 |
B3GALT1 | 3901 |
ST3GAL6 | 9285 |
Cleavage of the damaged purine
193 | |
---|---|
set | Cleavage of the damaged purine |
setSize | 24 |
pANOVA | 0.0052 |
s.dist | -0.329 |
p.adjustANOVA | 0.0512 |
Top enriched genes
GeneID | Gene Rank |
---|---|
H2AZ1 | -8776 |
H2BC12 | -8742 |
H2BC17 | -8346 |
MUTYH | -7969 |
H2BC4 | -7928 |
MPG | -7571 |
H2AJ | -7536 |
H2BC9 | -6894 |
ACD | -6691 |
H2BC11 | -5751 |
H2BC21 | -5415 |
TINF2 | -4662 |
H2BC15 | -4416 |
H2AC6 | -4383 |
TERF2IP | -3454 |
H2BC5 | -3070 |
H2AZ2 | -2475 |
OGG1 | -1535 |
H2BU1 | 2721 |
H2AC20 | 3907 |
GeneID | Gene Rank |
---|---|
H2AZ1 | -8776 |
H2BC12 | -8742 |
H2BC17 | -8346 |
MUTYH | -7969 |
H2BC4 | -7928 |
MPG | -7571 |
H2AJ | -7536 |
H2BC9 | -6894 |
ACD | -6691 |
H2BC11 | -5751 |
H2BC21 | -5415 |
TINF2 | -4662 |
H2BC15 | -4416 |
H2AC6 | -4383 |
TERF2IP | -3454 |
H2BC5 | -3070 |
H2AZ2 | -2475 |
OGG1 | -1535 |
H2BU1 | 2721 |
H2AC20 | 3907 |
NEIL3 | 3946 |
TERF2 | 4874 |
TERF1 | 8885 |
POT1 | 10140 |
Depurination
277 | |
---|---|
set | Depurination |
setSize | 24 |
pANOVA | 0.0052 |
s.dist | -0.329 |
p.adjustANOVA | 0.0512 |
Top enriched genes
GeneID | Gene Rank |
---|---|
H2AZ1 | -8776 |
H2BC12 | -8742 |
H2BC17 | -8346 |
MUTYH | -7969 |
H2BC4 | -7928 |
MPG | -7571 |
H2AJ | -7536 |
H2BC9 | -6894 |
ACD | -6691 |
H2BC11 | -5751 |
H2BC21 | -5415 |
TINF2 | -4662 |
H2BC15 | -4416 |
H2AC6 | -4383 |
TERF2IP | -3454 |
H2BC5 | -3070 |
H2AZ2 | -2475 |
OGG1 | -1535 |
H2BU1 | 2721 |
H2AC20 | 3907 |
GeneID | Gene Rank |
---|---|
H2AZ1 | -8776 |
H2BC12 | -8742 |
H2BC17 | -8346 |
MUTYH | -7969 |
H2BC4 | -7928 |
MPG | -7571 |
H2AJ | -7536 |
H2BC9 | -6894 |
ACD | -6691 |
H2BC11 | -5751 |
H2BC21 | -5415 |
TINF2 | -4662 |
H2BC15 | -4416 |
H2AC6 | -4383 |
TERF2IP | -3454 |
H2BC5 | -3070 |
H2AZ2 | -2475 |
OGG1 | -1535 |
H2BU1 | 2721 |
H2AC20 | 3907 |
NEIL3 | 3946 |
TERF2 | 4874 |
TERF1 | 8885 |
POT1 | 10140 |
Recognition and association of DNA glycosylase with site containing an affected purine
940 | |
---|---|
set | Recognition and association of DNA glycosylase with site containing an affected purine |
setSize | 24 |
pANOVA | 0.0052 |
s.dist | -0.329 |
p.adjustANOVA | 0.0512 |
Top enriched genes
GeneID | Gene Rank |
---|---|
H2AZ1 | -8776 |
H2BC12 | -8742 |
H2BC17 | -8346 |
MUTYH | -7969 |
H2BC4 | -7928 |
MPG | -7571 |
H2AJ | -7536 |
H2BC9 | -6894 |
ACD | -6691 |
H2BC11 | -5751 |
H2BC21 | -5415 |
TINF2 | -4662 |
H2BC15 | -4416 |
H2AC6 | -4383 |
TERF2IP | -3454 |
H2BC5 | -3070 |
H2AZ2 | -2475 |
OGG1 | -1535 |
H2BU1 | 2721 |
H2AC20 | 3907 |
GeneID | Gene Rank |
---|---|
H2AZ1 | -8776 |
H2BC12 | -8742 |
H2BC17 | -8346 |
MUTYH | -7969 |
H2BC4 | -7928 |
MPG | -7571 |
H2AJ | -7536 |
H2BC9 | -6894 |
ACD | -6691 |
H2BC11 | -5751 |
H2BC21 | -5415 |
TINF2 | -4662 |
H2BC15 | -4416 |
H2AC6 | -4383 |
TERF2IP | -3454 |
H2BC5 | -3070 |
H2AZ2 | -2475 |
OGG1 | -1535 |
H2BU1 | 2721 |
H2AC20 | 3907 |
NEIL3 | 3946 |
TERF2 | 4874 |
TERF1 | 8885 |
POT1 | 10140 |
NOTCH3 Activation and Transmission of Signal to the Nucleus
707 | |
---|---|
set | NOTCH3 Activation and Transmission of Signal to the Nucleus |
setSize | 23 |
pANOVA | 0.00629 |
s.dist | -0.329 |
p.adjustANOVA | 0.0577 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NEURL1B | -9789 |
PSEN2 | -8735 |
TACC3 | -8710 |
RPS27A | -8388 |
APH1A | -8076 |
UBA52 | -7375 |
DLL1 | -7224 |
MIB2 | -6846 |
JAG1 | -6208 |
NOTCH3 | -5144 |
UBB | -4944 |
YBX1 | -4896 |
WWP2 | -4221 |
UBC | -4177 |
MIB1 | -2896 |
PSENEN | -1485 |
JAG2 | 96 |
EGF | 514 |
NEURL1 | 3966 |
NCSTN | 4145 |
GeneID | Gene Rank |
---|---|
NEURL1B | -9789 |
PSEN2 | -8735 |
TACC3 | -8710 |
RPS27A | -8388 |
APH1A | -8076 |
UBA52 | -7375 |
DLL1 | -7224 |
MIB2 | -6846 |
JAG1 | -6208 |
NOTCH3 | -5144 |
UBB | -4944 |
YBX1 | -4896 |
WWP2 | -4221 |
UBC | -4177 |
MIB1 | -2896 |
PSENEN | -1485 |
JAG2 | 96 |
EGF | 514 |
NEURL1 | 3966 |
NCSTN | 4145 |
PSEN1 | 5605 |
ADAM10 | 7907 |
APH1B | 8804 |
Biosynthesis of DHA-derived SPMs
111 | |
---|---|
set | Biosynthesis of DHA-derived SPMs |
setSize | 14 |
pANOVA | 0.0336 |
s.dist | -0.328 |
p.adjustANOVA | 0.179 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PTGS2 | -10227 |
ALOX15 | -10146 |
CYP2D6 | -9540 |
CYP2E1 | -8914 |
LTC4S | -8566 |
GSTM4 | -5489 |
ALOX12 | -3352 |
EPHX2 | -3039 |
GPX4 | -2653 |
CYP2C9 | -93 |
ALOX5 | 932 |
HPGD | 4018 |
LTA4H | 5996 |
CYP1A2 | 9770 |
GeneID | Gene Rank |
---|---|
PTGS2 | -10227 |
ALOX15 | -10146 |
CYP2D6 | -9540 |
CYP2E1 | -8914 |
LTC4S | -8566 |
GSTM4 | -5489 |
ALOX12 | -3352 |
EPHX2 | -3039 |
GPX4 | -2653 |
CYP2C9 | -93 |
ALOX5 | 932 |
HPGD | 4018 |
LTA4H | 5996 |
CYP1A2 | 9770 |
Chondroitin sulfate/dermatan sulfate metabolism
179 | |
---|---|
set | Chondroitin sulfate/dermatan sulfate metabolism |
setSize | 39 |
pANOVA | 0.000415 |
s.dist | -0.327 |
p.adjustANOVA | 0.00737 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UST | -10325 |
B3GAT3 | -9818 |
XYLT1 | -9723 |
GPC4 | -9454 |
B3GALT6 | -8920 |
CHST13 | -8851 |
XYLT2 | -8645 |
CHPF2 | -8533 |
B4GALT7 | -8207 |
GPC1 | -8099 |
CHST14 | -7842 |
GPC2 | -7735 |
HYAL3 | -7583 |
CHST7 | -7467 |
CHPF | -7214 |
CHST11 | -6832 |
HSPG2 | -5458 |
IDS | -5405 |
CSPG4 | -4429 |
IDUA | -4267 |
GeneID | Gene Rank |
---|---|
UST | -10325 |
B3GAT3 | -9818 |
XYLT1 | -9723 |
GPC4 | -9454 |
B3GALT6 | -8920 |
CHST13 | -8851 |
XYLT2 | -8645 |
CHPF2 | -8533 |
B4GALT7 | -8207 |
GPC1 | -8099 |
CHST14 | -7842 |
GPC2 | -7735 |
HYAL3 | -7583 |
CHST7 | -7467 |
CHPF | -7214 |
CHST11 | -6832 |
HSPG2 | -5458 |
IDS | -5405 |
CSPG4 | -4429 |
IDUA | -4267 |
HEXA | -4137 |
CHSY1 | -3078 |
CSGALNACT1 | -2785 |
B3GAT2 | -1900 |
SDC4 | -1368 |
CHST12 | -1069 |
B3GAT1 | 18 |
CHST15 | 1540 |
SDC3 | 1680 |
VCAN | 1854 |
DCN | 2926 |
DSE | 3281 |
ARSB | 3778 |
SDC2 | 3889 |
HEXB | 4049 |
AGRN | 6202 |
HYAL1 | 6747 |
DSEL | 8172 |
CSGALNACT2 | 10728 |
Common Pathway of Fibrin Clot Formation
201 | |
---|---|
set | Common Pathway of Fibrin Clot Formation |
setSize | 14 |
pANOVA | 0.0359 |
s.dist | -0.324 |
p.adjustANOVA | 0.184 |
Top enriched genes
GeneID | Gene Rank |
---|---|
PRTN3 | -10161 |
CD177 | -9288 |
PF4 | -8535 |
PROCR | -7828 |
F13A1 | -7712 |
PF4V1 | -5752 |
PROC | -5663 |
THBD | -5008 |
PROS1 | -2517 |
SERPINE2 | 1211 |
F2R | 1412 |
F5 | 4372 |
F8 | 6093 |
SERPIND1 | 8734 |
GeneID | Gene Rank |
---|---|
PRTN3 | -10161 |
CD177 | -9288 |
PF4 | -8535 |
PROCR | -7828 |
F13A1 | -7712 |
PF4V1 | -5752 |
PROC | -5663 |
THBD | -5008 |
PROS1 | -2517 |
SERPINE2 | 1211 |
F2R | 1412 |
F5 | 4372 |
F8 | 6093 |
SERPIND1 | 8734 |
Packaging Of Telomere Ends
804 | |
---|---|
set | Packaging Of Telomere Ends |
setSize | 20 |
pANOVA | 0.0122 |
s.dist | -0.324 |
p.adjustANOVA | 0.0874 |
Top enriched genes
GeneID | Gene Rank |
---|---|
H2AZ1 | -8776 |
H2BC12 | -8742 |
H2BC17 | -8346 |
H2BC4 | -7928 |
H2AJ | -7536 |
H2BC9 | -6894 |
ACD | -6691 |
H2BC11 | -5751 |
H2BC21 | -5415 |
TINF2 | -4662 |
H2BC15 | -4416 |
H2AC6 | -4383 |
TERF2IP | -3454 |
H2BC5 | -3070 |
H2AZ2 | -2475 |
H2BU1 | 2721 |
H2AC20 | 3907 |
TERF2 | 4874 |
TERF1 | 8885 |
POT1 | 10140 |
GeneID | Gene Rank |
---|---|
H2AZ1 | -8776 |
H2BC12 | -8742 |
H2BC17 | -8346 |
H2BC4 | -7928 |
H2AJ | -7536 |
H2BC9 | -6894 |
ACD | -6691 |
H2BC11 | -5751 |
H2BC21 | -5415 |
TINF2 | -4662 |
H2BC15 | -4416 |
H2AC6 | -4383 |
TERF2IP | -3454 |
H2BC5 | -3070 |
H2AZ2 | -2475 |
H2BU1 | 2721 |
H2AC20 | 3907 |
TERF2 | 4874 |
TERF1 | 8885 |
POT1 | 10140 |
Downregulation of ERBB2:ERBB3 signaling
306 | |
---|---|
set | Downregulation of ERBB2:ERBB3 signaling |
setSize | 12 |
pANOVA | 0.0533 |
s.dist | -0.322 |
p.adjustANOVA | 0.235 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AKT2 | -10102 |
AKT1 | -9799 |
ERBB2 | -8564 |
RPS27A | -8388 |
UBA52 | -7375 |
UBB | -4944 |
UBC | -4177 |
NRG1 | -1293 |
RNF41 | -1156 |
AKT3 | 2465 |
ERBB3 | 7160 |
USP8 | 11545 |
GeneID | Gene Rank |
---|---|
AKT2 | -10102 |
AKT1 | -9799 |
ERBB2 | -8564 |
RPS27A | -8388 |
UBA52 | -7375 |
UBB | -4944 |
UBC | -4177 |
NRG1 | -1293 |
RNF41 | -1156 |
AKT3 | 2465 |
ERBB3 | 7160 |
USP8 | 11545 |
HIV elongation arrest and recovery
487 | |
---|---|
set | HIV elongation arrest and recovery |
setSize | 32 |
pANOVA | 0.00164 |
s.dist | -0.322 |
p.adjustANOVA | 0.0247 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2L | -10282 |
CDK9 | -10180 |
CTDP1 | -9955 |
NELFB | -9862 |
GTF2F1 | -9355 |
POLR2I | -9194 |
POLR2F | -9158 |
POLR2E | -9034 |
ELL | -8355 |
ELOB | -8164 |
POLR2G | -8006 |
SUPT5H | -7930 |
POLR2A | -6255 |
POLR2J | -5993 |
SSRP1 | -5218 |
NELFA | -5007 |
POLR2H | -4752 |
NELFCD | -4629 |
CCNT1 | -3403 |
POLR2C | -2998 |
GeneID | Gene Rank |
---|---|
POLR2L | -10282 |
CDK9 | -10180 |
CTDP1 | -9955 |
NELFB | -9862 |
GTF2F1 | -9355 |
POLR2I | -9194 |
POLR2F | -9158 |
POLR2E | -9034 |
ELL | -8355 |
ELOB | -8164 |
POLR2G | -8006 |
SUPT5H | -7930 |
POLR2A | -6255 |
POLR2J | -5993 |
SSRP1 | -5218 |
NELFA | -5007 |
POLR2H | -4752 |
NELFCD | -4629 |
CCNT1 | -3403 |
POLR2C | -2998 |
NELFE | -2081 |
ELOC | 1200 |
SUPT4H1 | 1271 |
SUPT16H | 2912 |
ELOA | 2983 |
POLR2D | 4912 |
CCNK | 5104 |
GTF2F2 | 5332 |
POLR2B | 7601 |
CCNT2 | 8285 |
TCEA1 | 8287 |
POLR2K | 9927 |
Pausing and recovery of HIV elongation
807 | |
---|---|
set | Pausing and recovery of HIV elongation |
setSize | 32 |
pANOVA | 0.00164 |
s.dist | -0.322 |
p.adjustANOVA | 0.0247 |
Top enriched genes
GeneID | Gene Rank |
---|---|
POLR2L | -10282 |
CDK9 | -10180 |
CTDP1 | -9955 |
NELFB | -9862 |
GTF2F1 | -9355 |
POLR2I | -9194 |
POLR2F | -9158 |
POLR2E | -9034 |
ELL | -8355 |
ELOB | -8164 |
POLR2G | -8006 |
SUPT5H | -7930 |
POLR2A | -6255 |
POLR2J | -5993 |
SSRP1 | -5218 |
NELFA | -5007 |
POLR2H | -4752 |
NELFCD | -4629 |
CCNT1 | -3403 |
POLR2C | -2998 |
GeneID | Gene Rank |
---|---|
POLR2L | -10282 |
CDK9 | -10180 |
CTDP1 | -9955 |
NELFB | -9862 |
GTF2F1 | -9355 |
POLR2I | -9194 |
POLR2F | -9158 |
POLR2E | -9034 |
ELL | -8355 |
ELOB | -8164 |
POLR2G | -8006 |
SUPT5H | -7930 |
POLR2A | -6255 |
POLR2J | -5993 |
SSRP1 | -5218 |
NELFA | -5007 |
POLR2H | -4752 |
NELFCD | -4629 |
CCNT1 | -3403 |
POLR2C | -2998 |
NELFE | -2081 |
ELOC | 1200 |
SUPT4H1 | 1271 |
SUPT16H | 2912 |
ELOA | 2983 |
POLR2D | 4912 |
CCNK | 5104 |
GTF2F2 | 5332 |
POLR2B | 7601 |
CCNT2 | 8285 |
TCEA1 | 8287 |
POLR2K | 9927 |
NOTCH2 Activation and Transmission of Signal to the Nucleus
705 | |
---|---|
set | NOTCH2 Activation and Transmission of Signal to the Nucleus |
setSize | 20 |
pANOVA | 0.0133 |
s.dist | -0.32 |
p.adjustANOVA | 0.0912 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NEURL1B | -9789 |
PSEN2 | -8735 |
RPS27A | -8388 |
APH1A | -8076 |
UBA52 | -7375 |
DLL1 | -7224 |
MIB2 | -6846 |
MDK | -6468 |
JAG1 | -6208 |
NOTCH2 | -5057 |
UBB | -4944 |
UBC | -4177 |
MIB1 | -2896 |
PSENEN | -1485 |
JAG2 | 96 |
NEURL1 | 3966 |
NCSTN | 4145 |
PSEN1 | 5605 |
ADAM10 | 7907 |
APH1B | 8804 |
GeneID | Gene Rank |
---|---|
NEURL1B | -9789 |
PSEN2 | -8735 |
RPS27A | -8388 |
APH1A | -8076 |
UBA52 | -7375 |
DLL1 | -7224 |
MIB2 | -6846 |
MDK | -6468 |
JAG1 | -6208 |
NOTCH2 | -5057 |
UBB | -4944 |
UBC | -4177 |
MIB1 | -2896 |
PSENEN | -1485 |
JAG2 | 96 |
NEURL1 | 3966 |
NCSTN | 4145 |
PSEN1 | 5605 |
ADAM10 | 7907 |
APH1B | 8804 |
NGF-stimulated transcription
701 | |
---|---|
set | NGF-stimulated transcription |
setSize | 33 |
pANOVA | 0.00149 |
s.dist | -0.32 |
p.adjustANOVA | 0.0234 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FOSB | -10380 |
EGR2 | -10349 |
EGR1 | -10288 |
SGK1 | -10263 |
FOS | -9975 |
JUND | -9967 |
ID1 | -9733 |
MEF2D | -9627 |
JUNB | -9564 |
DNM2 | -9367 |
TRIB1 | -8748 |
EGR3 | -8231 |
ELK1 | -7817 |
SRF | -7749 |
CDK5R1 | -5195 |
LYL1 | -5089 |
ARC | -5010 |
CHD4 | -4423 |
RRAD | -3005 |
EP300 | -2667 |
GeneID | Gene Rank |
---|---|
FOSB | -10380 |
EGR2 | -10349 |
EGR1 | -10288 |
SGK1 | -10263 |
FOS | -9975 |
JUND | -9967 |
ID1 | -9733 |
MEF2D | -9627 |
JUNB | -9564 |
DNM2 | -9367 |
TRIB1 | -8748 |
EGR3 | -8231 |
ELK1 | -7817 |
SRF | -7749 |
CDK5R1 | -5195 |
LYL1 | -5089 |
ARC | -5010 |
CHD4 | -4423 |
RRAD | -3005 |
EP300 | -2667 |
NAB2 | -2510 |
TCF12 | -482 |
CDK5 | -342 |
ID3 | 2031 |
FOSL1 | 3109 |
TF | 3982 |
REST | 5083 |
CREB1 | 6457 |
ID2 | 6591 |
TPH1 | 7055 |
NAB1 | 9587 |
ATF2 | 11312 |
ATF1 | 11420 |
EGFR downregulation
321 | |
---|---|
set | EGFR downregulation |
setSize | 27 |
pANOVA | 0.00423 |
s.dist | -0.318 |
p.adjustANOVA | 0.0463 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ARHGEF7 | -10122 |
EPN1 | -8948 |
PTPRK | -8514 |
HBEGF | -8469 |
SH3GL1 | -8459 |
AREG | -8418 |
RPS27A | -8388 |
SPRY1 | -7724 |
EREG | -7409 |
UBA52 | -7375 |
EPS15L1 | -6954 |
SPRY2 | -6106 |
PTPN3 | -5217 |
TGFA | -5162 |
UBB | -4944 |
UBC | -4177 |
CBL | -2683 |
HGS | -1976 |
GRB2 | 75 |
EGF | 514 |
GeneID | Gene Rank |
---|---|
ARHGEF7 | -10122 |
EPN1 | -8948 |
PTPRK | -8514 |
HBEGF | -8469 |
SH3GL1 | -8459 |
AREG | -8418 |
RPS27A | -8388 |
SPRY1 | -7724 |
EREG | -7409 |
UBA52 | -7375 |
EPS15L1 | -6954 |
SPRY2 | -6106 |
PTPN3 | -5217 |
TGFA | -5162 |
UBB | -4944 |
UBC | -4177 |
CBL | -2683 |
HGS | -1976 |
GRB2 | 75 |
EGF | 514 |
PTPN12 | 1657 |
SH3KBP1 | 3420 |
EPGN | 3595 |
STAM | 3859 |
CDC42 | 9019 |
STAM2 | 10760 |
EPS15 | 11556 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
332 | |
---|---|
set | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression |
setSize | 32 |
pANOVA | 0.00194 |
s.dist | -0.317 |
p.adjustANOVA | 0.0273 |
Top enriched genes
GeneID | Gene Rank |
---|---|
EHMT2 | -9644.0 |
MBD3 | -9418.0 |
MTA1 | -9323.0 |
CHD3 | -8886.0 |
H2AZ1 | -8776.0 |
H2BC12 | -8742.0 |
H2BC17 | -8346.0 |
GATAD2A | -8189.0 |
H3C15 | -8038.5 |
H2BC4 | -7928.0 |
ERCC6 | -7792.0 |
H2AJ | -7536.0 |
H2BC9 | -6894.0 |
H2BC11 | -5751.0 |
H2BC21 | -5415.0 |
CHD4 | -4423.0 |
H2BC15 | -4416.0 |
H2AC6 | -4383.0 |
MTA2 | -4303.0 |
MTA3 | -3076.0 |
GeneID | Gene Rank |
---|---|
EHMT2 | -9644.0 |
MBD3 | -9418.0 |
MTA1 | -9323.0 |
CHD3 | -8886.0 |
H2AZ1 | -8776.0 |
H2BC12 | -8742.0 |
H2BC17 | -8346.0 |
GATAD2A | -8189.0 |
H3C15 | -8038.5 |
H2BC4 | -7928.0 |
ERCC6 | -7792.0 |
H2AJ | -7536.0 |
H2BC9 | -6894.0 |
H2BC11 | -5751.0 |
H2BC21 | -5415.0 |
CHD4 | -4423.0 |
H2BC15 | -4416.0 |
H2AC6 | -4383.0 |
MTA2 | -4303.0 |
MTA3 | -3076.0 |
H2BC5 | -3070.0 |
H2AZ2 | -2475.0 |
GATAD2B | 1694.0 |
H2BU1 | 2721.0 |
H2AC20 | 3907.0 |
HDAC1 | 4414.0 |
RBBP7 | 4858.0 |
H3-3A | 5193.0 |
RBBP4 | 6165.0 |
HDAC2 | 6675.0 |
TTF1 | 10139.0 |
CBX3 | 10802.0 |
Cyclin A/B1/B2 associated events during G2/M transition
222 | |
---|---|
set | Cyclin A/B1/B2 associated events during G2/M transition |
setSize | 24 |
pANOVA | 0.00749 |
s.dist | 0.315 |
p.adjustANOVA | 0.064 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CCNA1 | 11725 |
PPP2R2A | 11691 |
XPO1 | 11455 |
CCNH | 11324 |
CDK7 | 10265 |
CDK1 | 9135 |
PPP2CB | 8622 |
FOXM1 | 6055 |
CCNB1 | 5971 |
PPP2CA | 5682 |
CCNB2 | 5588 |
MNAT1 | 5358 |
CCNA2 | 4976 |
WEE1 | 4830 |
PPP2R1B | 3643 |
CDK2 | 2315 |
PPME1 | 2078 |
LCMT1 | 1586 |
PKMYT1 | 927 |
CDC25B | -11 |
GeneID | Gene Rank |
---|---|
CCNA1 | 11725 |
PPP2R2A | 11691 |
XPO1 | 11455 |
CCNH | 11324 |
CDK7 | 10265 |
CDK1 | 9135 |
PPP2CB | 8622 |
FOXM1 | 6055 |
CCNB1 | 5971 |
PPP2CA | 5682 |
CCNB2 | 5588 |
MNAT1 | 5358 |
CCNA2 | 4976 |
WEE1 | 4830 |
PPP2R1B | 3643 |
CDK2 | 2315 |
PPME1 | 2078 |
LCMT1 | 1586 |
PKMYT1 | 927 |
CDC25B | -11 |
PLK1 | -2414 |
CDC25A | -3555 |
PPP2R1A | -7631 |
PPP2R3B | -9759 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
718 | |
---|---|
set | Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters |
setSize | 21 |
pANOVA | 0.013 |
s.dist | -0.313 |
p.adjustANOVA | 0.0895 |
Top enriched genes
GeneID | Gene Rank |
---|---|
AP1M1 | -9320 |
HLA-A | -9057 |
AP2M1 | -8930 |
AP1B1 | -8263 |
ARF1 | -8086 |
AP2A2 | -7814 |
CD28 | -7250 |
PACS1 | -7044 |
AP1M2 | -6981 |
AP2A1 | -6826 |
LCK | -4371 |
AP2S1 | -3863 |
AP2B1 | -3395 |
CD4 | -1298 |
AP1S1 | -931 |
AP1S3 | 2474 |
CD8B | 3054 |
AP1G1 | 4301 |
ATP6V1H | 5572 |
B2M | 9465 |
GeneID | Gene Rank |
---|---|
AP1M1 | -9320 |
HLA-A | -9057 |
AP2M1 | -8930 |
AP1B1 | -8263 |
ARF1 | -8086 |
AP2A2 | -7814 |
CD28 | -7250 |
PACS1 | -7044 |
AP1M2 | -6981 |
AP2A1 | -6826 |
LCK | -4371 |
AP2S1 | -3863 |
AP2B1 | -3395 |
CD4 | -1298 |
AP1S1 | -931 |
AP1S3 | 2474 |
CD8B | 3054 |
AP1G1 | 4301 |
ATP6V1H | 5572 |
B2M | 9465 |
AP1S2 | 10082 |
Formation of ATP by chemiosmotic coupling
387 | |
---|---|
set | Formation of ATP by chemiosmotic coupling |
setSize | 18 |
pANOVA | 0.0216 |
s.dist | -0.313 |
p.adjustANOVA | 0.131 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MT-ATP8 | -10332 |
ATP5ME | -9874 |
MT-ATP6 | -9606 |
ATP5F1D | -9424 |
ATP5MG | -8771 |
ATP5MF | -8024 |
ATP5MC2 | -7490 |
ATP5MC3 | -4398 |
ATP5F1A | -4172 |
ATP5F1E | -3220 |
ATP5F1B | -2212 |
ATP5PB | 704 |
ATP5MC1 | 1413 |
ATP5PF | 2504 |
ATP5PO | 3036 |
ATP5PD | 5191 |
ATP5F1C | 5198 |
DMAC2L | 9430 |
GeneID | Gene Rank |
---|---|
MT-ATP8 | -10332 |
ATP5ME | -9874 |
MT-ATP6 | -9606 |
ATP5F1D | -9424 |
ATP5MG | -8771 |
ATP5MF | -8024 |
ATP5MC2 | -7490 |
ATP5MC3 | -4398 |
ATP5F1A | -4172 |
ATP5F1E | -3220 |
ATP5F1B | -2212 |
ATP5PB | 704 |
ATP5MC1 | 1413 |
ATP5PF | 2504 |
ATP5PO | 3036 |
ATP5PD | 5191 |
ATP5F1C | 5198 |
DMAC2L | 9430 |
Influenza Infection
529 | |
---|---|
set | Influenza Infection |
setSize | 154 |
pANOVA | 2.27e-11 |
s.dist | -0.312 |
p.adjustANOVA | 1.41e-09 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SLC25A6 | -10385 |
RPL37 | -10308 |
POLR2L | -10282 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
POM121C | -9374 |
GTF2F1 | -9355 |
FAU | -9334 |
RPS18 | -9321 |
GeneID | Gene Rank |
---|---|
SLC25A6 | -10385 |
RPL37 | -10308 |
POLR2L | -10282 |
RPS2 | -10243 |
RPLP2 | -10185 |
RPS29 | -10049 |
RPS17 | -9962 |
RPL36 | -9899 |
RPL3 | -9867 |
RPL8 | -9738 |
RPL38 | -9692 |
RPS16 | -9633 |
RPS21 | -9530 |
RPLP1 | -9501 |
RPS4Y1 | -9458 |
RPS12 | -9407 |
POM121C | -9374 |
GTF2F1 | -9355 |
FAU | -9334 |
RPS18 | -9321 |
RPS27 | -9308 |
RPL36AL | -9271 |
RPS10 | -9222 |
POLR2I | -9194 |
POLR2F | -9158 |
RPS5 | -9130 |
NUP210 | -9099 |
POLR2E | -9034 |
RPLP0 | -9032 |
RPL27A | -9016 |
RPL7A | -8955 |
RPS28 | -8941 |
POM121 | -8910 |
RPL35 | -8896 |
RPL29 | -8882 |
RPL37A | -8844 |
RPS19 | -8814 |
RPL18A | -8789 |
RPL10 | -8752 |
RPL27 | -8691 |
RPS11 | -8677 |
RPS3 | -8434 |
RPS27A | -8388 |
RPL39 | -8259 |
RPL31 | -8234 |
RPL41 | -8197 |
RPS14 | -8173 |
TGFB1 | -8091 |
RPL32 | -8070 |
CPSF4 | -8008 |
POLR2G | -8006 |
HSPA1A | -7940 |
RPS15A | -7835 |
RPL30 | -7798 |
RPL18 | -7720 |
RPS23 | -7714 |
RPS9 | -7668 |
RPS15 | -7663 |
RPL12 | -7427 |
UBA52 | -7375 |
RPS6 | -7364 |
RPL17 | -7051 |
RPL35A | -6977 |
RPL15 | -6926 |
RPL19 | -6701 |
RPL7 | -6643 |
RPL22 | -6602 |
RPS7 | -6568 |
RPL14 | -6402 |
RPL21 | -6288 |
POLR2A | -6255 |
POLR2J | -5993 |
RPL36A | -5966 |
NUP188 | -5843 |
RPL39L | -5829 |
RPL4 | -5814 |
RPL13 | -5675 |
RPS25 | -5670 |
RPL5 | -5445 |
RPL26 | -5374 |
RPL28 | -5271 |
RPL13A | -5249 |
RPL11 | -5206 |
RPS13 | -5170 |
PARP1 | -4864 |
RPL10A | -4820 |
PABPN1 | -4813 |
POLR2H | -4752 |
RPL23 | -4456 |
RPL24 | -3939 |
RPS26 | -3701 |
SEC13 | -3159 |
NUP62 | -3119 |
RPS8 | -3073 |
RPS20 | -3024 |
POLR2C | -2998 |
RPL9 | -2451 |
RPL26L1 | -2412 |
RPL34 | -2254 |
IPO5 | -1917 |
AAAS | -1609 |
RPS24 | -89 |
NDC1 | -77 |
RPL23A | 138 |
CLTA | 509 |
CLTC | 1283 |
RPL6 | 1290 |
RPS4X | 1825 |
NUP214 | 2090 |
NUP98 | 2149 |
NUP93 | 3043 |
CALR | 3069 |
NUP155 | 3103 |
RPS3A | 3173 |
NUP160 | 3296 |
CANX | 3437 |
NUP205 | 3520 |
NUP153 | 3654 |
NUP37 | 3973 |
GRSF1 | 4059 |
NUP88 | 4512 |
POLR2D | 4912 |
TPR | 4956 |
RAN | 5082 |
RPSA | 5249 |
GTF2F2 | 5332 |
NUP133 | 5417 |
RANBP2 | 5691 |
RAE1 | 6124 |
KPNA2 | 6216 |
NUP85 | 6578 |
NUP58 | 6817 |
NUP50 | 7082 |
KPNB1 | 7251 |
POLR2B | 7601 |
DNAJC3 | 7755 |
NUP107 | 7988 |
KPNA1 | 8096 |
RPL22L1 | 8317 |
HSP90AA1 | 8431 |
NUP35 | 8941 |
RPL3L | 8978 |
KPNA3 | 9027 |
RPS27L | 9625 |
ISG15 | 9822 |
SEH1L | 9849 |
KPNA4 | 9875 |
POLR2K | 9927 |
KPNA5 | 9958 |
NUP43 | 10569 |
NUP42 | 10900 |
XPO1 | 11455 |
NUP54 | 11540 |
EIF2AK2 | 11688 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.0.3 (2020-10-10)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.2 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] parallel stats4 stats graphics grDevices utils datasets
## [8] methods base
##
## other attached packages:
## [1] pkgload_1.2.0 GGally_2.1.1
## [3] beeswarm_0.3.1 gtools_3.8.2
## [5] echarts4r_0.4.0 topconfects_1.6.0
## [7] limma_3.46.0 eulerr_6.1.0
## [9] mitch_1.2.2 MASS_7.3-53.1
## [11] fgsea_1.16.0 gplots_3.1.1
## [13] DESeq2_1.30.0 SummarizedExperiment_1.20.0
## [15] Biobase_2.50.0 MatrixGenerics_1.2.0
## [17] matrixStats_0.58.0 GenomicRanges_1.42.0
## [19] GenomeInfoDb_1.26.0 IRanges_2.24.0
## [21] S4Vectors_0.28.0 BiocGenerics_0.36.0
## [23] reshape2_1.4.4 forcats_0.5.1
## [25] stringr_1.4.0 dplyr_1.0.5
## [27] purrr_0.3.4 readr_1.4.0
## [29] tidyr_1.1.3 tibble_3.1.0
## [31] ggplot2_3.3.3 tidyverse_1.3.0
## [33] zoo_1.8-9
##
## loaded via a namespace (and not attached):
## [1] colorspace_2.0-0 ellipsis_0.3.1 rprojroot_2.0.2
## [4] XVector_0.30.0 fs_1.5.0 rstudioapi_0.13
## [7] farver_2.1.0 bit64_4.0.5 AnnotationDbi_1.52.0
## [10] fansi_0.4.2 lubridate_1.7.10 xml2_1.3.2
## [13] splines_4.0.3 cachem_1.0.4 geneplotter_1.68.0
## [16] knitr_1.31 polyclip_1.10-0 jsonlite_1.7.2
## [19] broom_0.7.5 annotate_1.68.0 dbplyr_2.1.0
## [22] shiny_1.6.0 compiler_4.0.3 httr_1.4.2
## [25] backports_1.2.1 assertthat_0.2.1 Matrix_1.3-2
## [28] fastmap_1.1.0 cli_2.3.1 later_1.1.0.1
## [31] htmltools_0.5.1.1 tools_4.0.3 gtable_0.3.0
## [34] glue_1.4.2 GenomeInfoDbData_1.2.4 fastmatch_1.1-0
## [37] Rcpp_1.0.6 cellranger_1.1.0 jquerylib_0.1.3
## [40] vctrs_0.3.6 polylabelr_0.2.0 xfun_0.22
## [43] ps_1.6.0 testthat_3.0.2 rvest_1.0.0
## [46] mime_0.10 lifecycle_1.0.0 XML_3.99-0.6
## [49] zlibbioc_1.36.0 scales_1.1.1 promises_1.2.0.1
## [52] hms_1.0.0 RColorBrewer_1.1-2 yaml_2.2.1
## [55] memoise_2.0.0 gridExtra_2.3 sass_0.3.1
## [58] reshape_0.8.8 stringi_1.5.3 RSQLite_2.2.4
## [61] highr_0.8 genefilter_1.72.0 desc_1.3.0
## [64] caTools_1.18.1 BiocParallel_1.24.1 rlang_0.4.10
## [67] pkgconfig_2.0.3 bitops_1.0-6 evaluate_0.14
## [70] lattice_0.20-41 labeling_0.4.2 htmlwidgets_1.5.3
## [73] bit_4.0.4 tidyselect_1.1.0 plyr_1.8.6
## [76] magrittr_2.0.1 R6_2.5.0 generics_0.1.0
## [79] DelayedArray_0.16.0 DBI_1.1.1 pillar_1.5.1
## [82] haven_2.3.1 withr_2.4.1 survival_3.2-10
## [85] RCurl_1.98-1.3 modelr_0.1.8 crayon_1.4.1
## [88] KernSmooth_2.23-18 utf8_1.2.1 rmarkdown_2.7
## [91] locfit_1.5-9.4 grid_4.0.3 readxl_1.3.1
## [94] data.table_1.14.0 blob_1.2.1 reprex_1.0.0
## [97] digest_0.6.27 xtable_1.8-4 httpuv_1.5.5
## [100] munsell_0.5.0 bslib_0.2.4
END of report